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Spinal cord injuries cost the United States $20 billion per year, with an existing 
patient population of 256,000 growing by an estimated 12,000 each year.  Current clinical 
therapies for spinal cord injury are limited to spinal immobilization and realignment via 
traction, surgery, administration of methylprednisolone sodium succinate (MPSS) within 
eight hours post-injury, and rehabilitation exercises.  While these therapies are important 
and may minimize damage and restore limited function, there is a dire clinical need for 
treatments to address the growing population of chronically-injured patients. 
Varying degrees of axonal regeneration and functional recovery following spinal 
cord injury have been achieved in animal models by transplantation of glial cells from the 
peripheral nervous system and olfactory region.  The recent identification of bioactive 
soluble and adhesive molecules produced by glial cells provides the opportunity to 
deliver these stimuli through biomaterial-mediated approaches, such as controlled 
release, gene therapy, and recombinant protein immobilization.  The long-term objective 
of this project is a biomimetic, multi-factorial approach utilizing grooved fibers to restore 
structure and provide guidance for regenerating axons coupled with bioactive dhesive 
molecule delivery via immobilization to a hydrogel within the fiber grooves and 
controlled release of neurotrophic factors from the hydrogel.  The implant design can 
serve as a platform for both in vitro and in vivo analysis of combination therapies for 
different injured nerve populations.   
The first part of this research focused on cloning and expression of a bioactive 
140kDa fragment of L1 neural cell adhesion molecule.  L1 is a particularly attractive 
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candidate for neural regeneration because it is critical for pr per nervous system 
development and in vitro studies have demonstrated selectivity of neuron adhesion to L1 
in the presence of astrocytes, which play a major role in nervous system inflammation.  
The second part of this research focused on the synthesis and purification of acrylated 
Tetronic macromers, and the development of Michael addition methods for hydrogel 
crosslinking and protein immobilization.  In order to establish the feasibility of these 
hydrogels for neural regeneration, initial testing was conducted using NIH 3T3 
fibroblasts and fibronectin because of the well-known RGD-dependent interaction. 
Results demonstrated that fibronectin encapsulation and surface-immobilization through 
acrylation of fibronectin positively influenced fibroblast spreading ad proliferation.  The 
last part of this research focused on evaluating neuronal cell lin  and primary neuron 
response to L1, evaluating cytocompatibility of T904-acrylate hydrogels with neural 
cells, and developing immobilization methods for L1. Results indicate that surface-
immobilization of L1 to hydrogels may be the most promising method of bioactive cell 
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Spinal cord injury requires continuous medical care as a result of the devastating 
physical and psychological consequences to the affected individual, including paralysis, 
respiratory deficiency, bladder and bowel dysfunction, loss of reproductive and sexual 
function, and ultimately, loss of personal independence. According to the National Spinal 
Cord Injury Statistical Center (NSCISC, Facts and Figures at a Glance, January 2008), 
approximately 12,000 new spinal cord injuries occur in the United States each year, in 
addition to an existing patient population of approximately 256,000.  The average patient 
age at injury is 39.5 years, with life expectancies and lifetime medical costs ranging from 
approximately 20-40 years and $494,000 to $3,000,000, respectively.  Spinal cord 
injuries typically occur during an individual’s most productive years, re ulting in a 
substantial economic burden to society, not only because of medical costs but also the 
ongoing disability support and lost productivity due to unemployment or reduced 
employment.  A 1998 analysis estimated that spinal cord injuries cost the United States 
over $14.5 billion per year in direct medical costs and disability support, as well as an 
additional $5.5 billion per year in lost productivity, for an estimated total $20 billion per 
year. [1]  
Current clinical therapies for spinal cord injury are limited to spinal 
immobilization and realignment via traction, surgery, administraton of 
methylprednisolone sodium succinate (MPSS) within eight hours post-injury, and 
rehabilitation exercises.  MPSS is thought to attenuate the secondary i jury cascade and 
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improve functional recovery, and has been adopted as the standard of care sin e 1990 in 
most of North America. [2]  Other experimental methods for treatm n  of acute injuries 
include decompression surgery and moderate hypothermia. [3]  While these therapies are 
important and may minimize damage and restore limited function, there is a dire clinical 
need for treatments to address the growing population of chronically-injured patients. 
Spinal cord injury and paralysis have been considered severe and irreversible 
conditions throughout much of scientific history, beginning with an account from an 
Egyptian papyrus roll manuscript as early as 1700 B.C. describing spinal cord injury 
accompanied by paralysis as "an ailment not to be treated." [4]  Evidence of the first 
nerve graft in dogs resulting in limited degree of functional resto ation was reported in 
France in the 1860s [5]; however, pioneering work by Spanish neuroanatomist and 
histologist Ramόn y Cajal in the early 1900’s provided evidence that nerve cells from the 
peripheral nervous system (PNS) have the capacity to repair themselv s, but nerve cells 
from the adult central nervous system (CNS) display only an abortive sprouting attempt 
in response to injury. [6, 7]  Cajal hypothesized that the differences in regenerative 
capacity were likely a result of the cellular environment thatsupports the nerve cells, and 
stated, “From this it may be inferred that if experimental neurology is some day to supply 
artificially the deficiencies in question it must accomplish these two objects: First, it must 
give to the sprouts by means of adequate alimentation a vigorous capacity for growth, 
and second, place in front of the disoriented nerve cones and in the thickness of white 
matter tracks, specific orienting substances.”  [8]  Cajal believ d the regenerative 
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capacity of the adult central nervous system could be enhanced through bioengineering 
efforts. 
A number of mechanisms have been implicated in regenerative failure of th adult 
CNS following injury and are broadly classified into two categories: intrinsic barriers, or 
an inherent decline in growth capacity that occurs with neuronal cell maturation; and 
extrinsic barriers, or the non-permissive regenerative environment in the adult CNS 
following injury as compared to the permissive PNS and developing CNS environments.  
Proposed mechanisms of intrinsic regenerative failure include a decrease in the rate of 
retrograde transport of injury signals with increasing distance between axotomy site and 
cell body, delayed synthesis and diminished anterograde transport of cytoskeletal proteins 
required for growth cone and axon formation, a developmentally-regulated decreas  in 
endogenous levels of neuronal cyclic adenosine monophosphate (cAMP) in mature 
neurons, and variable ability of different neuronal cell types to sustain expression of 
regeneration-associated genes. [9-12]  Surviving neurons in the CNS generally do sprout 
axons in an attempt at regeneration; however, this attempt is quickly aborted upon 
encountering the hostile external environment. [13]  Proposed mechanisms of extrinsic 
regenerative failure include delayed and incomplete clearance of axon and myelin debris; 
exposure to myelin-associated inhibitory glycoproteins that are not present during early 
stages of development; exposure to inhibitory chondroitin sulfate proteoglycans (CSPGs) 
present in reactive astrocytic glial scar tissue; the formation of cystic cavities; the loss of 
the structural organization of the mature CNS; and a lack of supporting neurotrophic 
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factors and growth-promoting adhesion ligands that are present during development. [9, 
11, 12, 14]  
Varying degrees of axonal regeneration and functional recovery following spinal 
cord injury have been achieved in animal models by transplantation of glial cells from the 
peripheral nervous system and olfactory region; however, major limitat ons of cell 
transplantation approaches include the time required to isolate, purify, genetically 
modify, and expand suitable autologous cells for transplantation and immune 
complications inherent to allographic or xenographic cell transplantatio . Cell therapies 
for spinal cord repair do not necessarily address the disorganized structure of the injured 
CNS, and are plagued with additional challenges including limited cell survival and 
migration out of the lesion area following transplantation.  Current approaches seek to 
address these challenges by incorporating cells within biomaterial-based scaffolds with 
channels to improve cell survival, limit migration, and also provide guidance for 
regenerating axons [15-17]; however, the recent identification of bioactive soluble and 
adhesive molecules produced by glial cells provides the opportunity to deliver these 
stimuli through biomaterial-mediated approaches, such as controlled re ase, gene 
therapy, and recombinant protein immobilization.   
Synthetic degradable acellular biomaterial bridges with customizable properties 
and combinations of adhesive stimuli and growth factors offer the unique opportunity to 
tailor implants to the desired nerve populations that are to be regenerated, and also 
potentially open the door to readily available, large-scale production of “off-the-shelf” 
implants for patients with both CNS and PNS nerve injuries. [12, 18]  Thelong-term 
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objective of this project is a biomimetic, multi-factorial approach utilizing grooved fibers 
to restore structure and provide guidance for regenerating axons coupled with bioactive 
adhesive molecule delivery via immobilization to a hydrogel within e fiber grooves and 
controlled release of neurotrophic factors from the hydrogel (Figure 1.1).  The implant 
design can serve as a platform for both in vitro and in vivo analysis of combination 





















Figure 1.1  Proposed Implant Design 
 
Neurotrophic factors are excellent promoters of neurite outgrowth on permissive 
substrates, but they are not sufficient for growth cone or cell adhesion to a biologically 
inert material; therefore, this research is focused on covalent immobilization of cell 
adhesion proteins to acrylated Tetronic® hydrogels with future plans of neurotrophin 
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incorporation to further enhance neural regeneration rates.  The goals of thi  research 
were: (1) cloning and expression of a bioactive 140kDa fragment of L1 neural cell 
adhesion molecule, chosen for its critical role in proper nervous system development and 
because it has demonstrated selectivity of neuron adhesion in the presence of astrocytes, 
which play a major role in nervous system inflammation, (2) synthesis and purification of 
acrylated Tetronic macromers and the development of Michael addition methods for 
hydrogel crosslinking and protein immobilization, (3) evaluation of hydrogel 
cytocompatibility, immobilized protein bioactivity, and immobilization efficiency in 
terms of cell spreading and proliferation using NIH 3T3 fibroblasts and fibronectin 
because of the well-known RGD-dependent interaction, to demonstrate the feasibility of 
this system for neural repair, and (4) assessment of neuronal cell line and primary neuron 
response to L1, evaluation of the cytocompatibility of T904-acrylate hydrogels with 
neural cells, and development of immobilization methods for L1. 
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CHAPTER TWO 
LITERATURE REVIEW  
 
INTRODUCTION  
This chapter begins by studying the mechanisms of regenerative f ilure in the 
adult CNS and investigating the differences in CNS and PNS anatomy, physiology, and 
response to injury in order to gain an understanding of the cues driving egeneration as 
well as factors contributing to the inhibition of regeneration.  An understanding of these 
cues and factors is of crucial importance in developing therapies for functional neural 
regeneration (axonal regeneration with restoration of function).  Current reported 
experimental approaches to regeneration and those that have made it to human clinical 
trials will also be discussed.   
 
THE NERVOUS SYSTEM 
General Anatomy/Physiology of Nervous Tissue 
The human nervous system is classified into two main categories: th  central 
nervous system (CNS), consisting of the brain and spinal cord; and the peripheral nervous
system (PNS), consisting of twelve pairs of cranial nerves; thirty-one pairs of spinal 
nerves; and dorsal root ganglia, which are bundles of sensory nerve cell bodies with 
processes that branch into both the CNS and PNS.  Both branches function as one 
actively conducting axon, which transmits information from the periphery to the CNS.  
Spinal nerves are connected to the spinal cord by two short roots: the dorsal root (toward 
the back), where sensory signals from dorsal root ganglia enter the grey matter of the 
 8
CNS; and the ventral root (toward the abdomen), where motor signals are transmitted 
from motor neuron cell bodies in the grey matter of the CNS to the periphery.  The two 
roots join to form the spinal nerve just before the nerve leaves the vertebral column. [19]  
Figure 2.1 depicts a cross-section of the spinal cord and the position of the dorsal and 
ventral roots as they join to form a spinal nerve. 
 
 
Figure 2.1  Cross-Section of the Spinal Cord 
(http://webanatomy.net/anatomy/spinal_neurons.jpg) 
Permission granted by Dr. Jim Swan, University of New Mexico 
 
Cells of the Nervous System 
The two main cell types in the human nervous system are neurons and neuroglia.  
Neurons are the main functional conducting units of the nervous system and are post-
mitotic cells.  They typically consist of a cell body, one axon, ad one to several 
dendrites; however, dorsal root ganglia generally do not exhibit dendrits due to 
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bifurcation of their axon.  Dendrites appear as branches of a tree or spikes and receive 
messages for the cell body.  Axons may be long, short, single, or branched, and they 
transmit messages from the cell body to other neurons or target cells.  Dendrites are most 
commonly observed in grey matter, where neural cell bodies are concentrated.  The three 
classes of neurons include sensory (afferent) neurons, which transmit sensory informat on 
to the brain; motor (efferent) neurons, which have long axons and transmit i formation to 
the muscles and glands of the body; and interneurons, which provide connecti s 
between sensory and motor neurons, have short axons, only communicate within their 
immediate region, and are prevalent in grey matter of the spinal cord.   
Neuroglia are nonconductive, mitotic cells and serve to support, nourish, and 
protect neurons by providing physical structure and insulation, supplying nutrients and 
oxygen, and destroying pathogens and removing necrotic neural tissue.  Ne roglia in the 
CNS consist of oligodendrocytes, which myelinate axons [20]; astrocytes, which are 
fibroblast-like cells that secrete neurotrophic factors and are involved in signaling, energy 
metabolism, extracellular ion homeostasis, volume regulation, and neuroprotection [21]; 
and microglia, which are phagocytic, specialized macrophages of theCNS that normally  
maintain a resting phenotype.  The brain and spinal cord are considered “immune 
privileged” because they are separated from the blood circulation by a series of 
endothelial cells known as the blood-brain barrier (BBB). The BBB prevents blood-borne 
immune cells such as lymphocytes, monocytes and neutrophils, as well as antibodies, 
from entering the CNS; therefore, microglia are thought to enabl the CNS to mount a 
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prompt immune response to infectious or inflammatory stimuli despite the inability of 
blood-borne immune cells to cross the blood-brain barrier. [22] 
Oligodendrocyte precursor cells (OPCs) are a newly recognized glial cell type of 
unknown function in the normal adult CNS; however, these cells have been shown to 
rapidly proliferate following injury in localized areas close to the site of damage, and 
their distribution in the developing CNS may point to a function in axon l guidance. [23]  
In addition, these cells appear to possess similar characteristi s a  neuronal and glial stem 
cells.   
Schwann cells function as neuroglia in the PNS and may be divided into four 
classes in the mature nervous system: myelinating Schwann cells (MSCs), 
nonmyelinating Schwann cells (NMSCs), perisynaptic Schwann cells (PSCs), and 
satellite cells of peripheral dorsal root ganglia (DRG). [24]  MSCs are the most well-
characterized category and function similarly to oligodendrocytes in the CNS in that they 
wrap around large-diameter PNS axons to form the myelin sheath.  The function of 
NMSCs is not as well-characterized but they wrap around several sm l-diameter 
unmyelinated sensory axons to form a Remak bundle, keeping individual axons separated 
by thin extensions of the Schwann cell body.  The interaction of NMSCs with 
unmyelinated axons may play a key role in sensitivity to pain and other sensory stimuli.  
PSCs express similar proteins to MSCs and are important in developm nt and 
maintenance of the neuromuscular junction.  Little is known about the function of 
satellite cells except that they surround DRG cell bodies to form a discrete anatomical 
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unit. [25]  Schwann cells appear to be able to switch their function by a change in gene 
expression. [26] 
 
Peripheral Nerve Structure 
Figure 2.2 depicts a cross-section of a peripheral nerve. Individual myelinated 
axons are surrounded by spirally-wrapped myelinating Schwann cells.  The myelin sheath 
is called the neurilemma. [27]  Myelinated nerves and Remak bundles of unmyelinated 
axons are individually-encased by endoneurium.  The perineurium then binds bundles of 
endoneurium-encased axons together to form fascicles.  Epineurium, a loose connective 
tissue layer, is the collagen-rich outer nerve covering forming a sheath around a b le of 
fascicles.  Fibroblasts secrete the type I collagen fibers and are located in the 
endoneurium. [28]  Each peripheral nerve typically contains twice as many unmyelinated 




Figure 2.2  Peripheral Nerve Structure 
(Reprinted from Schmidt and Leach 2003 [28]) 
 
The blood supply of peripheral nerves is composed of an intrinsic system of 
capillaries ensheathed along with axons within the perineurium, arterioles ensheathed 
within the epineurium [9], and an extrinsic system made up of vessels that penetrate the 
nerve from surrounding arteries and veins. [28]  Figure 2.3 depicts a diagram of potential 





Figure 2.3  Peripheral Nerve Blood Supply Patterns 
(Reprinted from el-Barrany et al. 1999 [29]) 
 
Spinal Cord Structure 
The human spinal cord is highly organized and is divided into a central can l, 
remaining from embryonic development and containing cerebrospinal fluid (CSF); grey 
matter, the inner region consisting of unmyelinated cell bodies and short fibers; and white 
matter, the outer region consisting of myelinated long fibers in bundles called tracts.  The 
grey-brown color of the grey matter results from the capillary blood vessels and neuronal 
cell bodies.  The white matter appears white because of the high concentration of lipids in 
the myelin sheath surrounding the axons. Reflexes are also mediated in the spinal cord 
without going to the higher brain centers. 
White matter axon tracts provide a route for signals to be transmitted up and down 
the spinal cord between the brain and spinal nerves.  Knowledge of th  functions of the 
different spinal cord tracts aids a neurologist in determining if an injury is complete or 
incomplete based on what type of sensory, motor, and reflex informatin the injured 
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patient has lost, as damage to white matter affects function at all levels below the 
neurological injury site.  Complete lesions result in loss of all sensory and motor 
functions below the level of injury.  Incomplete lesions result in retention of some 
sensory and motor functions, which can be used to diagnose which side of the spinal cord 
the injury has occurred.  For example, the dorsal column medial lemniscus system 
transmits ipsilateral fine touch, proprioception, and vibration information to the brain.  
The lateral spinothalamic tract transmits contralateral pain and temperature sensations.  
The corticospinal tract is primarily responsible for skilled motor movements and injury 
results in ipsilateral paralysis. [19]  One important consideration to take into account 
when developing therapies for spinal cord injury is that different axon tracts may respond 
differently to injury and therapeutic measures, and may have specific r quirements for 
regeneration. [12] 
Blood supply to the spinal cord is complex. [30]  Briefly, arterial supply of the 
spinal cord is from the vertebral arteries and radicular arteries originating from the 
thoracic and abdominal aortae.  Vertebral arteries supply upper cervical levels and branch 
into two posterior spinal arteries, which are located along the dorsal roots; and two 
anterior spinal arteries which fuse to form a single midline antrior spinal artery that runs 
the length of the spinal cord.  Lower cervical levels are supplied by vertebral and 
radicular arteries but are generally dependent upon radicular arteries for survival.  Figure 
2.4 depicts the horizontal view of blood distribution from the posterior (dorsal) and 




Figure 2.4  Horizontal View of Spinal Cord Blood Supply 
(http://www.anaesthesiauk.com/images/spinal-cord4.jpg) 
Reprinted with permission 
 
The PNS-CNS Transitional Zone 
The transitional zone consists of the thin dorsal and ventral roots that connect 
spinal nerves to the spinal cord.  It is the location where CNStissue is separated from 
PNS tissue by the glia limitans and the basal lamina of blood vessels. [31]  On the CNS 
side of the glia limitans, nerves are surrounded mainly by astrocytic processes along with 
a small population of oligodendrocytes and microglia.  On the PNS side of the glia 
limitans, nerves are ensheathed by endoneurial connective tissue consisting of Schwann 
cells, fibroblasts, and collagen.  Lesioned dorsal root ganglia (DRG) axons that 
successfully regenerate the peripheral segment have been shown to stop upon reaching 
 16
the transitional zone [9], thus demonstrating the inhibitory nature of the CNS 
environment to regeneration. 
 
PATHOPHYSIOLOGY OF CENTRAL NERVOUS SYSTEM INJURY  
Spinal cord injuries are classified clinically according to their s gmental level, as 
depicted in Figure 2.5; as complete or incomplete depending upon which sensory a d 
motor functions are spared; and according to the mechanism leading to injury. [11]  The 
human spinal cord is approximately 45 cm (1.5 ft) with 30 levels, and each spinal level in 
the spinal cord is around 1-2 cm. [14]  Regeneration over even just one or two spinal 




Figure 2.5  Spinal Levels and Effects of Injury 
(Reprinted from Verma and Fawcett 2005 [14]) 
 
Because of clinical confusion as to the terminology associated with sp nal cord 
injury levels, severity, and classification, the American Spinal Injury Association (ASIA) 
Impairment Scale (www.asia-spinalinjury.org) was developed with further classifications 
of complete and incomplete injuries, resulting in more consistent terminology being used 
to describe the findings in spinal cord injury around the world, depicted in Figure 2.6. 
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Figure 2.6  ASIA Impairment Scale 
(Reprinted from Thuret et al. 2006 [32]) 
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The ASIA Scale also includes other classifications of incomplete spinal cord inju ies: 
• Central cord syndrome often is associated with a cervical region injury leading to 
greater weakness in the upper limbs than in the lower limbs with sacral sensory 
sparing.  
• Brown-Séquard syndrome often is associated with a hemisection lesi  of the cord, 
causing a relatively greater ipsilateral proprioceptive and motor loss with contralateral 
loss of sensitivity to pain and temperature.  
• Anterior cord syndrome often is associated with a lesion causing variable loss of 
motor function and sensitivity to pain and temperature, while proprioceptin is 
preserved.  
• Conus medullaris syndrome is associated with injury to the sacral cord and lumbar 
nerve roots leading to areflexic bladder, bowel, and lower limbs, while t e sacral 
segments occasionally may show preserved reflexes (e.g., bulbocavernosus and 
micturition reflexes).  
• Cauda equina syndrome is due to injury to the lumbosacral nerve roots in the spinal 
canal leading to areflexic bladder, bowel, and lower limbs. 
 
The spinal column normally experiences four forces: flexion, extension, rotation, 
and compression, and any combination of forces may lead to injury resulting in fractured 
vertebral bodies or dislocated vertebrae.  These injuries result in concussion, contusion, 
or laceration of the spinal cord.  Concussion produces no anatomical dam ge resulting in 
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transient loss of function.  Both contusion and laceration injuries involve anatomical 
damage resulting in permanent deficits, [11].  
This primary, mechanical disruption of tissue is quickly followed by a secondary 
injury cascade.  Schwab and Bartholdi completed an extensive review of spinal cord 
injury and have described three main phases of the secondary injury cascade: the acute 
phase, the subacute phase, and the late phase. [11]  The acute phase immediately follows 
injury and is characterized by hemorrhage, local ischemia, and edema followed by 
necrosis and inflammation.  Hemorrhage begins in the highly vascularized gray matter 
adjacent to the central canal or anterior horns and spreads radially to the posterior horns 
and into white matter in a rostral and caudal direction. [33]  The first signs of necrotic 
endothelial, neuronal and glial cells appear within the first hour following injury and peak 
within 6-12 hours of injury, along with necrosis of white matter axons.  Local ischemia 
may result from posttraumatic hypotension or loss of autoregulation nd results in 
predominantly anaerobic metabolism for the first 4 hours following injury followed by an 
increase in metabolic rate between 4 and 24 hours.  Injury results in circumferential 
spreading of vasogenic edema into white matter caused by a disruption of the blood-brain 
barrier; this disruption results in increased vascular permeability which allows an 
abnormal accumulation of fluid in intercellular spaces of the spinal cord, which may 
result in compression and an abnormal electrolyte environment consisting of excess 
calcium and potassium followed by a chronic loss of potassium.  Tissue damage may be 
exacerbated by compression of the swollen spinal cord tissue against the vertebrae 
causing an increase in ischemia.  The altered electrolyte environment coupled with 
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oxygen free radical and lipid peroxidation reactions catalyzed by hemorrhage and the 
resultant ischemia, as well as release of the excitatory amino acids glutamate and 
aspartate, ultimately lead to necrotic cell death. Oxygen and glucose deprivation followed 
by reoxygenation may also induce apoptosis of neurons. [33]  The inflammatory response 
begins within hours of injury and peaks within several days. 
The subacute phase follows necrosis and is characterized by an ongoing 
inflammatory response resulting from reactive gliosis by microglia and astrocytes, as well 
as disruption of the blood-brain barrier which allows blood-borne immune cells from the 
periphery to infiltrate the spinal cord.  Neuronal degeneration signal  microglia to 
upregulate cell surface proteins such as major histocompatability complex II (MHC II) 
leading to transformation into macrophages, with markers being prominent by 3 days 
following injury; however, these markers decline sharply after 3 days and are not evident 
again until 18-20 days following dorsal root axotomy. [34]  Reactive astrocytes begin 
proliferating within 2 days following injury and begin to accumulate at the lesion margins 
within 1 week, peaking at 14 days and still present at 28 days.  Neutrophils infiltrate the 
lesion first, within 6-12 hours following injury with maximum infiltration occurring 
within 24 hours; however, neutrophils disappear from the lesion site at 3 days post-injury.  
Macrophage infiltration from the periphery follows neutrophil infilatration, and 
macrophages persist in the lesion site for weeks.  Schwann cells, meningeal cells, and 
fibroblasts from the periphery also infiltrate the injured spinal cord.  Meningeal cells 
proliferate following injury and migrate into the lesion to aid astrocytes in reestablishing 
the blood-brain barrier. [35]  Demyelination begins within 24 hours and increases over 
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several days as Wallerian degeneration of distal axons progresses.  Interestingly, an 
accurate neurological examination requires patients to be at least 72 hours post-injury, or 
in the subacute phase of injury. [2] 
The late phase, also termed chronic injury, occurs weeks to months following 
injury and is characterized by well-defined cyst formation by two weeks, with some cysts 
containing fluid, followed by resolution of the inflammatory response with a 
disappearance of macrophages.  In post-traumatic cystic cavitation, the size and severity 
of a CNS injury progress from a small area of direct trauma to  greatly enlarged 
secondary injury due to persistent inflammation. [36]  Reactive astrocytes that migrate to 
the margin of the lesion site form the glial scar, which may also include reactive 
microglial cells.  The glial scar serves to repair the blood-brain barrier and encapsulate 
the injury site in order to limit the inflammatory response and resulting cellular 
degeneration. [37]  Ablation of reactive astrocytes adjacent to a forebrain stab injury in 
adult transgenic mice resulted in a failure of blood-brain barrier epair and a sustained 
increase in infiltration of immune cells from the periphery. [38]  The BBB remains 
disrupted for up to 14 days following injury, with areas of greatest glial scarring 
corresponding to areas with the most extensive BBB disruption. [39]  Lastly, late phase 
demyelination may continue to increase for a period of two weeks following injury, even 
in spared axon tracts. [11]  
In summary, spinal cord injury results in cell death, both of neuronal cells and 
their supporting glial cell populations; destruction of the physical structure of axons and 
myelin resulting from Wallerian degeneration; progressive cystic cavitation and the 
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formation of glial scar tissue; and continued destruction of myelin r ative to secondary 
injury or lack of remyelination resulting in a loss of conduction in spared axons. 
 
REGENERATIVE FAILURE OF THE ADULT CENTRAL NERVOUS SYSTEM  
A number of mechanisms have been implicated in regenerative failure of th adult 
CNS following injury and are broadly classified into two categories: intrinsic barriers, or 
an inherent decline in growth capacity that occurs with neuronal cell maturation; and 
extrinsic barriers, or the non-permissive regenerative environment in the adult CNS 
following injury as compared to the permissive PNS and developing CNS environments. 
Proposed mechanisms of intrinsic regenerative failure include a decrease in the rate of 
retrograde transport of injury signals with increasing distance between axotomy site and 
cell body, delayed synthesis and diminished anterograde transport of cytoskeletal proteins 
required for growth cone and axon formation, a developmentally-regulated decrease in 
endogenous levels of neuronal cyclic adenosine monophosphate (cAMP) in mature 
neurons, and variable ability of different neuronal cell types to sustain expression of 
regeneration-associated genes. [9-12] Surviving neurons in the CNS generally do sprout 
axons in an attempt at regeneration; however, this attempt is quickly aborted upon 
encountering the hostile external environment. [13] Proposed mechanisms of extrinsic 
regenerative failure include delayed and incomplete clearance of axon and myelin debris; 
exposure to myelin-associated inhibitory glycoproteins that are not present during early 
stages of development; exposure to inhibitory chondroitin sulfate proteoglycans (CSPGs) 
present in reactive astrocytic glial scar tissue; and a loss of the structural organization of 
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the mature CNS, the formation of cystic cavities, and a lack of supporting neurotrophic 
factors and growth-promoting adhesion ligands that are present during development. 
 
Intrinsic Regenerative Failure 
Embryonic neurons will grow axons when transplanted into the same environment 
that blocks adult axon regeneration, but adult neurons do not regenerate ito embryonic 
environments [40, 41], suggesting intrinsic mechanisms for regenerative f ilure of mature 
neurons. 
Failure of Upregulated Gene Expression and Transport 
Injury signals are transported retrogradely from the site of injury to the cell body 
in the grey matter, and successful regeneration occurs only when the cell body is able to 
increase the rate of transport.  Axotomy at more distal sitesresults in a marked decrease 
in retrograde transport, thus delaying changes in gene expression required for initiation of 
regeneration. [42]  This also corresponds to observations that PNS regeneration rates are 
slower when lesions are far from the cell body. [27]  The synthesis and anterograde 
transport of cytoskeletal proteins, such as actin, tubulin, and neurofilaments, is essential 
for the formation of growth cones and axons during development and regeneratio .  
These cytoskeletal proteins are transported from the cell body to the growth cone by slow 
axonal transport, and successful regeneration occurs only when the cell body is able to 
increase the rate of transport.  CNS neurons do not successfully upregulate gene 
expression and transport rates following injury [43, 44] as compared to the upregulation 
in gene expression demonstrated in the PNS following injury. [45] 
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In addition to mRNA translation and protein synthesis by the cell body, recent 
studies have shown that mRNAs are also transported from the cell body for local protein 
synthesis in developing and mature axons [46, 47], although it is unclear if adult CNS 
axons contain ribosomes. [48]  Protein synthesis in developing axons may allow the distal 
axon to autonomously respond to guidance cues by rapidly changing its direction of 
outgrowth. Injury of mature axons triggers formation of a growth cone through locally 
synthesized proteins and proteolysis in the proximal axon, and locally synthesized 
proteins provide the retrogradely transported signaling complex that initiates the 
regenerative response. Neurotrophins may have the potential to enhanc t e localized 
protein synthesis of axons. 
Reduced cAMP Levels 
Myelin has been shown to inhibit regeneration from mature neurons; hwever, 
embryonic or neonatal neurons are capable of growth on myelin inhibitory m lecules. 
Neuronal cyclic adenosine monophosphate (cAMP) is a cyclic nucleotide whose 
endogenous levels are dramatically higher in young neurons, suggesting that the switch 
from permissive to non-permissive growth on myelin during development is due to a 
developmentally regulated decrease in cAMP levels. [10]   Lesion models of dorsal root 
ganglion neurons that project axons in both the PNS and CNS have shown t at a
conditioning lesion of the peripheral segment one to two weeks prior to a lesion of the 
central segment enables central processes to regenerate with no modification of the 
external environment. One theory regarding the conditioning lesion is that it allows CNS 
axons to overcome inhibition by myelin via a transient increase in cAMP, and that 
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elevation of cAMP is not only necessary but sufficient to promote reg neration. [49, 50]  
Spencer et al. “primed” postnatal CNS neurons overnight with neurotrophins and found 
that they were able to regenerate on inhibitory myelin substrates, nd an increase in 
cAMP levels was able to mimic the effect of this neurotrophin “priming”; in fact, an 
increase in endogenous cAMP levels followed neurotrophin treatment. [50] In vivo 
injection, prior to injury, of cyclic AMP (cAMP) into DRG neurons resulted in 
regenerative sprouting of sensory axons following CNS lesion, with an elongated pattern 
of neurite outgrowth. [51]  Protein kinase A (PKA) is a downstream effector of cAMP, 
and activation of PKA may phosphorylate Rho thus rendering it inactive. [52, 53]  Figure 





Figure 2.7  Signaling Pathways in Myelin-Related Growth Cone Collapse  
(Reprinted from He et al. 2004 [52]) 
 
A conditioning lesion of DRG peripheral segments one to two weeks prior to a 
lesion of the central segment enables central processes to regene ate, suggesting that PNS 
injury activates a “growth program” that improves the inherent growth capacity of mature 
CNS neurons. [54]  Growth-associated protein 43kDa (GAP-43) and cortical 
cytoskeleton-associated protein 23kDa (CAP-23) are proteins localized to the growth 
cone that influence axonal growth and synaptic plasticity. In vivo concomitant 
overexpression of both GAP-43 and CAP-23 has been shown to promote significant 
regeneration of central DRG axons into peripheral nerve implants in ransgenic mice, 
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although not as extensive as the regeneration produced by a conditioning lesion. Also, 
overexpression of either protein alone failed to promote regeneration, demonstrating that 
each proteins is necessary, but not sufficient for regeneration. [55]  The transient 
elevation in cAMP levels following a conditioning lesion may, in part, be responsible for 
the improvement in the mature CNS growth capacity, possibly mimicking that of 
embryonic or newborn neurons whose endogenous cAMP levels are higher. Obviously, a 
conditioning lesion made prior to spinal cord injury is useless clinica ly; however, 
Neumann et al. have demonstrated that conditioning lesions made at the time of spinal 
cord injury and again one week later promoted regeneration within and beyond the lesion 
site, perhaps by elevating cAMP levels or by accelerating retrograde and anterograde 
transport rates, thus enhancing and sustaining intrinsic growth capacity. [56] 
Axonal type also affects regeneration as different axons have different intrinsic 
regeneration capabilities. Cerebellar Purkinje cells of the brain appear to have no 
regenerative response to axotomy; however, spinal motor neurons mount a robust 
regenerative response. [14] Dorsal root ganglia sensory axons regene ate vigorously into 
permissive environments. [48] Deumens et al. presented a detailed review of the 
sprouting responses of descending axon tracts in response to injury and descending axon 
tract-specific regenerative therapies. [12] 
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Extrinsic Regenerative Failure 
Delayed and Incomplete Clearance of Axon and Myelin Debris 
One drawback to the “immune-privilege” of the CNS is a delay in phagocytic 
clearance of degenerating axon and myelin debris, in part due to th delay in infiltration 
of blood-borne immune cells from the periphery and in fewer numbers than seen in the 
PNS; macrophages are rapidly recruited in large numbers to peripheral injury sites. [9] In 
addition, resident reactive microglia that transform into macrophages in the CNS abort 
their phagocytic response at 3 days post-injury. [34] Sensory axon and myelin debris are 
almost completely cleared from peripheral nerve roots by 30 days post-injury; however, 
axon and myelin debris in sensory axons of the spinal cord are still visible 90 days after 
injury. [34] Another factor contributing to differences in clearance is that Schwann cells 
in the PNS exhibit the unique ability to aid in phagocytosis following injury, being the 
primary contributors in the first two days. Myelinating Schwann cells in the distal nerve 
are induced to dedifferentiate into non-myelinating Schwann cells by axon and myelin 
debris and proliferate extensively. In the CNS, however, adult oligodendrocytes will 
either undergo apoptosis or enter a state of rest following injury. [57] Unlike Schwann 
cells in the PNS, oligodendrocytes do not participate in phagocytosis of axon and myelin 
debris in the CNS. 
Inhibitory Molecules in the CNS 
Interaction of regenerating CNS axons with inhibitory molecules results in two 
forms of stalled growth: growth cone collapse and formation of dystrophic endbulbs. 
Growth cone collapse occurs when mature regenerating axons encounter myelin debris 
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and oligodendrocytes following injury. Myelin inhibitors are only exposed after damage; 
adult sensory neurons implanted into degenerating white matter of the adult rat spinal 
cord extended long axons on the outer surface of undamaged myelin. [58] Myelin 
inhibitory molecules arrest normal growth cone progression, causing collapse and often 
retraction into a shrunken, quiescent growth cone.  Growth cones form dystrophic 
endbulbs upon encountering the glial scar and it is thought that they are an aberrant 
growth cone that adult neurons form in order to survive in a hostile environment.  These 
endbulbs have been shown to be highly active structures capable of returning to active 
growth states after extended periods of time with the appropriate stimuli. [39] Myelin 
inhibitors are early impediments to regeneration immediately following injury, before the 
formation of the glial scar. 
Inhibitory myelin-associated proteins 
Regeneration of injured axons recapitulates development to a certin xtent; 
however, the regenerating axons are exposed to molecules not seen during early stages of 
development. Spinal cord lesions in embryos and newborns of higher vertebrat s a e 
capable of robust regeneration following injury; however, axons are no longer able to 
regenerate post-injury in embryonic chicken following myelin formation in the spinal 
cord, suggesting that oligodendrocytes and myelin play an important role in inhibition of 
CNS regeneration. [59]  These myelin inhibitory molecules are thought to prevent 
aberrant sprouting of mature CNS neurons in order to prevent axon connection to 
inappropriate targets; however, following CNS injury, incomplete clearance of myelin 
debris results in growth cone collapse of regenerating axons. Some studi s suggest that 
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myelin inhibitory molecules serve to orient neurite outgrowth in a parllel direction [60, 
61] and in vitro studies demonstrated that disruption of axon tract geometry in 
relationship to myelin is sufficient to inhibit neurite outgrowth. [61] 
The inhibitory molecules in myelin debris of the adult CNS include Nogo-A, -B, 
and -C; Nogo-66, a 66 amino acid sequence found in the extracellular domain of all three 
Nogo isoforms thought to be responsible for their inhibitory function; myelin-associated 
glycoprotein (MAG); and oligodendrocyte-myelin glycoprotein (OMgp). [13, 48, 62-64] 
Additional myelin inhibitory molecules include Semaphorin4D and versican,  
chondroitin sulfate proteoglycan. [48]  Nogo, MAG, and OMgp have been found to 
compete for binding to the same Nogo receptor, NgR, suggesting redundancy in their 
action. [65] The Nogo receptor NgR lacks an intracellular signal ng domain and partners 
with the p75 neurotrophin receptor, the TROY receptor, and possibly other currently 
unknown receptors to activate Rho and its downstream target ROCK, which has 
demonstrated inhibitory influences on axon growth. [66, 67]  Another intracellular 
component of Nogo signaling involves calcium-dependent cytoplasmic protein 
phosphorylation mechanisms; however, the role of calcium in myelin inhibition is not 
completely understood. [52, 68, 69]  
Many groups of CNS axons are capable of regenerating into peripheral nerve 
grafts, suggesting that there are differences in CNS and PNS myelin and that CNS myelin 
is selectively inhibitory.  For example, Nogo has been shown to be highly expressed by 
CNS oligodendrocytes but not by PNS Schwann cells. [70]  In fact, regulated transgenic 
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expression of Nogo-A by PNS Schwann cells impaired axonal regeneration and 
functional recovery after sciatic nerve crush. [71]  
Inhibition by the glial scar 
An unfortunate complication of CNS injury occurs due to the secondary injury 
cascade when a small area of trauma progresses to a much larger cystic cavity that may 
be fluid-filled and is surrounded by glial scar tissue. In Chapter 3 of “CNS 
Regeneration”, Fitch and Silver provide a review of the mechanisms by which glial cells 
contribute to CNS failure to regenerate.  For many years, it was thought that the glial scar 
was simply a mechanical barrier to regeneration because axons will ot traverse a purely 
fluid environment [72]; however, regeneration does not occur even in the absence of a 
fluid-filled cyst at the lesion site, suggesting that there are additional causes of inhibition 
by the glial scar. [9]   
The glial scar is comprised of a lesion core populated by meningeal fibroblasts, 
vascular endothelial cells, and oligodendrocyte precursor cells (OPCs); and a surrounding 
area comprised of reactive astrocytes, OPCs, and microglia. [48]  It has been 
demonstrated that neonatal astrocytes are supportive of axon growth in vi ro, whereas 
mature reactive astrocytes are nonpermissive substrates for axon growth; typically 
dendrites but not axons form on reactive astrocyte substrates. [9]  In response to injury, 
mature reactive astrocytes produce extracellular matrix components of the glial scar, 
including proteoglycans and tenascin, which may inhibit neurite outgrowh.  The ECM of 
the glial scar also consists of hyaluronic acid, the most abundant ECM protein in the 
CNS.   
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Proteoglycans consist of a protein core with covalently attached polysaccharide 
chains termed glycosaminoglycans (GAGs) and are characterized by their GAG 
compositions as chondroitin sulfate, heparin sulfate, keratin sulfate, and dermatan sulfate. 
[9]  Chondroitin sulfate proteoglycans (CSPGs) have been shown to be upregulated 
following injury; they persist in the extracellular matrix ofthe glial scar and inhibit 
neurite outgrowth.  The hyalectan family of CSPGs includes neurocan, aggrecan, 
versican, brevican and these molecules share a common structure that includes an N-
terminal hyaluronic acid binding site and a C-terminal with epidermal growth factor 
(EGF). [73] Other CSPGs include NG2, versican, [73] and biglycan, as well as other 
inhibitory molecules including ephs/ephrins and semaphorins. [48]  Ephrins and 
semaphorins are primary axon guidance molecules that demarcate non-permissive 
regions of the developing CNS for certain classes of neurons. [23] 
Neurocan is expressed by astrocytes and OPCs.  Versican appears to only be 
expressed by immature oligodendrocytes (OPCs) in the adult CNS.  Brevican is one of 
the most abundant CSPGs in the adult CNS and is expressed by astrocyte  and mature 
oligodendrocytes and is present in myelin debris contained in the glial scar.  NG2 is 
expressed by OPCs and may be expressed by reactive astrocytes following injury.  
Phosphacan expression is limited to neuronal tissues and is expressed by both astrocytes 
and OPCs.  Deletion of ephs/ephrins in animals almost completely abo ished reactive 
gliosis by astrocytes thus improving regeneration, and meningeal c lls produce 
semaphorins as well as NG2. [48] 
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CSPGs may inhibit neuronal outgrowth through several mechanisms.  Neurocan 
and phosphacan have high affinity for L1 and NCAM via the chondroitin sulfate 
sidechains, and binding may potentially inhibit homophilic interactions of these cell 
adhesion molecules, thus inhibiting regeneration. [73]  CSPGs are also capable of binding 
to laminin, potentially masking its growth-promoting properties.  An interesting feature 
of CSPGs in the glial scar is that they signal through the Rho/ROCK pathway, the same 
signaling pathway used by myelin inhibitory molecules. [74] 
Loss of Organized Structure and Lack of Growth-Promoting 
Neurotrophic Factors and Adhesion Ligands 
 
In humans, peripheral axons regenerate at a rate of approximately 2-5 mm/day 
following crush injury that leaves the endoneurial tube structure intact  [27, 75]; however, 
transection injury without surgical intervention typically results in slower regeneration 
rates and lack of functional recovery, suggesting that PNS regeneratio  is highly 
dependent on the ensheathed nerve anatomy for guidance. Following degeneration of the 
PNS distal axons, Schwann cells remaining in the phagocytosed endoneurial tubes 
proliferate and align along the basement membrane of the endoneurial tube into linear 
arrays known as Bands of Büngner, providing a spatial scaffold for axon regeneration. In 
addition to their phagocytic activities following injury, Schwann cells a so increase their 
synthesis of surface cell adhesion molecules (CAMs), such as NCAM, NgCAM, and L1; 
they secrete extracellular matrix (ECM) molecules such as collagen, laminin, fibronectin, 
and tenascin; and they produce and spatially present neurotrophic factorssuch as nerve 
growth factor (NGF), neurotrophin 4/5 (NT-4/5), brain-derived neurotrophic factor 
(BDNF), and glial-cell derived neurotrophic factor (GDNF). [26]   
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Although the CNS does not exhibit the ensheathed nerve anatomy like the PNS, 
there is evidence of temporal and spatial alignment of immature glial cells during 
development that provides a bridge-like structure along with ECM molecules, 
predominantly laminin; cell adhesion molecules, such as NCAM and L1; and
neurotrophic factors. [28, 76, 77]  Several studies highlight the importance of organized 
expression of growth-promoting molecules by glial cells during development.  
Temporospatial expression of neural cell adhesion molecule (NCAM) produced by 
neuroepithelial cells aligned to form tunnel-like structures is involved in guidance of 
optic and olfactory axons, and lack of NCAM functions as an axon-refractory barrier. 
[78-80]  During development of the corpus callosum, there is evidence of an aligned glial 
bridge-like structure to guide axons across the midline that disappears n onatally. [81] 
Immature astrocytes oriented perpendicular to corticospinal tract (CST) axons align in 
longitudinal tiers and participate in axon guidance during rat CST development. [82, 83]  
Additionally, laminin produced by aligned immature astrocytes serve  to guide optic 
nerve and corpus callosum axons. [76]  Mechanically lesioned neuron-astcyte mouse 
cortical cocultures treated to prevent glial scarring demonstrated neuron migration and 
neurite outgrowth with increased astroglial laminin production [84], thusreinforcing the 
idea that “unreactive” astrocytes generate an environment permissive to growth. Aligned 
glial/biomatrix bridges developed by culturing neonatal astrocytes on PLA and 
PLA/PLA-b-PEO matrices directed in vitro neonatal cerebral cortex neurite outgrowth 
over the aligned glial cells, thus highlighting importance or temporal and spatial 
alignment in directing neurite outgrowth. [85].  The glial structures that guide developing 
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axons in the CNS disappear upon maturation and are not reformed by mature reactive 
astrocytes following spinal cord injury.  Non-native fibroblasts and meningeal cells that 
migrate in from the periphery following injury may deposit collagen, but no organized 
deposition of ECM occurs. [9]  Finally, incomplete phagocytosis of axon and myelin 
debris and fluid-filled cystic cavities that form at injury site  severely disrupt the 
organized structure of the uninjured mature CNS. 
Schwann cells are the one-stop-shop for PNS neurons providing them with 
guidance, ECM molecules, CAMs, and growth factors required for succe sful 
regeneration following injury; however, glial cells of the mature CNS play a major role in 
mediating the secondary injury cascade following injury, and as a result, mature CNS 
neurons lose the glial support that is evident during CNS development and is required for 
successful regeneration. 
 
REPORTED EXPERIMENTAL APPROACHES TO REGENERATION  
Experimental approaches to regeneration includes pre-clinical  vitro and animal 
models and focus on modification of the non-permissive external environment of the 
CNS and limited studies into modifying the intrinsic regeneration capability of CNS 
neurons. 
Improvement of Clearance 
Clearance of axon and myelin debris occurs rapidly and efficiently in the PNS 
following injury, in part, because of the rapid infiltration of peri heral macrophages into 
the lesion site; therefore, several groups have studied transplants of macrophages 
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activated by exposure to PNS or skin tissue in the injured spinal cord of animal models 
and have demonstrated partial functional recovery. [86-89]  Although this approach is 
controversial because macrophages are believed to contribute to worsening of damage by 
the inflammatory cascade [90], clinical trials of autologous transplants are being pursued 
by two groups: Schwartz and Yoles [91, 92] and Knoller et al. in conjunction with 
Proneuron Biotechnologies (Procord). [93]) 
 
Neutralization of the Inhibitory Environment 
Neutralization of the inhibitory molecules in myelin and the glial scar for CNS 
regeneration involves many different approaches. [14, 48, 62, 94]  
A monoclonal murine IgM antibody (mAB IN-1) has been shown to block the 
myelin inhibitory molecule Nogo-A; in vivo application in the adult rat CNS resulted in 
substantial axon sprouting and some long-distance corticospinal regeneratio  following 
complete transection of the corticospinal tract, which is significant as no spontaneous 
regeneration of corticospinal fibers is typically observed. [95]  A recombinant, partially 
humanized IgG version of the IN-1 antibody (rIN-1 Fab) has demonstrated long-distance 
regeneration of corticospinal axons in adult rats [96], also observed in the marmoset 
monkey following thoracic lesions treated with mAB IN-1. [97]  Clinical trials using anti-
Nogo antibodies are in the planning stages in association with Novartis. [98] 
Intrathecal administration of NEP1-40 derived from Nogo-66, a competitive 
antagonist of the Nogo receptor common to all myelin inhibitors, improved corticospinal 
axon growth and functional recovery following mid-thoracic spinal cord hemisection in 
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adult rats. [99]  An anti-Nogo receptor monoclonal antibody has been shown to promote 
neurite outgrowth of P3 rat DRG neurons culture on CNS myelin substrate . [100]  
Biogen Idec Inc. has licensed Nogo receptor-related therapeutics and may pursue clinical 
trials. [94] 
Semaphorins are inhibitory molecules produced at sites of CNS injury and they 
signal through plexin and neuropilin receptors expressed in neurons.  An in vitro model 
of the astrocyte/meningeal cell interface found that meningeal c lls expressed NG2, 
versican, and semaphorins 3A and 3C, and antibody blocking of NG2 and neuropilin 2 
but not neuropilin 1 promoted DRG axon growth from astrocytes to meningeal cells. 
[101]  Ephrins expressed on astrocytes have been shown to inhibit regeneration, and adult 
mice lacking EphA4 exhibited reduced gliosis and regeneration of corticospinal and 
rubrospinal tracts across the lesion site following spinal cord hemisection, as evidenced 
by anterograde and retrograde tracing. [102]  Astrocyte EphA4 was also blocked by 
monomeric EphrinA5-Fc to produce longer neurite outgrowth in this study. 
Chondroitin sulfate proteoglycans (CSPGs) exist in large quantities n the 
damaged CNS, particularly the glial scar. [48]  Chondroitinase ABC (Ch-ABC) is a 
bacterial enzyme that catalyzes hydrolysis of chondroitin sulfate GAG chains into 
dissacharides that diffuse away, thus reducing the inhibitory effects of CSPGs. 
Administration of Ch-ABC has been shown to induce axonal growth and functional 
recovery in adult rats [103, 104], as well as promote autonomic motor recovery. [105] 
Blocking Rho has the unique potential to overcome inhibition by both myelin and 
glial scar inhibitory molecules, since their signaling pathways appear to converge on this 
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downstream effector.  Blocking RhoA with C3 transferase (botulinum toxin) enabled 
regeneration following over-hemisection of the adult mouse spinal cord. [106]  In 
addition to enhancement of regeneration, inactivation of Rho is also believed to offer 
neuroprotection by protecting cells from apoptosis, and inactivation of Rh kinase may 
alleviate pain following injury. [107]  Cethrin® (BioAxone Therapeutic, Inc.) is a Rho 
antagonist currently undergoing clinical trials. [98, 108] 
Neuronal cyclic adenosine monophosphate (cAMP) is a key player in the i trinsic 
inability of the CNS to regenerate, perhaps by influencing its ability to overcome 
inhibition by myelin and glial scar molecules.  The pharmaceutical rolipram, originally 
developed as an anti-depressant, is a phosphodiesterase inhibitor that preven s hydrolysis 
of cAMP, and it has been shown to prevent the reduction in endogenous cAMP levels in 
adult rats following spinal cord contusion, and combined with Schwann cell grafts 
improved axon sparing and myelination. [109]  Rolipram delivery in conjunction with 
implantation of embryonic spinal tissue improved axon growth into the implant and 
attenuated reactive gliosis. [110] 
The application of treatments to block inhibition by the CNS external 
environment must be approached with great care and designed to only affect injured 
neurons, as they not only enhance regeneration but also promote significant sprouting and 
plasticity, which may account for functional recovery.  Maladaptive sprouting and growth 
of non-injured neurons may be an undesirable side effect of these types of treatments.  
Hyperalgesia is one side effect that has resulted from aberrant sprouting of uninjured 
small pain fibers in nerve growth factor-treated animal models. [111] 
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Delivery of Neurotrophic Factors 
Neurotrophic factors are key nervous system regulatory proteins that modulate 
neuronal survival, axonal growth, synaptic plasticity, and neurotransmission.  They have 
also been shown to promote and direct growth cone motility [112]; they exhibit a 
chemotactic effect for axon guidance, and they aid in sensory nerve growth across the 
PNS-CNS transition zone.  As a result, their role in axon development and regeneration is 
being studied extensively for application in spinal cord repair [28, 94, 113-115].     
The family of neurotrophic factors includes nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), 
ciliary neurotrophic factor (CNTF), glial cell line-derived growth factor (GDNF), and 
acidic and basic fibroblast growth factor (aFGF, bFGF). Schwann cells produce 
neurotrophic factors following PNS injury; however, levels following spinal cord injury 
are almost undetectable.  The neural responses promoted by neurotrophic factors are 
summarized in Table 2.1. [28] 
NEURAL RESPONSES PROMOTED NEUROTROPHIC FACTORS 
Motor neuron survival BDNF, NT-3, NT-4/5, CNTF, GDNF 
Motor neuron outgrowth BDNF, NT-3, NT-4/5, CNTF, GDNF 
Sensory neuron survival  NGF, NT-4/5, GDNF 
Sensory neuron outgrowth  NGF, BDNF, NT-3 
Spinal cord regeneration  NGF, NT-3, CNTF, FGFs 
Peripheral nerve regeneration  NGF, NT-3, NT-4/5, CNTF, GDNF, 
FGFs 
Sensory nerve growth across PNS-CNS 
transitional zone 
NGF, NT-3, GDNF, FGFs 
 
 




There is a significant amount of overlap in the responses promoted by 
neurotrophic factors, and this must be taken into account when considering their use in 
therapeutic applications.  For example, NGF was the first and most widely studied 
neurotrophic factor and is best known for its essential role during the dev lopment of 
peripheral sensory and sympathetic neurons [116]; however, it has been shown to be 
clinically useless for regeneration of peripheral nerves becaus it affects pain-sensitive 
neurons, resulting in hyperalgesia, or increased sensitivity to pain. [117]  NT-3 is useful 
for regenerating corticospinal axons [77]; however, NT-3 can trigger apoptosis of BDNF-
dependent neurons. [118] 
Neurotrophins have a very short half-life, are digested in the gastrointestinal tract, 
and do not pass the blood-brain barrier; as a result, oral or systemic d livery will not 
promote regeneration of CNS neurons and may result in unwanted side effects due to 
nonspecific delivery. In addition, there is rapid clearance of drugs injected directly into 
the spinal cord due to the constant exchange of cerebrospinal fluid (CSF).  As a result, 
delivery methods must be tailored to provide biologically relevant amounts of long-term, 
localized neurotrophins at the site of injury in order to avoid unwanted side effects.  
Reviews of reported methods of delivery include direct injection, continuous infusion, in 
situ gene therapy, and transplantation of ex vivo genetically engineered cells. [28, 113, 
114] 
Direct injection to the cerebrospinal fluid (CSF) by means of 
intracerebroventricular, intraparenchymal, or intrathecal infusion does n t provide long-
term delivery of growth factors because there is rapid clearance due to the constant 
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exchange of CSF and does not provide localized delivery. [114]  Continuous infusion 
using an implanted osmotic minipump may be used as a temporary intervention strategy 
following spinal cord injury or to study the effects of neurotrophins; however, it is not a 
solution for extended delivery because depleted pumps have to be replaced at 4 weeks, 
and it also does not provide localized delivery. [119, 120] 
In situ gene therapy via vector-mediated expression of neurotrophic factors to the
spinal cord has advantages over local or systemic administration.  Vectors can be 
delivered to the spinal cord by single injection, expression can be targ ted to lesioned 
neurons, and vector expression of a neurotrophic factor mimics their physiological 
production. [114]  Two types of vector systems exist: viral vectors and nonviral vectors.  
Viral vectors include: (1) herpes viral vectors (HSV), (2) adenoviral vectors, (3) adeno-
associated viral vectors (AAV), and (4) lentiviral vectors (LV).  Nonviral vectors are 
typically not used for this application due to their inefficiency.  Table 2.2 is a summary of 
research groups studying the viral-mediated vector expression of neurotrophins.  AAV 
and LV vectors do not display detectable inflammatory or cytotoxic responses and may 
be a good choice for future gene therapy; however, HSV and adenoviral vectors are not 
suitable because they require immunosuppression and are cytotoxic. 
 GROUP VECTOR GROWTH FACTOR  
1. Geschwind et al., 1994 [121] HSV vector NGF 
2. Zhang et al., 1998 [122] Adenoviral vector NT-3 
3. Ruitenberg et al., 1998 [123] AAV vector BDNF 
4. Hottinger et al., 2000 [124] LV vector GDNF 
 
Table 2.2  Groups Researching In Situ Gene Therapy 
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Ex vivo gene therapy is a combination therapy involving i  vitro genetic 
modification of autologous cells to deliver a specific growth factor, followed by 
transplantation of the cells back into the host.  This approach eliminates the risk of 
immunological rejection and may provide a high concentration of long-term, localized 
growth factor delivery to a site of injury [113].  Table 2.3 is a ummary of research 
groups studying this method of neurotrophic factor delivery. 
 
 GROUP CELLS GROWTH FACTOR  
1. Grill et al., 1997 [125] Fibroblasts NT-3 
2. Tuszynski et al., 2002 [126] Fibroblasts NGF 
3. Lu et al., 2003 [127] Neural stem cells NT-3 
4. Tuszynski et al., 2003 [128] Fibroblasts NT-3 
5. Blesch et al., 2004 [129] Fibroblasts NT-4/5 
6. Lu et al., 2005 [130] Marrow stromal cells BDNF 
 
Table 2.3  Groups Researching Ex Vivo Genetically Engineered Cells 
 
Groups 1, 3, and 5 reported partial amelioration of functional deficits by the 
Basso, Beattie, and Bresnahan (BBB) locomotor rating scale for rats or other functional 
test methods.  Groups 2, 4, and 6 reported extensive axonal growth following cell 
transplantation.  Additional examples of genetically-modified cells used for neurotrophic 
factor delivery have been reported by Schmidt and Leach. [28]  None of the groups 




The idea of bridging strategies in the CNS arose from the need to restore structure 
and provide necessary adhesion molecules and growth factors in order to prom te 
regeneration of axons, much in the same way immature CNS glia provide these elements 
for developing axons and PNS Schwann cells provide these elements for developing and 
injured PNS neurons.  Several approaches are currently under investigation, including 
transplantation of fetal and embryonic tissue, mechanically-engineered nervous tissue 
constructs, peripheral nerves, and cells. 
Nervous Tissue Transplantation 
Neural tissue transplants from human embryos and fetuses have shown promise in 
promoting CNS regeneration in animal models.  Transplants of fetalspinal cord 
following resection lesions of adult rat spinal cord and contused adult rat and cat spinal 
cord demonstrated short-distance regeneration into the grafts and atte uation of scar 
tissue but limited regeneration across the host/graft interface. [131-133] These neural 
tissue transplants have the potential to not only replace cells but may also provide sources 
of growth factors, improvement of conduction by remyelination, or neuroprotection.  
Despite the inherent issues in scale-up as well as the ethical c allenges, human fetal 
spinal cord tissue has been grafted into human patients with syringomyelia in clinical 
trials. [134, 135]  
Mechanically-Engineered Nervous Tissue Constructs 
Another unique approach involves the development of transplantable tissue 
constructs comprised of DRG axons induced to grow by application of mechanical stretch
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to the central portion of the axon, thus mimicking the growth of integratd nerves and 
axon tracts that do not have growth cones and are under mechanical strain du ing 
development. [136]  Pfister et al. created 5 cm long axon tracts in 8 days, encased them in 
an 80% collagen hydrogel, and inserted them into a poly(glycolide) (PGA) conduit 
(Neurotube®).  Nervous tissue constructs could be grown at the rate 1 cm/day up to 10 cm 
in length using this stretch-growth system.  Collagen hydrogel-coated 10 mm long 
constructs were implanted into rats 10 days following modified lateral hemisection injury 
and were found to survive 4 weeks following implantation and to extend axons int  the 
host spinal cord tissue. [137]  This approach not only serves to bridge the injury site but 
may also circumvent the issue of long-distance regeneration in the inhibitory CNS 
environment by potentially allowing the creation of new intraspinal connections. 
Peripheral Nerve Grafts 
In the 1980’s, Richardson et al. established that regeneration of CNS axons into 
autologous peripheral nerve grafts in rats could be accomplished as evidenced by 
retrograde tracing, although functional recovery was lacking, the axons did not leave the 
graft, and corticospinal axons did not grow into the graft.  [138, 139]  These studies 
reinforced the idea of the permissive regeneration environment of the PNS, and in fact, 
peripheral nerve contains Schwann cells that aid in phagocytosis, production of ECM and 
cell adhesion molecules as well as neurotrophic factors, and remyelination following 
peripheral nerve injury.   
Autologous peripheral nerve grafts are typically derived from cutaneous nerves, 
such as the sural or saphenous nerve, with up to 40 cm available length and 2-3 cm 
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diameter. [28]  It is interesting to note that the sural and saphenous nerves are two of the 
most vascularized peripheral nerves and are therefore considered extr mely suitable for 
vascularized grafting. [29]  Autologous grafts are advantageous becaus  they reduce the 
risk of immune rejection; however, donor site morbidity is a major drawback, and non-
critical sensory nerves must be chosen thus limiting availability.  Peripheral nerve 
allografts are an alternative and have the advantages of large supply and no donor site 
morbidity; however, there is a risk of disease transmission and immunosuppression is 
required during the time it takes cells in the allograft to be replaced with host cells. Even 
so, allografts have been used clinically and may not require long-term 
immunosuppression. [140] 
Autologous intercostal nerves with fibrin glue and acidic fibroblast growth factor 
(aFGF) were implanted into monkeys after lateral spinal hemisection and demonstrated 
regeneration of myelinated CNS axons into the graft but not beyond the lesion site. [141]  
Cheng et al. demonstrated regeneration of corticospinal axons into intercostal nerve 
implants with fibrin glue, aFGF, and compressive wiring in adult paraplegic rats [142], 
and extended their studies to one case of peripheral nerve transplant into a human 
paraplegia patient with a 4-year old ASIA-C injury. [143] The subject r ceived a sural 
nerve graft with fibrin glue and aFGF. Two and one-half years following the surgery his 
functional status improved from wheelchair-bound to ambulatory and ASIA-D 
classification. Although this case included no control subjects and is contradictory, it 
does suggest that combination therapies may be of real benefit to patients, even those 
with chronic spinal cord injury.   
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Cell Transplantation 
Several cell types are under investigation for use in bridging strategies, including 
Schwann cells, olfactory ensheathing cells (OECs), and stem cells. [28, 94, 144, 145] 
Schwann Cells 
Schwann cells are key players in the success of peripheral nerve regeneration and 
in the success of CNS regeneration into peripheral nerve grafts, so i  is no surprise that 
grafts of these cells are being pursued as a spinal cord therapy.  Richardson et al. 
documented one of the earliest attempts at bridging a spinal cord inju y in the 1980’s 
where regeneration of CNS axons into autologous peripheral nerve grafts in rats was 
accomplished as evidenced by retrograde tracing. [138, 139]  Schwann cell 
transplantation for CNS repair was a logical next step and has demonstrated varying 
degrees of axonal regeneration and partial functional recovery in animal models. [94, 
145, 146]   
These cells also migrate into the injured spinal cord, possibly from the dorsal and 
ventral roots, upon disruption of the blood-brain barrier and have been found in long-term 
human spinal cord injuries, indicating that they are able to survive in the human CNS 
environment as abnormally-organized tumors termed Schwannomas, but in a detrimental 
manner causing compression of CNS axons. [147]  Schwann cells in the PNS provide 
spatial alignment via linear arrays known as Bands of Büngner; however, Schwann cells 
do not migrate along CNS white matter tracts, suggesting that they may not provide 
spatial alignment for CNS axons. [148]  Schwann cells may also have t e unique ability 
to aid CNS axons in remyelination following regeneration; however, it has been 
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demonstrated that the cues for myelination in the CNS and PNS are different, and that 
nerve growth factor (NGF) promotes myelination by Schwann cells but reduces 
myelination by oligodendrocytes [149], a factor that warrants further investigation and 
should be taken into account when designing combination therapies with Schwann cell 
grafts.  Genetic engineering of Schwann cells to alter interactions with migration and 
myelination cues is a potential way to account for these differences. [146] 
Challenges facing Schwann cell grafts include failure to regen rate axons out of 
the graft, lack of remyelination of axons beyond the injury site, and unfavorable 
interactions with astrocytes leading to increased inhibitory CSPG production. [146]  As a 
result, several groups are studying ex vivo genetic modification of Schwann cells in order 
to overcome these challenges.  Schwann cells genetically modified to secrete upregulated 
concentrations of NGF were grafted into the midthoracic region of the uninjured adult rat 
spinal cord and were found to survive for up to one year and to induce robust growth and 
myelination of neurotrophin-receptive sensory axons; however, it was noted that 
Schwann cell grafts may enlarge over time, possibly attributable to immortalization of the 
cells after multiple passages in vitro. [150]  Expression of neural cell adhesion molecule 
L1 on Schwann cells and axons correlated with axon-Schwann cell ensheathment, and 
transduction of Schwann cells to overexpress NGF robustly increased axonal growth, 
following implantation into adult rat spinal cord injury. [151]  Schwann cells genetically 
modified to secrete upregulated concentrations of BDNF enabled supraspinal axon 
regeneration across and beyond the transection site in an adult rat model. [152]  Genetic 
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modification may be a viable method of overcoming the inherent challenges i  Schwann 
cell transplantation strategies. 
Olfactory Ensheathing Cells 
One of the major issues impacting all bridging techniques is that regenerating 
axons do not want to leave the permissive substrate and reenter the inhibitory CNS 
environment to reconnect with their target synapses.  Olfactory ensheathing cells (OECs) 
are glial cells of the olfactory system, and the olfactory system has the distinctive 
capacity to support neurogenesis throughout life [153].  OECs have the unique i trinsic 
ability to guide and ensheath, but not myelinate, new olfactory receptor axons into the 
CNS across the normally inhibitory PNS-CNS transition zone [154, 155], and are thought 
to have the potential to aid regenerating axons in navigating inhibitory environments.  
Another theory is that OECs aid in preventing an astrocytic response, thus limiting 
expression of inhibitory CSPGs. [28, 145]  OECs are thought to be capable of migrating 
through glial scar regions, as studies utilizing suspension transplant  of OECs enabled 
regenerating corticospinal axons to cross the lesion site in adult r ts [156, 157]; however, 
a combination of Schwann cells and OECs plus administration of chondroitinase ABC 
following complete spinal cord transection in adult rats produced improvements in 
functional scores but no evidence of regeneration of corticospinal or reticulospinal tracts. 
[158]  Major concerns with studies of this cell type include the methods of preparation. 
[153]  Animal studies conducted have used neonatal and adult cells as well as different 
purification methods, such that the impact of other cell types on results cannot be 
elucidated. [154]  There is also recent controversy as to whether these cells actually 
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enable axons to regenerate past the lesion site, or if the functional recovery seen is a 
result of plasticity and neuroprotection, as there is little evidence to support that OEC 
grafts are able to reestablish functional connections as of yet [159], and migration of 
injected OECs does not appear to be different than migration of injected bone marrow 
stromal cells or fibroblasts. [160] 
Another caveat of this approach is that centrally-derived autologous cell ources 
from the olfactory bulb have been used in most animal studies; however, harvest of these 
cells compromises the host’s sense of smell, so peripherally-derive  OECs from olfactory 
endothelium are being explored as a viable alternative. [28]  These peripherally-derived 
cells may not behave the same as the centrally-derived cells and will require further 
testing.  Even with the discrepancies in reported results from animal models, 
transplantation of human fetal and adult OECs is currently one of the larg st human 
clinical trials, being pursued in China.  [161-164] 
Embryonic and Adult Stem Cells 
Significant loss of neurons and glial cells occurs following spinal cord injury.  
Pluripotent stem cells are sources for new cells in embryos that are capable of indefinite 
self-renewal and differentiation into any cell type.  In adults, multipotent progenitor cells, 
also called adult stem cells, are sources for new cells that are capable of differentiation 
into a limited number of cell types. [94, 165]  These cells have the potential to not only 
bridge the injury site, but may also be able to replace cells that have been lost to injury.  
Embryonic stem (ES) cells have the advantage of being a potential indefinite cell 
source and are being studied extensively for their potential use in spinal cord injury. [140, 
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166]  ES cells from mice were committed to the nervous system lineage by exposure to 
retinoic acid and transplanted into rats more than 9 days following injury; the 
transplanted cells differentiated into neurons, astrocytes, and oligodendrocytes and 
promoted some functional recovery and remyelination, although regeneratio  has not 
been demonstrated yet. [167]  Major concerns with embryonic stem cells include the 
ethical debate regarding their use and the long-term immunosuppresion that is required 
following the transplant of foreign cells.  Spinal cord injured patients are vulnerable to 
infection, and long-term immunosuppression in these patients is contraindicated.  One 
method that is being developed to avoid the use of foreign cells is somatic-cell nuclear 
transfer, which allows the generation of “autologous” embryonic stem cells by replacing 
the nucleus of a human egg with the nucleus from a somatic cell of the patient, then 
allowing the embryo to develop to the blastocyst stage from which ES cells can be 
harvested and grown in culture. [140]   
Another source of new cells is the endogenous stem cells in the mature CNS that 
are capable of differentiating into neurons and glial cells, termed neural progenitor cells 
(NPCs) [168], but typically only produce oligodendrocytes and astrocytes in the spinal 
cord. [14, 140, 169]  These cells reside around the central canal of the spinal cord. [140]  
Mouse NPC grafts were found to constitutively secrete several neurotrophins and 
promoted extensive axon growth in adult rats following dorsal column lesions. [127]  
Glial cell progenitors are multipotent cells with restricted fates, and include cells capable 
of differentiating into myelinating Schwann cells in the PNS or oligodendrocytes in the 
CNS.  Transplantation of these cells has been shown to remyelinate axons but has not 
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demonstrated axonal regeneration. [170]  Disadvantages of these cell types is that their 
populations may also be significantly reduced upon injury to the spinal cord, biopsy is 
required to obtain this cell source, and it does take time to grow en ugh cells in the 
laboratory for transplantation; however, their advantages lie in that they are a true 
autologous cell source in comparison to ES cells and it may be possible to stimulate their 
response in vivo, thus avoiding transplantation altogether. [94] 
The ability of embryonic and endogenous stem cells to proliferate and their multi-
potentiality make them ideal candidates for CNS regeneration; however, preventing 
proliferation of undesirable cell and tissue masses through controlled diff rentiation is of 
utmost importance and is a significant factor in designing implantation strategies. [171]  
 
CLINICAL THERAPIES AND TRIALS  
Current Clinical Therapies for Spinal Cord Injury 
Methylprednisolone sodium succinate (MPSS) was the first and is currently the 
only treatment for the management of acute spinal cord injury, and h s been adopted as 
the standard of care since 1990 in most of North America [2]; however, no official FDA 
review of the drug for this indication has been sought and the analysis of the data 
supporting its use for SCI has been criticized. [172]  This steroid drug, when 
administered within 8 hours of injury, is thought to attenuate the secondary injury 
cascade and improve functional recovery; however, the National Acute Spinal Cord 
Injury Studies (NASCIS) II and III only showed modest improvement in patients 
receiving MPSS, with extensive complications including sepsis, pneumonia, and potential 
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steroid myopathy. [2, 14, 98])  Although controversy regarding the effectiveness and 
safety of MPSS remains, establishment of the 8 hour “therapeutic window” by the 
NASCIS clinical trials led to evaluation of other neuroprotective pharmacological 
therapies, including GM-1 ganglioside (Maryland and Sygen) and numerous other 
candidates. [173]  Researchers are also investigating the neuroprotective effects of mild 
hypothermia (about 92°F) for several hours immediately following spinal cord injury. [3]  
One major issue confounding results from pharmaceutical clinical tr als for acute SCI is 
inconsistency in the use of methylprednisolone in conjunction with the new 
pharmaceutical agents being tested and lack of control for the use of m thylprednisolone 
in the studies. [2] 
The ultimate goal for a spinal cord injured patient is recovery of function, which 
may result from axonal regeneration, nervous system plasticity, res oration of conduction 
by remyelination of spared axons, or any combination of these factors. Rehabilitation 
following spinal cord injury is a clinical therapy that may improve motor recovery of 
postural and locomotor tasks, such as standing and stepping, by taking advantage of 
peripheral sensory information that can be used by the spinal cord without nvolving the 
brain, thus demonstrating the remarkable plasticity of spinal motor neu al circuits to 
“learn” tasks. [174]  Although rehabilitation is not a useful strategy in and of itself to 
promote axonal regeneration, it has the capacity to improve patient quali y of life now, 
depending upon the type of injury sustained [175], and its potential to limit muscle 
atrophy may ultimately improve functional recovery from reinnervation of muscle targets 
by regenerated motor axon tracts.   
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Standardization of Animal Studies and Clinical Trials 
Common animal spinal cord injury models include contusion, transection, 
compression, ischemic, and combinations of these four. [94]  Contusion injuries represent 
the largest sect of human spinal cord injuries.  One major problem with most animal 
contusion models is that they are applied to the dorsal surface following laminectomy 
resulting in a posterior compression injury, which standardizes the location and severity 
of injury; however, most human injuries are the result of ventral impact associated with 
anterior compression of the vertebrae. [33]  Another issue is the contusion device speed is 
much slower and results in less impact than what is typical for most human injuries.  In 
addition, the compressive force in contusion models is typically removed immediately 
after injury whereas it may be hours or days before a human injury is decompressed. 
[108]  The Basso, Beattie, and Bresnahan (BBB) locomotor rating scale has been widely 
accepted as a method to assess locomotor function in rats following spinal cord contusion 
injury [176]; however, there is no correlation of the BBB scale to the ASIA scale used for 
human injuries, and differences in innate immune and inflammatory responses to injury 
compromise the predictive value of findings in rats. [108]  Primate models are being 
explored but their expense is a significant limiting factor.  True regeneration is difficult to 
ascertain in contusion models.  Complete transection models allow undeniable 
determination of regeneration, but these models are not representative of the majority of 
human injuries nor do they generate the cystic cavitation more commonly seen with 
contusion injuries. [94] 
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It has been demonstrated repeatedly that functional improvement does not 
necessarily correlate to axonal regeneration, and axonal regeneatio  does not necessarily 
produce functional improvement.  Demonstration of functional regeneration (axonal 
regeneration with functional recovery) must be validated by several criteria, including 
anatomical tracing, specific behavioral tests corresponding to the regenerated axon 
phenotype, electrophysiology to confirm connectivity, and ultimately, subsequent 
reinjury of the regenerated axons to demonstrate their requirement for functional 
recovery. [13] 
There is a great need for standardization of human clinical trials for spinal cord 
injury, as is evidenced by several reviews dedicated to discussing i ues with past and 
current human clinical trials. [2, 98, 108, 177]  In response to the lack of standardization, 
the International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP) supported 
an international panel charged with reviewing the methodology for clinical trials in spinal 
cord injury, and they have established guidelines for future clinical trials. [178-181] 
 
Worldwide Clinical Trials 
As discussed previously, clinical trials investigating implantation of activated 
autologous macrophages (ProCord®; Proneuron Biotechnologies) and the Rho pathway 
antagonist, Cethrin® (BioAxone Therapeutic, Inc.) in patients with thoracic and cervical 
SCI are currently underway. [98, 173]  Also, a large-scale clinical trial investigating 
transplantation of human fetal and adult OECs is currently being pursued in China. [98, 
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161, 163, 164]  Figure 2.8 represents a summary of recent human clinical trials around 
the world. [98] 
 
Figure 2.8  Worldwide Clinical Trials 
(Reprinted from Tator 2006 [98]) 
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CONCLUSION  
Most of the current approaches in human clinical trials involve either peripheral 
nerve grafts or cell transplantation.  Peripheral nerve grafts fce challenges of limited 
availability and donor site morbidity associated with autografts, and the immune 
complications inherent to allographic or xenographic transplantation, along with potential 
complications arising from cell types within peripheral nerve that are foreign to the CNS.  
Inflammation within the CNS is particularly detrimental and may exacerbate existing 
injury.  Cells are an excellent source of the myriad of factors required for regeneration; 
however, a major limitation of all cell transplantation approaches is the time required to 
isolate, purify, genetically modify, and expand suitable autologous cells for 
transplantation, or the immune complications inherent to allographic or xenographic 
transplantation.  Cells may produce undesirable side effects and do notallow for specific 
delivery of molecules without genetic modification.  Cell transplantation strategies also 
face the unique challenges of cell survival and migration and do not necessarily address 
the disorganized structure of the injured CNS; however, current appro ches seek to 
address these challenges by incorporating cells within biomaterial-based scaffolds with 
channels to improve cell survival, limit migration, and provide guidance for extending 









Most of the current approaches in human clinical trials involve either peripheral 
nerve grafts or cell transplantation; however, biomaterial-based bridging strategies are an 
alternative approach with a wide range of applications for neural repair.  This chapter will 
briefly review the incorporation of biomaterial scaffolds into cell transplantation 
approaches in order to improve cell survival, limit migration, and provide guidance to 
regenerating axons, but will ultimately focus on acellular biomaterial-based bridging 
strategies with combination therapy for synergistic improvement of neural regeneration. 
 
BIOMATERIALS FOR NEURAL APPLICATIONS  
Biomaterials used for bridging strategies may be classified into two main 
categories: natural materials, including ECM components and other natural polymers; 
and synthetic polymers . [28, 171].   
Natural Materials 





ECM proteins Collagen, fibronectin, laminin, 
Proteoglycans Permissive heparin sulfate proteoglycans (HSPGs) [182] 
Glycosaminoglycans Hyaluronic acid 
Fibrinogen/fibrin gels Blood clotting 
Self-assembling 
peptide scaffolds 
Various peptides [183] 
Alginate Brown algae (seaweed, giant kelp) 
Agarose Red algae or seaweed 
Chitosan  
 
Chitin/exoskeleton of crustaceans (shrimp, crabs) and 
insects, bacterial and fungal cell walls 
Matrigel™ BD Biosciences 
 
Table 3.1  Natural Polymers used for Neural Scaffolds [28, 171] 
 
Type I collagen and laminin have proven to be useful molecules for spinal cord 
repair; however, fibronectin has not demonstrated significant promise. [171] Fibronectin 
in the CNS is associated with macrophages and endothelial cells and increased deposition 
has been found in active multiple sclerosis lesions [184], so it is not an ideal substrate for 
CNS repair.  Matrigel™ is a commercially available hydrogel material generated from 
mouse Englebreth-Holm-Swarm (EHS) sarcoma that not only contains basement 
membrane components such as collagen, laminin, and proteoglycans; but also matrix 
degrading enzymes, their inhibitors, and growth factors.  Alginate hydrogels and alginate 
hydrogels with fibronectin have been shown to possess less bioactivity than Matrigel in 
inducing proliferation of cultured cells, maintaining morphology, and induci g DRG 
neurite outgrowth. [185]  Also, alginate is not strictly biodegradable; however, 
modification by crosslinking with calcium enables dissolution through calcium chelation, 
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and ultra purified sources of alginate must be used due to cytotoxic impurities present in 
commercial sources. [171]   
Natural polymers are biodegradable because they form hydrogels that are 
susceptible to enzymatic degradation; however, this also limits their mechanical and 
design properties and they typically require some type of adhesive (e.g., fibrin glue) to 
hold them in place.  Disadvantages of these materials include a lack of control over 
degradation rates, potential inconsistencies in material quality between different batches, 
and potential for microbe or virus contamination. [186]  Chitosan purity is of utmost 
importance for those individuals with shellfish allergy due to the risk of anaphylactic 
shock. 
Synthetic  Materials 
Synthetic biomaterials are currently under investigation for use in bridging 
strategies for spinal cord repair because of the ability to customize their chemical and 
physical properties, including degradation rate, porosity, and mechanical strength.  For 
example, these materials can be designed to be tear resistant for ease in handling and 
gluing or suturing.  Another advantage of synthetic biomaterials is the ability to fabricate 
them into virtually any design through a variety of polymer processing methods.  Table 




POLYMER ABBREV DEGRADABLE COMMENTS 
Poly(glycolide) PGA Biodegradable FDA approved 
Poly(lactide) PLA Biodegradable FDA approved 
Poly(lactide-co-glycolide) PLGA Biodegradable FDA approved 
Poly(D,L-lactide) PLLA Biodegradable FDA approved 
Poly(caprolactone) PCL Biodegradable  
Biodegradable 
poly(urethane) 
 Biodegradable  
Poly(organo phosphazene)  Biodegradable  
Poly(ethylene glycol) PEG Biodegradable FDA approved 
Polycarbonate  Biodegradable  
Poly(3-hydroxybutyrate)  Biodegradable  
Poly(vinylidene fluoride) PVDF Nondegradable Piezoelectric 
Poly(pyrrole) PPy Biodegradable Electrically 
conducting 







Nondegradable Inert, impermeable 
Poly(2-
hydroxyethylmethacrylate) 









PHPMA Nondegradable  
Poly(acrylonitrile-co-
vinylchloride) 
PAN/PVC Nondegradable  
 
Table 3.2 Synthetic Polymers used for Neural Scaffolds [28, 171] 
 
Silicone has been studied in research and clinical settings since the early 1960s; 
silicone and ePTFE are impermeable materials that limit nutrie t and waste transport into 
and out of the scaffold and cell permeation of the scaffold.  Although porous 
nondegradable materials have been developed, nondegradable materials used  implants 
traditionally pose a high risk of infection and chronic inflammation, and when used for 
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neural scaffolds, they cause chronic reactive gliosis and compression of regenerated 
nerves as they remyelinate [187, 188]; therefore, biodegradable materials are preferred.  
Tunable biodegradation is important not only to ensure that the material rem ins intact 
long enough for regeneration of axons through and out of the graft, but also to ensure that 
the material is sufficiently degraded before remyelination of axons occurs to avoid 
compressing the newly regenerated nerves.  
 
DESIGN OF NEURAL SCAFFOLDS 
Gels and Sponges 
Gels and sponges have limited applicability in long-distance spinal cord 
regeneration therapies and are not suitable to provide guidance to regenerating axons; 
therefore, they will be briefly discussed.  Gels are viscous, cross-linked liquids and are 
useful for filling small cavities such as cystic cavities formed from contusion injury or 
small gaps between transected nerves.  For example, PEG fusiogens coupled with PEG 
hydrogels as a tissue adherent have been used to fuse severed nerve endings together to 
maintain continuity. [189]  Sponges are porous structures with slightly higher mechanical 
strength that can fill a slightly wider defect than gels.  In situ thermoreversible gelation of 
agarose gels has been used for simultaneous neurotrophin delivery and conformational 
repair of an irregular spinal cord defect, and supported adult rat neuri e xtension into the 
implant.  [190]  Collagen impregnated poly-2-hydroxyethyl methacrylate sponges 
implanted into complete adult spinal cord lesions limited cystic cavitation and enabled 
axon penetration into the sponge. [191]   
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Tubes and Fibers 
Tubes and fibers are potentially the most appropriate scaffold for long-distance 
regeneration of axons because of their guidance capabilities.  Figure 3.1 demonstrates 
some of the properties of such devices for nerve guidance that have demonstrated 




Figure 3.1  Desired Properties of Bridges for Nerve Guidance 
(Reprinted from Schmidt and Leach [28]) 
 
Electrical Activity 
Electric fields (EFs) resembling those in the developing and regenerating nervous 
systems steer growth cones towards the cathode, and recent research i  examining the 
role of galvanotactic mechanisms in neurite outgrowth and the specific signaling 
molecules involved.  Growth cone steering by EFs has been shown to require dynamic 
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microtubules, microfilaments and regulation of filopodia and lamellipodia by the 
GTPases Cdc42 and Rac. [192]  In bovine corneal epithelial cells, attenu ion of Cdc42 
signaling abolished galvanotaxis and enhanced contact guidance wheras attenuation of 
Rho signaling enhanced galvanotaxis and Rho stimulation enhanced contact guidance. 
[193, 194]  These are the same molecules implicated in glial scar and myelin inhibition of 
neurite outgrowth, and the negative charge of glycosaminoglycans on sulfated 
proteoglycans may contribute to their inhibitory effect on neurite outgr wth.  Cationic 
biopolymers such as chitosan have demonstrated longer neurite outgrowth than anionic 
biopolymers such as alginate. [195-197]  Polypyrrole (PPy) is an electrically conducting 
polymer that has been shown to support neurite outgrowth through electrical s imulation 
of the membrane [198, 199] Poled PLGA tubes implanted into a 1 cm rat sciatic nerve 
gap demonstrated increased numbers of regenerated and myelinated axons as c mpared 
to unpoled tubes 4 weeks postlesion. [200] 
Mechanical Properties 
 
Mechanical properties are a somewhat overlooked design element for eural 
scaffolds, in part because the response of spinal cord tissue to mechanical loading is not 
well understood; however, recent studies are focused on characterizing the viscoelastic 
behavior of the spinal cord.  [201-204]  Although scaffolds must be designed to r sist 
collapse upon implantation, materials that are significantly stiffer than the surrounding 
tissue may lead to necrosis and inflammation. [205] 
Several groups have reported discrepancies in the values of elastic (Young’s) 
modulus of the spinal cord using different measurement methods.  The reported modulus 
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as measured in dogs and cats is estimated to be between 200-600 kPa; however, 
significant increases in modulus were found to occur quickly after death, making accurate 
measurement a difficult task. [206]  Ozawa et al. reported that the spinal cord gray and 
white matter have similar moduli of elasticity as measured by the pipette aspiration 
method in rabbits.  The axial direction of gray and white matter, respectively, measured 
3.4 ± 1.4 kPa and 3.4 ± 0.9 kPa, the frontal section measured 3 ± 0.3 kPa and 3.5 ± 0.5 
kPa, and the sagittal section measured 3.5 ± 0.9 kPa and 2.8 ± 0.4 kPa. [207]  This same 
research group reported that rabbit spinal cord with intact pia mater has an elastic 
modulus of 2.3 MPa whereas the spinal cord parenchyma elastic modulus is 
approximately 5 kPa. [208]  Bilston and Thibault reported that human spinal cords 
averaged 1.4MPa with the pia mater intact and 89 kPa with incised p a mater. [203]  It is 
interesting to note that the elastic modulus of human tibial nerves has been reported to be 
16 MPa, significantly higher than any of the reported values for the spinal cord. [209] 
Although no consensus has been reached regarding the appropriate Young’s 
modulus for neural scaffolds, reports have demonstrated improved adult rat axonal 
regeneration into poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) [pHEMA-
MMA] channels with elastic moduli of 263 kPa and 311 kPa as compared to 177 kPa.  
[210, 211]  Peptide-modified poly(2-hydroxyethyl methacrylate-co-2-aminoethyl 
methacrylate) [pHEMA-co-AEMA] with elastic modulus of 192 kPa demonstrated chick 
DRG adhesion and neurite outgrowth comparable to PLL/laminin controls. [212] 
Growth cone advance is thought to be mediated by forward propulsion as a result 
of filopodial contractions [213, 214], and the elastic modulus of scaffolds has been 
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demonstrated to impact neurite outgrowth.  Hydrogels with increasing co centrations of 
PEG-diacrylate from 50 mg/mL to 200 mg/mL exhibited increasing elastic modulus but 
little change in ultimate tensile stress. Neurite extension fr m PC12 cells seeded on these 
hydrogels with equal concentrations of RGD peptides decreased as the elastic modulus 
increased, indicating that flexible materials with elastic modulus in the range of 
approximately 50-200 kPa may be more conducive to neurite outgrowth. [215]   
Intraluminal Channels 
Entubulation strategies are particularly useful for PNS repair as they mimic the 
ensheathed structure of the PNS, and they may hold promise for long-distance 
regeneration in the CNS because of the success of peripheral nerve implants for CNS 
repair.  Degradable, hollow, large diameter conduits were first developed due to the ease 
of fabrication, but faced challenges of collapse upon implantation. [15, 216] Large 
diameter conduits also do not accurately mimic nerve architecture, and led to the idea of 
filling large diameter hollow conduits filled with smaller hollow conduits, not only 
reduce the susceptibility of collapse but provide more surface area for cell and growth 
cone attachment. Implantation of poly(2-hydroxyethyl methacrylate-co-methyl 
methacrylate) [pHEMA-MMA] channels with 4.19±0.04 mm outer diameter ncasing 4 
smaller tubes with 790±45 µm inner diameter into adult rat complete spinal cord 
transections at T8 (4 mm gap) improved regeneration of vestibular neurons and showed 
consistent improvement in locomotor function at 7 and 8 weeks. [210, 211]   
In order to design conduits with appropriately sized channels for neu al 
regeneration, consideration of cell and nerve fiber diameters must be taken into account.  
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Mammalian cells typically range from 10-100 µm in diameter and Table 3.3 shows the 
diameters of various mammalian nerves. [217]   
MYELINATION?  FIBER TYPE FUNCTION DIAMETER 
(µm) 
Myelinated A - α Proprioception; somatic 
motor 
15-20 
Myelinated A - β Touch, pressure 5-12 
Myelinated A - γ Motor to muscle 
spindles 
3-6 
Myelinated A - δ Pain, temperature, 
touch 
2-5 
Myelinated B - Autonomic Preganglionic 
autonomic 
<3 
Unmyelinated C - Dorsal root Pain, reflex responses 0.4-1.2 




Table 3.3  Mammalian Nerve Fiber Types [217] 
 
Because of the difficulty in fabricating conduits with small diameter linear 
channels [212, 218, 219], an alternative entubulation approach involves filling guidance 
channels with filaments to produce small diameter channels to more accurately mimic 
nerve fiber diameters.  Guidance channels developed for PNS repair with 16 PLLA 
microfilaments within each PLA or silicone tube (1.5 mm inner diameter) were filled 
with Matrigel, implanted into 14 mm and 18 mm rat sciatic nerve lesions, and at 6 weeks 
postlesion, improved Schwann cell migration and regenerated nerves across the gap could 
be seen in all animals with microfilament-filled tubes, as compared to reduced efficiency 
of nerve formation in tubes without microfilaments. [220]  In addition, more axons were 
demonstrated to penetrate PLA tubes due to the porosity of PLA as compared to 
nonporous silicone tubes, thus highlighting the importance of nutrient and waste tr nsfer 
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for neural regeneration.  PLA tubes of 1.5 mm diameter filled with PLLA microfilaments 
of 60-70 µm diameter administered to 6 mm rat dorsal root lesion along with spinal NGF 
virus injection demonstrated recovery of function to almost normal leve s at 7-8 weeks 
postlesion; cutting the dorsal root through the center of the conduit reversed the recovery, 
thus demonstrating regeneration through the conduit was responsible for restoration of 
function. [221]   
Poly(acrylonitrile-co-vinyl chloride) [PAN/PVC] hollow fiber membranes 
(HFMs) with 900 µm inner diameter were filled with polypropylene filaments with 
smooth inner surface of supracellular size (500 µm to 100 µm), cellular size (30 µm), and 
subcellular size (5 µm) and were seeded with DRG explants for 7 days; neuriteoutgrowth 
on 500 µm filaments was organized into fascicles, and defasciculation and increasingly 
uniform linear alignment of Schwann cells and neurites was demonstrated as filament 
size decreased to 5 µm, with corresponding improvement in length of the neurites. [222]  
HFMs were also developed using PLGA and polyurethane with the incorporation of 
aligned grooves on the inner surface of the filaments. [223, 224]   
Fibers offer an alternative to filament-filled conduits.  Poly(l-lactide) (PLA) and 
polyethylene terephthalate (PET) capillary channel fibers (CCFs) containing eight open 
grooves with depth of 5-15 µm and width of 10 µm oriented rat skin fibroblast and aortic 
smooth muscle cell alignment and deposition of ECM proteins within the grooves parallel 
to groove direction; the alignment and fluid wicking capabilities of these fibers make 
them a potentially useful scaffold for nerve guidance strategies. [225, 226]  In addition, 
 69
the size of the fiber grooves is customizable and the variety of gro ve sizes on each fiber 
may enable regeneration of multiple motor and sensory axons. 
 
BIOMATERIAL SCAFFOLDS FOR CELL TRANSPLANTATION  
Many biomaterial approaches have been investigated to improve Schwann cell 
survival and limit migration while also improving regeneration.  PLGA foam conduits for 
peripheral nerve repair were created by a low-pressure injection molding technique 
producing aligned channels with diameters ranging from 60-550 µm; conduits coated 
with laminin and seeded with Schwann cells were implanted across a rat 7 mm sciatic 
nerve gap and demonstrated comparable neurite outgrowth to implanted autografts at 6 
weeks postlesion. [227]  Although this approach may be useful for peripheral n rve 
repair, there is less evidence supporting its use in CNS repair. 
Freeze-dried PLA macroporous scaffolds with channel diameters of 75-200 µm 
seeded with Schwann cells in fibrin solution were implanted into 4 mm rat transections; 
Schwann cells underwent apoptosis by 1 week post-implantation and at 6 weeks, 
myelinated axons were found within the graft but none exited into the caudal spinal cord, 
probably attributable to the limited survival of the Schwann cells. [17] Xu et al. reported 
survival of Schwann cells in 3.0 mm long PAN/PVC guidance channels beyond 30 days 
following implantation into adult rat spinal cord with limited migration for short 
distances into rostral and caudal host spinal cord; however, limited exnsion of axons 
beyond the distal graft-host interface was observed at 90 days. [16]  Porous PLGA 
scaffolds were created by injection molding followed by rapid solvent evaporation with 
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channel diameters of 450±9 µm and 600±10 µm and were seeded with Schwann cells 
suspended in Matrigel; histological analysis of the channels one m th after implantation 
into rat spinal cord injury revealed a centralized core of axons and capillaries surrounded 
by fibrous tissue and macrophages. [228] 
Schwann cells are not native to the CNS and lead to unfavorable interactions with 
astrocytes leading to increased inhibitory CSPG production and the astrogli l response. 
[146]  Although several groups are studying ex vivo genetic modification of Schwann 
cells in order to overcome these challenges, acellular biomaterial-based bridges with 
combination therapies offers an alternative approach to avoid the immune complications 
and glial scarring response inherent to PNS glial cell transpl tation in the CNS while 
still delivering the bioactive soluble and adhesive molecules produced by these glial c lls.  
A major advantage of the acellular approach is the ability to provide controlled 
presentation of bioactive stimuli through controlled release, gene therapy, and 
recombinant protein immobilization.   
 
ACELLULAR SYNTHETIC BIOMATERIAL BRIDGES  
Neurite outgrowth is dependent upon a delicate balance of chemotactic, 
haptotactic, and contact guidance cues, and careful consideration of specific 
combinations of molecules must be made depending upon which axon tracts are to be 
regenerated. [12]  Bridges must also be designed to promote axon growth into and 
through the scaffold via continued availability of active biomolecules, to be selective for 
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axons while inhibiting attachment of other cells, and to promote axon growth out of the 
bridge into the inhibitory host environment.  [18]   
 
Bioactive Stimuli for Combination Therapies 
During PNS development and following injury, Schwann cells increase their
synthesis of surface cell adhesion molecules (CAMs), such as NCAM, NgCAM, and L1; 
they secrete extracellular matrix (ECM) molecules such as collagen, laminin, fibronectin, 
and tenascin; and they produce and spatially present neurotrophic factors such as nerve 
growth factor (NGF), neurotrophin 3 (NT-3), neurotrophin 4/5 (NT-4/5), brain-derived 
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial-cell derived 
neurotrophic factor (GDNF), and acidic and basic fibroblast growth facor (aFGF, bFGF). 
[26, 28] 
Adhesion Molecules 
The extracellular matrix (ECM) protein laminin and the L1 neural cell adhesion 
molecule (NCAM) are of particular interest for spinal cord regeneration strategies 
because of their significant contributions during CNS development. 
Laminin 
Laminin is a protein that is abundantly expressed by immature astrocytes in the 
developing CNS [76] and by Schwann cells in the developing and regenerating PNS [26], 
making it an attractive candidate for use in combination therapies.  Deister et al. 
demonstrated that laminin concentration had the most impact on neurite extension from 
explanted dorsal root ganglia cultured within co-gels made from laminin, fibronectin, 
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collagen I, and hyaluronic acid and that the combinatorial effects were additive rather 
than synergistic, suggesting that the presence of laminin rather than interactions among 
the extracellular matrix components is key for neurite outgrowth. [229]   
Laminin is a large 900 kDa protein with at least 15 different types in mammals 
and structurally it is an αβγ trimer, with each trimer containing binding sites for 
predominantly integrins.  Human diseases caused by genetic mutations in laminin 
proteins give some insight into their importance in proper nervous system development 
and function.  Deficiencies in laminin α2 chains result in abnormal radial sorting of PNS 
axons to be myelinated by Schwann cells and abnormal myelin thickness and length, 
resulting in congenital muscular dystrophy (MDC) 1A; CNS white matter tracts in 
patients with MDC1A also demonstrate abnormal myelination, demonstrati g the 
importance of laminin to CNS oligodendrocytes. [230]  In addition, oligodendrocytes in 
knockout mice lacking the laminin integrin receptor α6β1 have reduced survival rates, 
and laminin-receptor signalling selectively enhances the survival of mature 
oligodendrocytes, not oligodendrocyte precursor cells (OPCs); however, Schwann cells 
lacking the β1 receptor proliferate and survive normally but fail to sort and myelinate 
axons.[230]  Laminin has also been shown to enhance the migration, expansion, 
differentiation, and elongation of neurites in both mouse and human neural stem cells as 
compared to poly-L-orthinine, fibronectin, and Matrigel through integrin receptors α3, 
α6, α7, β1, and β4. [231]  Mouse neural stem cells from the ventricular zone express high 
levels of laminin integrin receptor α6β1. [232]  
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Peptides are short, linear amino acid sequences that are useful for bridging 
strategies because of their small size and more specific cell interactions; however, they 
may not reproduce the bioactivity of the entire protein. [18].  Although laminin is an idel 
substrate for many different cell types because it is a ubiquitous constituent of basement 
membranes, it is this lack of specificity that makes it less than ideal for neural 
regeneration strategies, in particular because it does not inhibit astrocyte interactions.  
Laminin contains at least two peptide sequences that are not favorable for astrocyte 
interactions and bind integrin receptors on neuronal cells: Isoleucine-Lysine-Valine-
Alanine-Valine (IKVAV), an α1 chain peptide sequence that promotes adhesion and 
neurite outgrowth of some neuronal cell types; and Tyrosine-Isoleucin -Glycine-Serine-
Arginine (YIGSR), a β1 chain peptide sequence that promotes neuronal attachment but 
does not necessarily promote neurite outgrowth. [233]   
Numerous applications of these laminin peptide sequences have been used to 
characterize neural cell attachment and neurite outgrowth of cell lin s, including 
pheochromocytoma cells (PC12) that develop properties of sympathetic neurons in the 
presence of nerve growth factor (NGF) and neuroblastoma tumor cells derived from the 
sympathetic nervous system, as well as primary chick and rat dorsal r ot ganglia (DRG) 
neurons.  IKVAV and YIGSR sequences covalently immobilized to fluorinated ethylene 
propylene (FP) films mediated localized PC12 and NG108-15 neuroblast m  cell 
attachment and neurite outgrowth to patterned pathways [234, 235]; improved neurite 
outgrowth, cell adhesion and viability of rat embryonic day 18 hippocampal neurons 
[236]  The neurite outgrowth of chick dorsal root ganglia on expanded 
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poly(tetrafluoroethylene) fibers was enhanced with IKVAV and YIGSR peptides and the 
optimal fiber diameter for guidance was 30-50 µm. [237]   
Gunn and Turner examined PC12 response to PEG-diacrylate hydrogels with 
IKVAV and YIGSR peptides and found that neurites extended in response to IKVAV-
conjugated gels but only attached without neurite extension to YIGSR-conjugated gels. 
[215]  Copolymerized 2-hydroxylethyl methacrylate (HEMA) and 2-aminoethyl 
methacrylate (AEMA) gels (P(HEMA-co-AEMA) scaffolds) with covalently bound 
YIGSR and IKVAV were fabricated in aqueous conditions, thus avoiding organic solvent 
use, and demonstrated enhanced neural cell adhesion and guided neurite outgrowth of 
chick dorsal root ganglia neurons. [212]   
L1 Neural Cell Adhesion Molecule 
L1 is a key player in the overall development of both the CNS and PNS and 
functions in neuronal adhesion and migration; axon growth, guidance, and fascicul tion; 
as well as target selection, synapse formation, plasticity, survival, and myelination. [238-
243]  L1 is also expressed by Schwann cells of the peripheral nervous system. [244] 
L1 is a 220 kDa vertebrate neural cell adhesion molecule belonging to the L1 
subfamily of the immunoglobulin superfamily (IgSF), with members sharing a common 
structure of six immunoglobulin (Ig) domains followed by three to five bronectin type 
III (FNIII) repeats. [245]  Genetic deletions or mutations of the L1 gene result in severe, 
sometimes lethal, neurological deficits in humans and defects in the corticospinal tract 
and corpus callosum of L1 knockout mice.  [246-249]  There is also evidence that injury 
induces reexpression of L1, as three months following complete spinal cord transec io  in 
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neonate rats, L1 expression remained substantially increased surrounding the lesion site 
and L1 was reexpressed on descending fibers of the corticospinal tract above the lesion. 
[250]   
Several in vitro and in vivo experiments have demonstrated the value of L1 in 
spinal cord regeneration strategies, in both soluble and substrate-bound forms.  Rat 
cerebellar neurons on PLL extended longer neurites in response to soluble L1-Fc as 
compared to controls, and the response was inhibited by pretreatment of the neurons with 
antibodies to L1 or fibroblast growth factor (FGF) receptor. [251]  L1 attached to a 
nitrocellulose membrane stimulated chick tecta and mouse cerebellum neurite outgrowth 
while inhibiting astrocyte, oligodendrocyte and fibroblast attachment. [252]  Reduced L1-
Fc immobilized to polystyrene surfaces through Pluronic-pyridyl disulfide (F108-PDS) 
modification supported significantly higher levels of rat dorsal root ganglia, cerebellar, 
and hippocampal neurite outgrowth relative to fibronectin and PDL, while inhibiting the 
attachment of astrocytes, meningeal cells, and fibroblasts. [253]  Oliva et al. 
micropatterned the chimeric protein L1-Fc, consisting of the ectodomain of L1 linked to 
the Fc fragment of immunoglobulin G (IgG), onto poly-L-lysine coated glass by 
microcontact printing of bacterial protein A, which binds the Fc fragment, and 
demonstrated preferential growth of embryonic rat hippocampal axons into the L1-Fc 
patterned regions. [254]  Poly(glycolide) (PGA)-chitosan conduits coated with 
recombinant L1-Fc implanted into adult rats following optic nerve transection exhibited 
higher numbers of regenerated fibers and a significant increase in myelination of the 
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regenerated fibers as compared to PGA-chitosan conduits alone. [255] These studies 
suggest the usefulness of L1 in both controlled release and immobilized strategies. 
Neurotrophic Factors 
Neurotrophic factors are key nervous system regulatory proteins that modulate 
neuronal survival, axonal growth, synaptic plasticity, and neurotransmission.  They have 
also been shown to promote and direct growth cone motility [112]; they exhibit a 
chemotactic effect for axon guidance, and they aid in sensory nerve growth across the 
PNS-CNS transition zone.  As a result, their role in axon development and regeneration is 
being studied extensively for application in spinal cord repair [28, 94, 113-115].     
Diffusion and Controlled Release from Biomaterials 
Porous PLG single and multiple lumen conduits were created utilizing porogen 
(NaCl) and a gas foaming technique, and NGF was incorporated either by mixing with 
PLG microspheres prior to gas foaming or by encapsulating into the microspheres; 
sustained release of NGF from the scaffolds was demonstrated for 42 days and could be 
controlled by the method of incorporation and polymer molecular weight. [256] 
The network crosslinking density of photopolymerized acrylated PLA-b-PEG b-
PLA hydrogels was utilized to control release rates of CNTF, BDNF, and NT-3 with total 
release times reported as ranging from weeks to several months, and simultaneous 
delivery of multiple neurotrophins was developed by mixing microspheres of NT-3 
encapsulated in poly(lactide-co-glycolide) using a double emulsion technique into the 
hydrogel solution containing CNTF and photopolymerizing to produce constructs 
containing NT-3 in the microsphere phase and CNTF in the hydrogel phase; the release 
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profiles show very rapid release of the neurotrophin in the hydrogel phase and a slow 
continuous release from the degradable microspheres. [257] 
Controlled release of BSA from photopolymerized PEG hydrogels has been 
demonstrated using the metal chelating ligand iminodiacetic acid (IDA) to reversibly 
bind BSA in the presence of Cu2+ ions as well as protect the protein from free radicals 
produced during photopolymerization [258, 259]; these methods may be useful for 
application in controlled release of polyhistidine-tagged neurotrophic factors. 
Immobilization to Biomaterials 
MacInnis and Campenot [260] reported that a neuronal survival signal ca reach 
the cell bodies unaccompanied by the NGF that initiated it.  The discovery that growth 
factors do not have to be internalized by the cell body in order to promote survival 
opened the door for research into immobilized growth factors.  Neurotrophins have a very 
short half-life and immobilization is one method to provide a high concentration of long-
term, localized growth factor delivery to an injury site by preventing degradation, 
clearance, or internalization of the neurotrophins. 
Kapur and Shoichet [261] immobilized NGF concentration gradients within 
poly(2-hydroxyethyl-methacrylate) [pHEMA] microporous gels using a modified, 
commercially-available gradient maker (CBS Scientific, Temecula CA).  PHEMA was 
chosen because its material properties are good for soft tissue engine ring, it has been 
used clinically, and NGF has been stably encapsulated in it for othe applications; it was 
also modified with poly(allyamine) [pAA] to make it cell adhesive.  In this research, 
gradient stability, immobilized NGF bioactivity, and axon extension of
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pheochromocytoma (PC12) cells to the immobilized NGF gradients were tested.  Their 
results showed that PC12 cells adhere to the pHEMA-NGF-pAA gels, and respond to 
immobilized NGF by extending neurites in a manner similar to previous research with 
soluble NGF. [262, 263]  It was observed that PC12 neurites were thickr when cultured 
on immobilized NGF than when cultured in the presence of soluble NGF. 
 
Review of Combination Therapies 
It is likely that combinations of therapies with synergistic effects will be required 
for long-distance regeneration of axons. Review of combination strategies that have been 
tested gives some insight into the responses that may be expected from different 
combinations of growth-promoting stimuli.  Combinations of neural cell adhesion 
molecules L1 and neurofascin and growth and differentiation-5 factor (GDF-5) 
demonstrated synergistic effects on neurite outgrowth of embryonic chick dorsal root 
ganglia (DRG) neurons. [264]  Chick embryonic DRG cultured in anisotropic three-
dimensional (3D) agarose scaffolds with photoimmobilized gradients of laminin 
exhibited maximal neurite extension as compared to isotropic scaffolds with uniform 
distribution of laminin [265]; these anisotropic agarose scaffolds with gradients of 
laminin and nerve growth factor (NGF) exhibited comparable regen ration to peripheral 
nerve grafts across a 20 mm sciatic nerve gap in rats. [266].  Semipermeable polysulfone 
tubes with laminin and nerve growth factor (NGF) demonstrated comparable 
regeneration, myelination, and functional recovery as compared to autologous peripheral 
 79
nerve grafts two months after implantation into a 10 mm sciatic nerve gap in adult rats. 




A synergistic combination of pharmaceutical interventions and therapeutic 
approaches to spinal cord injury will likely be required to overcome the multitude of 
factors contributing to CNS regenerative failure and to ultimately achieve functional 
regeneration. This research is focused on the development of acellular synthethic 
biomaterial-based bridges because of the flexibility in design and f brication of scaffold 
properties coupled with the ability to use different combinations of bioactive adhesive 







The human spinal cord is approximately 45 cm long (1.5 ft) with 30 levels, and 
each spinal level is around 1-2 cm. [14]  The most common injury level for a tetraplegic 
is C5, thus requiring regeneration over 25 levels, or approximately 25-50 cm, for 
complete restoration of white matter axon tracts.  The most common injury level for a 
paraplegic is T12, requiring regeneration over 10 levels, or approximately 10-20 cm.  In 
1981, David and Aguayo reported axonal elongation of 3 cm into autologous peripheral 
nerve “bridges” between the medulla and spinal cord in adult rats. [268]  The maximum 
length to date of CNS regeneration demonstrated in animal models is around 4 cm, with 
most studies demonstrating only 1-2 cm of regrowth. [154, 269] This fact emphasizes the 
need for better combinations of therapies with synergistic effects for long-distance 
regeneration of axons.  
 
RATIONALE FOR BIOACTIVE BIOMATERIAL-BASED APPROACH  
The long-term objective of this project is a biomimetic, multi-factorial approach 
utilizing grooved fibers to restore structure and provide guidance for regenerating axons 
coupled with bioactive adhesive molecule delivery via immobilization to a hydrogel 






















Figure 4.1  Proposed Implant Design 
 
A major obstacle of all implant-based bridging techniques is the invasive nature 
of implantation and stimulation of the astroglial response; however, a unique advantage 
of this proposed fiber implant is the possibility to reroute regenerati g xons around an 
existing glial scar through the use of specialized surgical techniques that are currently 
being used for peripheral nerve grafts [270, 271], and perhaps incorporation of a 
complementary strategy to modify the inhibitory environment, using Chondroiti ase-
ABC or Rho antagonist, or to modify growth cone signaling pathways, will minimize the 
resultant astroglial response from implantation. [272, 273] 
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Synthetic degradable materials are potentially ideal for neural regeneration 
strategies, because tunable biodegradation enables the design of an impl t that will 
support axonal regeneration through and out of the graft but degrade prior to axon 
remyelination to avoid compression of newly regenerated nerves.   
Fibers are potentially ideal scaffolds to provide guidance for long-distance 
regeneration of axons, and the proposed PLA capillary channel fibers (CCFs) contain 
eight open grooves of adjustable depths and widths and have demonstrated orientation of 
rat skin fibroblast and aortic smooth muscle cell alignment and deposition of ECM 
proteins within the grooves parallel to the groove direction. [225, 226]   
Bioactivity will be incorporated by delivery of adhesion ligands and neurotrophic 
factors from a hydrogel coating within the fiber grooves, to mimic the bioactivity that 
peripheral nerve implants have demonstrated in CNS regeneration.  L1 is a particularly 
attractive candidate for neural regeneration because it is crit cal for proper nervous 
system development; genetic deletions or mutations of the L1 gene result in severe, 
sometimes lethal, neurological deficits in humans, including hypoplasia of the 
corticospinal tract [248, 249], and injury induces reexpression of L1 in the corticospinal 
tract. [250]  Recombinant human L1 has been shown to be a potent promoter f neurite 
outgrowth in both soluble and substrate-bound forms, to support selective neuronal 
adhesion in the presence of astrocytes when coupled to low-protein binding supports, and 
to function as a neuronal survival factor. [239, 253]  The selectivity of neuronal adhesion 
to L1 in the presence of astrocytes is particulary important, s astrocytes are the key 
players in nervous system inflammation and mediate the glial scar response.  All six 
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immunoglobulin domains of L1 have been shown to be required for full bioactivity [274]; 
therefore, based on the increased number and distribution of bioactive regons in L1, 
selection of an appropriate immobilization chemistry is likely to be critical for full 
retention of bioactivity.   
Neurotrophic factors have a very short half-life, are digested in the 
gastrointestinal tract, do not pass the blood-brain barrier, and are rapidly cleared from 
cerebrospinal fluid (CSF); as a result, oral, systemic, or intrathecal delivery will not 
promote regeneration of CNS neurons and may result in hyperalgesia or other unwanted 
side effects due to nonspecific delivery. [117]  Controlled release of n urotrophins from 
the proposed implant has the potential to provide biologically relevant amounts of long-
term, localized growth factors at the site of injury while avoiding unwanted side effects.  
NT-3 is an attractive candidate for regeneration of corticospinal tract neurons, a major 
motor axon tract with limited intrinsic regenerative potential. [77, 118]   
 
RATIONALE FOR HYDROGEL FABRICATION AND PROTEIN 
IMMOBILIZATION APPROACHES  
 
Tetronic® 904 (T904, BASF) is a tetrafunctional poly(ethylene oxide) – 
poly(propylene oxide), PEO/PPO, block copolymer that is a nonionic surfactant 
terminating in primary hydroxyl groups.  Selected Pluronics® and Tetronics® are 
commonly used in contact lens cleaning solutions and mouthwash, and are unique
surfactants that are resistant to protein adsorption, have low cytotoxicity, and elicit a 
reduced immune response.  Modified Pluronic® surfactants have been utilized to 
immobilize histidine-tagged proteins [275], and fibronectin and L1-Fc. [253, 276]  
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Tetronics® (poloxamines) were chosen over linear Pluronics® (poloxamers) because their 
four-arm, or star-shaped, structure contains more and shorter side chans as compared to 
linear block copolymers with similar molecular weight, thus allowing for increased 
functionality and higher degree of crosslinking with lower polymer concentrations, with 
single hydrolytically degradable ester bonds at each end. [277]  In addition, control over 
swelling and protein release has been demonstrated with multi-arm PEG acrylates. [278]  
Michael addition polymerization using acrylated polymers is an establi hed 
method of hydrogel fabrication in the absence of ultraviolet (UV) light [278-280]  and 
may also be used in protein immobilization strategies. [281-287]  A long-term goal of 
this project is to polymerize T904-acrylate hydrogels within t e capillary channel fiber 
grooves, and Michael addition polymerization may enable more uniform and complete 
polymerization within the grooves than is attainable with photopolymerization.  The fiber 
grooves also exhibit capillary-like properties that may be used for uptake of hydrogel 
solutions.  Another long-term goal of this project is controlled release of neurotrophins 
from the hydrogels, and Michael addition polymerization avoids potential damage to the 
protein structure from excessive heat that may occur with photopolymerization.   
 
ADVANTAGES OF PROPOSED IMPLANT DESIGN  
Biomaterial-based approaches to spinal cord repair are missing from clinical trials 
in large part because of the limited approval of devices incorporating biomaterials by the 
U.S. Food and Drug Administration (FDA).  Approval of a device with novel materials is 
costly and requires additional documentation associated with manufacture, q ality 
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control, durability and safety; however, PLA has been FDA-approved and is being 
studied for neural applications, and Pluronics® and Tetronics® are under investigation for 
drug delivery applications. [216, 288-290]  Entubulation strategies face challenges of 
channel collapse and obstruction of nerve regeneration, and the difficulty in fabricating 
conduits with small diameter linear channels [212, 218, 219] led to an alternative 
entubulation approach of filling guidance channels with filaments to produce small 
diameter channels.  The proposed fiber implant does not require entubulation, and the 
open channel design allows for unlimited transport of nutrients and waste.   
The hydrophobicity of PLA not only negatively impacts cell adhesion to the 
surface, but also favors protein adsorption that is detrimental to efforts to incorporate 
bioactivity into biomaterials through covalent protein immobilization. PLA 
hydrophilicity has been improved through methods such as copolymerization wi h PEG, 
which required solvents and high temperatures not suitable for encapsulation of proteins; 
surface chemical modification via alkali treatment, which increased PLA bulk 
degradation rate; and plasma treatment, which demonstrated instability of the surface 
layer. [291]  Otsuka et al. demonstrated surface functionalization of PLA via spin coating 
of acetal-PEG/PLA block copolymers in toluene. [292]  Surface coating of PLA with 
T904-acrylate takes advantage of the hydrophobic interaction of the Te ronic PPO blocks 
and PLA to enable a functionalized hydrophilic PEG surface that more closely mimics 
the viscoelastic properties of neural tissue.  The simplicity in manufacturing grooved 
PLA fibers via a melt-spin process (US Patent 1990, 4,954,398), coupled with capillary 
uptake of a hydrogel coating crosslinked in the absence of solvents and ultraviolet light 
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via Michael addition, make this a novel approach for application in neural regeneration 
strategies.  In addition, the implant design lends itself to lyophilization, making it suitable 
for long-term storage. The ability to customize scaffold properties and incorporate 
different combinations of adhesive stimuli and growth factors, and the simplicity in 
manufacturing and long-term storage ability, maximizes the potntial of this approach to 





Because neurotrophic factors are not sufficient for growth cone or cll adhesion to 
a biologically inert material, this research focused on covalent immobilization of the cell 
adhesion molecule L1 to acrylated Tetronic® hydrogels for neurite outgrowth with future 
plans of neurotrophic factor incorporation to further enhance survival and regeneration 
rates.  The objectives of this research were: (1) cloning and expression of a bioactive 
140kDa fragment of L1 neural cell adhesion molecule, chosen for its citical role in 
proper nervous system development and because it has demonstrated selectivity of 
neuron adhesion in the presence of astrocytes, which play a major role in nervous system 
inflammation, (2) synthesis and purification of acrylated Tetronic macromers and the 
development of Michael addition methods for hydrogel crosslinking and protein 
immobilization, (3) evaluation of hydrogel cytocompatibility, immobilized protein 
bioactivity, and immobilization efficiency in terms of cell spreading and proliferation 
using NIH 3T3 fibroblasts and fibronectin because of the well-known RGD-dependent 
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interaction, to demonstrate the feasibility of this system for neural repair, and (4) 
assessment of neuronal cell line and primary neuron response to L1, evaluation of the 
cytocompatibility of T904-acrylate hydrogels with neural cels, and development of 





CLONING AND EXPRESSION OF RECOMBINANT L1 
 
INTRODUCTION  
 L1 is a vertebrate neural cell adhesion molecule belonging to the L1 subfamily of 
the immunoglobulin superfamily (IgSF), with members sharing a common structure of 
six immunoglobulin (Ig) domains followed by three to five fibronectin type III (FNIII) 
repeats. [245]  The L1 subfamily is also comprised of the vertebrate members 
neurofascin, NrCAM and CHL1 and the invertebrate members neuroglian and tractin. 
[293]  L1 is a transmembrane glycoprotein consisting of six Ig domains, five FNIII 
repeats, a transmembrane region, and a highly conserved cytoplasmic do ain. [241, 294, 
295]  Unglycosylated L1 has a molecular weight of 140-150 kDa, with 21 N-
glycosylation sites on the extracellular portion of the protein, resulting in a 200-220 kDa 
protein depending upon how many residues are glycosylated. [296]  L1 also contains two 
proteolytic cleavage sites: plasmin-mediated cleavage in the third fib onectin repeat 
resulting in an approximate 140 kDa soluble form of L1, and ectodomain cleavage via the 
metalloprotease ADAM10 resulting in an approximate 200 kDa soluble form of L1. [297-




Figure 5.1  Structure of L1  
(Reprinted from Haspel and Grumet 2003[241]) 
 
 L1 is primarily expressed on the surface of neurons and is concentrated in growth 
cones and axons during development.  L1 functions in neuronal adhesion and migration; 
axon growth, guidance, and fasciculation; as well as target selection, synapse formation, 
plasticity, survival, and myelination. [238-241]  It is also expressed by Schwann cells of 
the peripheral nervous system, a subclass of leukocytes, intestinal crypt cells, and kidney 
tubule epithelia [244]; however, L1 expressed by neurons and glia includes an 
alternatively spliced YEGHH sequence at the N-terminus encoded by xon 2. [301]  The 
140 and 200 kDa L1 cleavage fragments have been detected in developing rat brain, 
cerebrospinal fluid (CSF), and the extracellular matrix. [302-304]  L1 is capable of 
interacting with multiple extracellular and intracellular binding partners.  The 
extracellular region may exhibit homophilic binding with L1 on the surface of other cells 
or soluble L1 or heterophilic binding with other neural cell adhesion mlecules, integrins, 
extracellular matrix constituents (laminin, phosphacan, neurocan), or signaling receptors. 
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[241, 305]  The cytoplasmic region interacts with the actin cytoskeleton via an ankyrin 
linkage. [306]  Homophilic interaction of L1 is closely linked to its ability to induce 
neurites in culture [305] and the cytoplasmic domain is not required for homophilic 
adhesion. [307]  
 Genetic deletions or mutations of the L1 gene result in severe, somtimes lethal, 
neurological deficits in humans, including X-linked hydrocephalus, mental re rdation, 
aphasia, shuffling gait, adducted thumbs (MASA) syndrome, spastic paraplegia type I, 
and X-linked mental retardation. [246, 247]  L1 mutant mice exhibit defects in the 
corticospinal tract and corpus callosum. [248, 249]   L1 is a key player in the overall 
development of both the central and peripheral nervous systems, making it an attractive 
candidate for promoting neural regeneration.  L1 expressed ectopically by mouse 
astrocytes was shown to enhance neurite outgrowth on both astrocyte monolayer cultures 
and on optic nerve cryosections derived from the transgenic mice; this increase in 
outgrowth was inhibited by polyclonal L1 antibodies. [308]  Purified full-length and 
recombinant L1 containing the entire extracellular region have been shown to stimulate 
neurite outgrowth in both soluble and substrate-bound forms. [252, 309]  Neurites 
induced by L1 in vitro were 2-3 times longer than those cultured on poly(ethyleneimine), 
although stronger neurite-promoting activity was shown on laminin. [309].  However, 
substrate-bound L1 has been shown to selectively support the adhesion of CNS-derived 
neurons in the presence of astrocytes, meningeal cells, and fibroblasts. [253]  Significant 
axonal regeneration was observed in a hemisection lesion of rat spinal cord two weeks 
following transplantation of fibroblasts genetically modified to produce L1. [310]  
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Soluble L1-Fc administered intrathecally to rat spinal cords following contusion injury 
promoted locomoter recovery. [311] 
 Production of recombinant L1 has been described in both mammalian and 
bacterial systems, although bioactive, bacterially-derived L1 is not glycosylated, and 
there has been debate regarding its mechanism of action.  Studies using bacterially-
derived L1 have shown that the Ig2 domain is necessary and sufficient or homophilic 
binding. [312]  Studies of mammalian-derived L1 have shown that Ig domains 1-6 
reproduce the full biological activity of the entire L1 extracellular region, while Ig 
domains 1-4 are the minimum regions necessary for homophilic binding. [274]  Haspel 
and Grumet theorized that these differences may be the result of non-authentic 
homophilic interactions that can be generated in isolated Ig domains as a result of 
nonnative folding pathways in bacterial systems. [241]  Insect-cell expression systems 
offer several potential advantages for the production of recombinant neural cell adhesion 
molecules, including generally higher yield relative to mammalian systems and improved 
posttranslational modification and glycosylation relative to bacterial systems.  A recent 
study described stable expression of the complete L1 extracellul r domain and an Ig5-6 
fragment in Sf9 cells and demonstrated the neurite outgrowth promoting bioactivity of 
both proteins using NT2N neurons derived from the NT2 human embryonic carcnoma 
cell line. [313]  The objective of this study was to express the L1 140 KDa physiological 
cleavage fragment in the baculovirus expression system and to evaluat its neurite 
outgrowth-promoting bioactivity relative to commercially available mammalian-derived 
L1-Fc in primary cultures of central nervous system neurons.  A C-terminal 6X histidine 
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tag was incorporated for purification and as a basis for oriented immobilization to 
biomaterial surfaces for neural regeneration applications.   
 
MATERIALS AND METHODS  
Figure 5.2 is a brief summary of the materials and methods used to produce and 
evaluate the bioactivity of insect-cell derived L1. 
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Figure 5.2  Materials and Methods Flowchart 
 
 
Insect Cell Culture 
 Sf9 cells (Spodoptera frugiperda) were purchased from Invitrogen and routinely 
maintained at 27°C in Sf-900 II Serum-Free Medium (Gibco) supplemented with 25 
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I.U./mL penicillin and 25 µg/mL streptomycin of penicillin-streptomycin (Mediatech).  
High Five™ cells (Trichopulsia ni) were a gift from Dr. Mark Kindy (MUSC, 
Charleston, SC) and were routinely maintained at 27°C in Express Five® Serum-Free 
Medium (Gibco) supplemented with 25 I.U./mL penicillin and 25 µg/mL streptomycin 
(Mediatech) and 90 µL/mL of 200 mM L-glutamine (Hyclone). 
 
PCR Cloning of the L1 Extracellular Fragment 
 Freeze-dried E.coli containing a plasmid encoding the full-length human L1 open 
reading frame (ORF) was purchased from ATCC (Clone #65996).  The bact ria were 
thawed and grown overnight in 15 mL tubes at 37°C.  Plasmids were purified using the 
QIAprep® Spin Miniprep Kit (Qiagen).  Gene-specific forward (5’-ATG GTC GTG GCG 
CTG CGG TAC GTG T-3’) and reverse (5’-CTT CCT CTG ACT GCC TC CCT CCA-
3’) primers were used to amplify an approximately 2500 bp sequence encoding the L1 
140 kDa plasmin cleavage fragment by polymerase chain reaction (PCR) using Platinum 
Taq DNA Polymerase High Fidelity (Invitrogen).  PCR was performed for 30 cycles 
(denaturation: 30 seconds, 94ºC; annealing: 25 seconds, 64 ºC; extension: 160 seconds,
68 ºC) with a final 20 minute hold at 68 ºC.  The formation of a single product of 
expected size was confirmed by agarose gel electrophoresis. 
 
Preparation of Entry Clone 
 The PCR product was ligated by T/A cloning into the pCR®8/GW/TOPO® 
(Invitrogen) Gateway Entry vector containing a spectinomycin resistance gene and 
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transformed into One Shot® chemically competent E.coli (Invitrogen).  The bacteria were 
plated on LB-spectinomycin (100 µg/mL) agar plates and grown overnight at 37°C.  
Individual colonies were selected and expanded and plasmids were purified.  A clone 
with appropriate orientation and sequence was identified by DNA sequencing using an 
ABI 3730 sequencer (DNA laboratory, Arizona State University).  The clone sequence 
was identical to human L1CAM (GenBank accession no. NM_000425) with the 
exception of a single non-coding base difference at position 855.   
 
Construction of Recombinant Baculovirus 
 Recombinant baculovirus was generated by an enzyme-catalyzed recombination 
reaction between the entry vector and BaculoDirect™ C-Term Linear DNA (Invitrogen) 
containing a C-terminal 6xHis fusion tag and herpes simplex virus thymidine kinase and 
and lacZ genes for negative selection and analysis of viral purity, respectively.  A 
mixture of 100 ng of the pCR®8/GW/TOPO® entry clone, 300 ng of BaculoDirect™ 
Linear DNA, 4 µL of 5X LR Clonase™ Reaction Buffer, 1 µL of TEBuffer pH 8.0, and 
4 µL LR Clonase™ enzyme mix was incubated at 25ºC overnight.  Afterov rnight 
incubation, 2 µL of Proteinase K solution was added to the mixture and incubated at 37ºC 
for 10 minutes. 
 
Transfection and Amplification of Recombinant Baculovirus 
 Sf9 cells were plated in 6-well plates (8.0 x105 cells/well) and allowed to adhere 
for one hour at 27ºC.  A transfection mixture consisting of 5 µL of the baculovirus 
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recombination reaction, 200 µL of Grace’s Insect Medium, Unsupplemented (Gibco), and 
6 µL of Cellfectin® Reagent (Invitrogen) was prepared, mixed, and incubated at room 
temperature for 45 minutes.  The cells were washed with Unsupplement d Grace’s Insect 
Medium, and the transfection mixture was diluted with 800 µL additional medium and 
added dropwise.  After 5 hours incubation at 27ºC, the transfection mixture was removed 
and replaced with Sf-900 II Serum-Free Medium (Gibco) supplemented wi h antibiotics 
and 100 µM ganciclovir.  The cells were monitored daily, and the P1 viral stock was 
collected when late stage infection characteristics were observed (8 days). 
 P2 viral stock was generated by infecting 8.0 x105 Sf9 cells/well with 10 µL of P1 
viral stock and was collected on day 5.  The infected cells were stained for β-
galactosidase expression using the β-Galactosidase Enzyme Assay System with Reporter 
Lysis Buffer (Promega) to confirm the absence of non-recombinant virus.  P3 viral stock 
was generated by infecting 1.0 x 107 cells/flask in T-75 flasks with 25 µL of the P2 viral 
stock and was collected after 96 hours.  End-point dilution assay was used to determine 
viral titer (multiplicity of infection, MOI) of the P3 viral stock, as previously described. 
[314] 
 
Localization of Recombinant L1 Expression in Insect Cells 
 Sf9 and High Five™ cells were plated in 6-well plates (1.5 x106 cells/well) and 
infected with 11 µL of P3 recombinant baculovirus stock (MOI 0.2).  The supernatants 
were harvested at 48 hours and 72 hours postinfection, complete EDTA-free protease 
inhibitor added (CPI, Roche, 2.5 µL 7X CPI stock solution per mL supernatant), 
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centrifuged (3000 x g for 5 mins) to remove c ll debris, and  immediately frozen at -80 
°C.  Cells were lysed with RIPA buffer containing CPI at 48 hours and 72 hours 
postinfection, the lysates centrifuged (3000 x g for 10 mins) to remove cell debris, and 
immediately frozen at -80 °C.  For gel electrophoresis, total protein concentrations of 
supernatant and lysate samples were determined by BCA assay (Pierce) using BSA 
standards and sample volumes were adjusted to achieve final protein loading amounts of 
30 µg/well supernatant and 3 µg/lane lysate. 
 
Kinetics and MOI Analysis of Recombinant L1  
Expression in High Five Cells 
 High Five™ cells were plated in T-175 flasks (2.73 x107 cells/flask) and infected 
with P3 recombinant baculovirus stock at varying MOI (.002, .02, .2, 2).  The supernatant 
was harvested at 48 hours, 72 hours, and 96 hours postinfection, CPI added, cell debris 
pelleted (3000 x g for 5 mins), and samples collected for Western Blot analysis (9 µL 
supernatant + 3 µL 4X reducing buffer) and immediately frozen at -80°C. 
 
SDS-PAGE and Western Blot Analysis 
 Protein samples were separated by SDS-PAGE on 6% polyacrylamide gels 
using Tris-glycine buffer under reducing conditions at 100V for 150 minutes.  Proteins 
were then transferred to PVDF membranes at 4°C overnight at 30V.  Western blotting 
was performed using the WesternBreeze®  Chromogenic Kit (Invitrogen).  Membranes 
were blocked, incubated with polyclonal goat anti-human L1 primary antibody (R&D 
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Systems, 1:200 dilution), incubated with rabbit anti-goat IgG alkaline-phosphatase 
conjugated secondary antibody (Molecular Probes, 1:10,000 dilution), and developed 
with chromogenic substrate.  Western Blots were imaged and analyzed using a GS-700 
densitometer and QuantityOne® software (Bio-Rad). 
 
Expression of Recombinant L1 in High Five™ Cells 
 High Five™ cells were plated in T-175 flasks (2.5 x107 cells/flask) and infected 
with recombinant baculovirus at an MOI of 0.2.  The supernatant was harvested 72 hours 
postinfection, CPI added, cell debris pelleted (3000 x g for 5 mins), and supernatant 
immediately frozen at -80°C. 
 
Protein Purification 
 The supernatant of infected cells was thawed and dialyzed against 50 mM 
Na2HPO4, 300 mM NaCl buffer, pH 8.0, for 48 hours with one buffer exchange using 
regenerated cellulose dialysis tubing with a molecular weight cut-off (MWCO) of 6-8 
kDa (Fisher).  CPI was added immediately prior to dialysis and at the buffer exchange.  
The dialyzed supernatant was adjusted to 500 mM NaCl, 5 mM imidazole pri r to 
binding.  Pre-equilibrated 50% Ni-NTA agarose slurry (Qiagen) wasadded to the 
dialyzed supernatant (450 µL equilibrated slurry / 4 flasks), mixed ov rnight on a shaker 
plate at 4°C, and transferred to a PolyPrep chromatography column (BioRad).  Beads 
were washed with 4 mL each of 50 mM Na2HPO4, 500 mM NaCl, pH 8.0 buffer with 
increasing imidazole concentrations (0mM, 5mM, 10mM).  Bound proteins were then 
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eluted in three 600 µL fractions using a 50 mM Na2HPO4, 500 mM NaCl, 250 mM 
imidazole, pH 8.0 buffer.  The three elutions were combined and a buffer exchange to 
phosphate buffered saline (PBS) was performed using Zeba desalt columns (Pierce) 
according to manufacturer’s instructions.  The purified protein was sterile-filtered 
through a 0.2 µm syringe filter and stored at 4°C.  Samples of the supernatant, wash 
buffer flow through, and eluted protein were normalized to the original supernatant 
volume and separated by SDS-PAGE.  Gels were silver stained (SilverSNAP® Stain Kit 
II, Pierce) and imaged using a Kodak Electrophoresis Documentation nd Analysis 
System 120.  The yield of purified recombinant L1 was determined by BCA assay 
(Pierce) using BSA standards. 
 
Bioactivity Assay 
 Sterile recombinant insect cell-derived L1 and commercial mamlian-derived 
L1-Fc (R&D Systems) were adsorbed onto 96-well ethylene-oxide sterilized polystyrene 
plates in 2 µL dots at 25 µg/mL concentration for 1 hour.  Control wells re coated with 
50 µL of 0.1% poly-l-lysine (PLL) for 1 hour (n=4 wells / group).  White leghorn chicken 
embryonic day 8 forebrain neurons were isolated as previously described [315] and 
cultured on the adsorbed L1, L1-Fc, and PLL at a density of 30,000 cells/well in Basal 
Medium Eagle (BME, Gibco) supplemented with 6 mg/mL glucose (Sigma), 1% 
antibiotic/antimycotic 100X stock solution (Gibco), 10% fetal bovine serum (FBS, 
Invitrogen), and 2 mM L-glutamine (Hyclone) for 24 hours.  Cells were then fixed for 1 
hour in 4% paraformaldehyde and stained for actin microfilaments using Alexa Fluor® 
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594 phalloidin (Molecular Probes, 0.161 µM) and nuclei using DAPI (Molecular Probes, 
3 µM).  Neurite outgrowth was quantitatively measured from digital fluorescent images 
using ImagePro software (n=60 neurites / experimental group, comprised of an average 
of 15 measurements from each of 4 independent wells).  Neurite outgrowth data were 
statistically analyzed by ANOVA using Tukey’s method for post-hoc comparisons with 
p<0.05 considered statistically significant. 
 
RESULTS AND DISCUSSION 
 Efficient expression and purification of bioactive, recombinant L1 is critical for 
its further investigation and development as a therapeutic molecule for stimulating axonal 
regeneration following brain and spinal cord injury.  Native human L1 contains 6 
disulfide bridges in the Ig domains and extensive glycosylation, which ac ounts for 
approximately 25% of molecular mass.  Baculovirus-mediated insect cell expression 
offers several potential advantages for recombinant L1 expression, including improved 
posttranslational processing relative to prokaryotic systems and relatively higher yields as 
compared to mammalian systems. [316]  Physiologically, L1 is expressed as a 
transmembrane protein that can be proteolytically cleaved to generat  two soluble 
extracellular fragments.  The objective of this study was the cloning and baculovirus 
expression of the 140 kDa extracellular plasmin cleavage product and the evaluation of 
its bioactivity relative to mammalian-derived L1-Fc containing the entire extracellular 
region.  L1 was expressed with a C-terminal 6X histidine tag for ease of purification and 
as a basis for oriented immobilization to biomaterial surfaces. 
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Localization of Recombinant L1 Expression in Insect Cells 
 L1 contains a 19 amino acid N-terminal signal sequence that targets it for 
membrane insertion.  We hypothesized that a truncated extracellular fragment lacking the 
transmembrane region would be secreted as a soluble protein.  To investigate protein 
expression and localization, small-scale cultures of Sf9 and High 5 cells were infected 
with recombinant baculovirus at MOI of 0.2.  Western blot analysis using an antibody to 
human L1 detected immunologically reactive protein in both cell lysates nd supernatants 
derived from both cell lines (Figure 5.3).  In both Sf9 and High 5 supernatants, L1 was 
detected as a distinct single band of approximately 140 kDa (Figure 5.3A), corresponding 
to the approximate molecular weight of the native human plasmin cleavag  fragment.  
Densitometry analysis of L1 demonstrated an approximate 1.5-2.0 -fold increase in 
secreted L1 expression in High Five cells relative to Sf9 cells (Figure 5.3B).  These 
results are consistent with previous observations of increased secreted p otein expression 
in High Five cells relative to Sf9 and Sf21 cells, although the lev l of increase was less 
than previously reported. [317, 318]  Intracellular protein exhibited a broade  distribution 
of molecular weight with a distinct band around 110 kDa and a broad band between 135-
150 kDa (Figure 5.3C).  These bands observed in the intracellular protein lik ly 
correspond to unglycosylated protein immediately following translation (110 kDa) and 
protein at varying stages of glycosylation (135-150 kDa).  Densitometry analysis 
indicated that intracellular L1 expression was substantially higher in High Five cells at 48 


























































Figure 5.3  Western blot and densitometry analysis of recombinant L1 localization 
in Sf9 and High Five cells using anti-human L1 polyclonal antibody.  Gels were 
loaded with equal quantities of total protein (supernatants: 30 µg/lane; lysates: 3 
µg/lane). Blots are representative of 3 independent experiments. (A) Representative 
western blot of Sf9 and High Five media supernatants. Lane 1, molecular weight 
marker; lane 2, 48 hr Sf9 supernatant; lane 3, 48 hr High Five supernatant; lane 4, 
72 hr Sf9 supernatant; lane 5, 72 hr High Five supernatant.  (B) Comparison of 
mean relative density of bands of secreted L1. (C) Representative western blot of Sf9 
and High Five cell lysates. Lane 1, molecular weight marker; lane 2, 48 hr Sf9 
lysate; lane 3, 48 hr High Five lysate; lane 4, 72 hr Sf9 lysate; lane 5, 72 hr High Five 
lysate.  (D) Comparison of mean relative density of bands of intracellular L1.  
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Kinetics and MOI Analysis of Recombinant L1  
Expression in High Five Cells 
 
 Following confirmation of L1 expression in insect cells, we investigated 
optimization of secreted recombinant protein production.  High Five cells ultured in T-
175 flasks were infected at varying MOI, and the supernatants were sampled and 
analyzed by Western blotting at varying timepoints postinfection (Figure 5.4A).  Secreted 
protein expression generally increased with increasing MOI and time postinfection, with 
the exception of 96-hour samples at 2.0 MOI, in which expression decreased relative to 
the 72-hour time point (Figure 5.4B).  Although gel loading was based on equal 
supernatant volumes to normalize expression levels to initial cell number, total protein 
analysis demonstrated that all supernatants contained approximately comparable protein 
levels (30.7 +/- 2.5 µg/sample).  Infections at 2.0 MOI resulted in the highest levels of 
protein production, however, light staining of lower molecular weight bands wa  
consistently observed at all time points, as well as at the 96 hour time point for 0.2 MOI 
infection.  These observations may be attributable to the high density of darkly colored 
cells observed at 2.0 MOI and the 0.2 MOI 96 hour time point which may be indicative 
of cell necrosis resulting in the release of intracellular L1 prior to completion of post-
translational modification and/or release of proteolytic enzymes.   On the basis of 
providing maximum expression in the absence of lower molecular weight bands, 0.2 MOI 
















































































































Figure 5.4  Western blot and densitometry analysis of the kinetics of secreted 
recombinant L1 expression from baculovirus-infected High Five cells using anti-
human L1 polyclonal antibody.  Gels were loaded with equal total volumes in order 
to normalize protein to initial cell density.  Blot is representative of 3 independent 
experiments. (A) Representative western blot of secreted L1 at varying infection 
conditions. Lane 1, molecular weight marker; lane 2, .002 MOI 48 hr; lane 3, .002 
MOI 72 hr; lane 4, .002 MOI 96 hr; lane 5, .02 MOI 48 hr; lane 6, .02 MOI 72 hr; 
lane 7, .02 MOI 96 hr; lane 8, .2 MOI 48 hr; lane 9, .2 MOI 72 hr; lane 10, .2 MOI 
96 hr; lane 11, 2 MOI 48 hr; lane 12, 2 MOI 72 hr; lane 13, 2 MOI 96 hr.  (B) 




Purification and Yield of Recombinant L1 in High Five™ Cells 
Secreted recombinant L1 was purified from culture supernatants using immobilized 
metal-affinity chromatography.  Due to the presence of disulfide bridges in the Ig 
domains, all purification procedures were conducted under non-denaturing conditions.  
Chemically-defined culture medium was used to avoid contamination by serum proteins.  
Preliminary experiments demonstrated that recombinant protein could n t be efficiently 
recovered directly from culture supernatants (data not shown).  Dialysis against 50 mM 
Na2HPO4, 300 mM NaCl buffer, pH 8.0 was performed to increase pH and to remove low 
molecular weight competing species.  The final purification procedure was documented 
by silver-stained SDS-PAGE (Figure 5.5), revealing a single band of recombinant L1 at 
approximately 140 kDa. 
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Figure 5.5  Documentation of the purification procedure for secreted recombinant 
L1 expression from the supernatant of baculovirus-infected High Five cells.  
Proteins were separated utilizing SDS-PAGE and silver stained.  Lane 1, molecular 
weight marker; lane 2, serum-free supernatant of baculovirus-infected High Five 
cells; lane 3, flow through; lane 4, 0 mM imidazole buffer wash; lane 5, 5 mM 
imidazole buffer wash; lane 6, 10 mM imidazole buffer wash; lane 7, combined 250 
mM imidazole elutions 1-3.  All samples were normalized to the original 
supernatant volume.  Representative of 3 independent experiments. 
 
BCA analysis demonstrated average yield of approximately 250-300 µg per 1x10
8
 
High Five cells.  Although diversity exists among expression methods and protein 
structure, this yield is approximately comparable to levels report d for other relatively 
high molecular weight, highly glycoylated proteins in insect cells.  Secreted human 
xylosyltransferase I (96 kDa) expression levels in High Five cells were reported as 5 mg / 
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1.0-2.5 x 109 cells [319], while intracellular expression levels of DNA (cytosine-C5)-
methyltransferase-1 (190 kDa) in Sf9 were reported at 1 mg / 3 x 108 cells[320].  Most 
comparable to our own study, a recent report of stable L1 expression in Sf9 cells using 
the honeybee melittin secretion signal achieved secreted protein yields of 3 mg / 4 x 109 
cells for the complete extracellular domain (203 kDa) and 32 mg / 4 x 109 cells for the Ig 
5-6 fragment (45 kDa). [313]   In general, insect cell expression levels ar  lower than 
prokaryotic systems and higher than mammalian systems.  Expression levels of L1-Fc in 
HEK 293 cells were reported as 1-5 mg/L, however the cell density was not reported and 
supernatant was repeatedly collected from stably transfected cells over a 4 week period. 
[274]  Yields of L1 extracellular fragments (30-85 kDa) expressed in E. Coli have been 
reported in the range of 3-5 mg/L. [312, 321]  
 
L1 Functional Bioactivity 
 As a cell-cell adhesion ligand, the most critical functional activity of L1 during 
development and as a potential therapeutic molecule is the promotion of axonal growth.  
Neurite outgrowth from primary central nervous system neurons was ev luated as a 
functional measure of protein bioactivity.  The bioactivity of the secret d insect cell-
derived 140 kDa extracellular L1 fragment was compared to mammalian-derived L1-Fc 
containing the entire extracellular region and poly-l-lysine (PLL), a routine substrate for 
neuronal cell culture.  Chick embryonic forebrain neurons were selected based on their 
ease of preparation at high yield and purity, allowing clear analysis of neuron-ligand 
interactions without interference from neuron adhesion and growth on contamina ing cell 
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types.  Previous studies have also demonstrated that neurite outgrowth of chick-derived 
neurons on mammalian L1 occurs through homophilic binding of mammalian L1 and its 
chick homologue, NgCAM. [305]  Both insect cell-derived L1 and mammalian-derived 
L1-Fc promoted robust neurite outgrowth at 24 hours that was much greater th n 
observed on PLL (Figure 5.6).  No neurite outgrowth was observed in blank control wells 
not coated with L1 or PLL (data not shown), indicating that the observed neurite 
outgrowth was mediated specifically by the protein/polymer coating applied to the wells.  
In addition, no neurite outgrowth was observed on intracellular L1 purified from High 
Five lysates under non-reducing conditions, indicating a lack of bioactivity probably due 
to incomplete glycosylation of the protein (data not shown).   
 
Figure 5.6  Demonstration of L1 bioactivity.  Embryonic day 8 chick forebrain 
neurons cultured on a 96 well polystyrene plate with (A) adsorbed 0.1% PLL, (B) 
adsorbed mammalian-derived L1-Fc (25 mg/ml), and (C) adsorbed insect cell-
derived L1 (25 µg/ml). Cells were cultured 24 hours and then stained for actin (red) 
and nuclei (blue).  Scale bar = 100 µm. 
 
Average measured neurite lengths at 24 hours were 40 µm for PLL, 155 µm for 
insect cell-derived L1, and 150 µm for mammalian-derived L1-Fc (Figure 4.5).  Neurite 
outgrowth was significantly greater for both insect cell-derived L1 and mammalian-
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derived L1-Fc than PLL; however, no statistically significant difference was observed 























Figure 5.7  Neurite outgrowth on L1.  Neurite lengths (mean +/- standard deviation) 
of embryonic day 8 chick forebrain neurons cultured on a 96 well polystyrene plate 
with adsorbed 0.1% PLL, adsorbed mammalian-derived L1-Fc (25 µg/ml), and 
adsorbed insect cell-derived L1 (25 µg/ml).  
 
CONCLUSION 
 These studies describe the expression of a 140 kDa extracellulr fragment of L1 
in the baculovirus/insect cell expression system.  Recombinant L1 was secreted as a 
soluble protein into the culture medium and through the incorporation of a C-terminal 6X 
histidine tag, it could be efficiently recovered at high purity by metal affinity 
chromatography.  Currently, L1 used for experimental studies is primarily expressed as a 
recombinant Fc-fusion protein in mammalian cells or directly purified rom brain lysates 
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by immunoaffinity chromatography.  The baculovirus expression and native purification 
approaches described here provide an alternative source of recombinant L1 with 
improved yield and equivalent bioactivity.  Continuing studies described in this 
dissertation examined the immobilization of L1 to biomaterial surfaces and investigated 




NIH 3T3 RESPONSE TO ACRYLATED TETRONIC ®  
 
HYDROGELS WITH IMMOBILIZED FIBRONECTIN 
 
INTRODUCTION  
The objectives of these experiments were (1) synthesis and purification of 
acrylated Tetronic macromers, (2) development of Michael addition methods for 
hydrogel crosslinking and protein immobilization, and (3) evaluation of hydrogel 
cytocompatibility, immobilized protein bioactivity, and immobilization efficiency in 
terms of cell spreading and proliferation using NIH 3T3 fibroblasts and fibronectin. 
This work established methods for adding acrylate groups to Tetronic® 904 and 
fabricating hydrogels using a Michael addition reaction. [322]  Michael addition is not 
only useful for hydrogel fabrication, but may also be used for protein immobilization.  
Murphy et al. immobilized calmodulin within Peg-tetraacrylate gels via Michael type 
addition of cysteine thiols to the acrylate groups [281], and Rydholm et al. have 
demonstrated that pendant thiols on thiol-acrylate polymers may be useful for post-
polymerization functionalization. [282]  Additionally, peptide acrylation is a well-
established method for covalent immobilization of peptides within hydrogels [283-285], 
and protein acrylation has been used in methods to conjugate antibodies and coll gen 
type I to polymer surfaces [286, 287] 
Three methods of protein immobilization to T904-acrylate hydrogels were 
evaluated (Figure 6.1): (A) Michael type addition of cysteine thiols from encapsulated 
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reduced protein to acrylate groups within the hydrogel, (B) Michael type addition of 
cysteine thiols from reduced protein to unreacted pendant acrylate groups on the hydrogel 
surface, and (C) Michael type addition of acrylated proteins using acrylate-PEG-NHS (N-

































Figure 6.1  Protein Immobilization Methods 
 
NIH 3T3 cells originated from Swiss mouse embryo tissue, and the cell line was 
established in 1962 by George Todaro and Howard Green at the Department of Patholgy 
in the New York University School of Medicine. [323]  These fibroblast cells double 
every 24 hours and reach a saturation density of approximately 50,000 cells per cm2, and 
they are widely used in research laboratories.  Fibronectin exists in two main forms: 1) as 
an insoluble glycoprotein dimer in the ECM, made by fibroblasts, chondrocytes, 
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endothelial cells, macrophages, as well as certain epithelial clls; and 2) as a soluble 
disulphide linked dimer found in the plasma, synthesized by hepatocytes.  Fibronectin is 
secreted as a disulfide-bonded dimer of approximate 440 kDa molecular weight, and each 
subunit contains three types of repeating modules: FN-I, -II, and FN-III, with disulfide 
bonds in FN-1 and FN-II but not FN-III modules. [324, 325]  It is widely known that the 
Arginine-Glycine-Aspartic Acid (RGD) integrin binding tripeptide in the FN-III repeat 
10 is an important bioactive site that induces fibroblast attachment to fibronectin via 
integrin binding [326-328], although there is also evidence of multiple functional synergy 
sites within the fibronectin protein. [329-332]  Fibronectin has free cysteine residues and 
numerous disulfide bonds that can participate in Michael addition and thiol/disulfide 
exchange reactions. [333]  It also contains multiple lysine residues making it an attractive 
candidate for acrylation through conjugation to the heterobifunctional PEG derivative, 
acrylate-PEG-NHS. 
 
MATERIALS AND METHODS  
Synthesis and Purification of T904-Acrylate 
Figure 6.2 is a schematic of the synthesis of acrylated Tetronic macromers [322], 




Figure 6.2  Synthesis of Acrylated Tetronic Macromers [322] 
 
Briefly, Tetronic® 904 (MW 6700) was dissolved in toluene, azeotropically 
distilled, and toluene was removed via solvent evaporation with a rotary ev porator.  The 
T904 was then dissolved in dehydrated dichloromethane and reacted with 4X molar 
excess triethylamine (TEA) and 8X molar excess acryloyl chloride for 24 hours at 4°C.  
At the completion of the reaction, the product was filtered, dichloromethane was removed 
via solvent evaporation, and it was precipitated in a 50/50 ether/hexane mixture.  Upon 
settling of the precipitated product, ether/hexane was decanted and the product was 
redissolved in dichloromethane, washed with NaHCO3 to neutralize the pH followed by 
multiple water washes, and water was removed using anhydrous sodium sulfate.  
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Dichloromethane was removed via solvent evaporation, and the product was precipitated 
in a 50/50 ether/hexane mixture two times followed by two 100% ether precipitations to 
ensure removal of all hexane.  Upon settling of the precipitated product, ether/h xane was 
decanted, the product was dried overnight in a cold dessicator on ice under vacuum to 
remove ether, and 1H-NMR (Brucker 300 MHz, CDCl3) was taken to evaluate the 
acrylation efficiency.  All T904-acrylate products were stored at -20°C protected from 
light. 
NIH 3T3 Cell Culture 
NIH 3T3 mouse fibroblasts were purchased from ATCC (American Type Culture 
Collection) and were routinely maintained 75 cm2 T-flasks in a humidified chamber at 
37°C with 7% CO2 atmosphere in 50/50 Dulbecco’s Modified Eagle’s Medium and 
Ham’s F-12 with L-glutamine (DMEM/F12 1X, Mediatech) supplemented with 10% v/v 
bovine growth serum (BGS, Hyclone) and 50 I.U./mL penicillin and 50 µg/mL 
streptomycin (Mediatech).  Culture medium was changed once every two days and cells 
were passaged weekly.  For hydrogel experiments, monolayers of fibr blasts were 
trypsinized, centrifuged, resuspended, counted in a hemacytometer, and adjusted to the 
appropriate final concentrations based on pilot studies. 
 
Preparation of T904-Acrylate Solution 
T904-acrylate was mixed with 50mM PBS pH 7.4 to make a 28.75% solution 
(287.5mg T904 + 712.5µL PBS) and was allowed to dissolve overnight with stirring at 
room temperature protected from light.  Because of batch-to-batch inconsistencies in 
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T904-acrylate pH due to variable efficiency of washing steps during synthesis and 
because of the dependency of solution pH on temperature, the solution was adjusted to 
pH 7.2 at room temperature with 6N hydrochloric acid to ensure consistent, appropriate 
pH for the Michael addition polymerization reaction.  Following pH adjustment, the 
solution was carefully filtered with a 25mm 0.2µm syringe filter (Nalgene) for removal of 
contaminants and sterilization.  The sterile solution was stored at 4°C protected from 
light, but was brought to room temperature prior to making hydrogels because of its basic 
pH at colder temperatures.   
 
Preparation of Hydrogels 
Prior to making hydrogels, all components were sterilized. Uncharged glass 
coverslips (Fisher) were UV sterilized for 20 minutes in the cell culture hood.  Binder 
clips, 1mm thick Teflon spacers, vacuum grease, spatulas, and forceps were autoclaved 
prior to use.  All experiments were conducted in the cell culture hood using aseptic 
technique. 
Hydrogel crosslinking via Michael addition reaction was initiated by the addition 
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Figure 6.3  Michael Addition Polymerization Scheme [322] 
 
Hydrogels for all conditions tested were fabricated by mixing the 28.75% T904-
acrylate solution previously described with 10% v/v fibronectin solution (encapsulated 
protein) or 50mM PBS solution (surface-immobilized protein) and 10% v/v DTT solution 
for a final concentration of 23% T904 acrylate (i.e., 80µL T904 acrylate + 10µL of 
fibronectin/50mM PBS + 10µL DTT = 23% T904-acrylate hydrogel for a 100µL 
hydrogel).   
T904 has a molecular weight of 6700 g/mol.  T904-acrylate has an estimated 
molecular weight of 6916 g/mol and 4 moles of acrylate per mole of T904 acrylate 
assuming 100% acrylation efficiency.  DTT has a molecular weight of 154.26 and 2 
moles of thiol per mole of DTT.  For encapsulated protein, the DTT concentration 
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required was calculated based on a 1:1 T904 acrylate:DTT thiol rati , thus requiring 1.03 
mg of DTT per 23 mg of T904 acrylate.  For surface-immobilization of acrylated peptide 
or protein, the DTT concentration required was calculated based on a 1:1.1 T904 
acrylate:DTT thiol molar ratio in order to leave unreacted pendant thiols on the hydrogel 
surface, thus requiring 1.13 mg of DTT per 23 mg of T904 acrylate.  For surface-
immobilization of reduced protein, the DTT concentration required was calculated based 
on a 1.1:1 T904 acrylate:DTT thiol molar ratio in order to leave unreacted pendant 
acrylate groups on the hydrogel surface, thus requiring 0.93 mg of DTT per 23 mg of 
T904 acrylate.  A new DTT stock solution was made for every experiment and was 
sterilized by filtering through a 13mm 0.2µm syringe-filter (Nalgene). 
 
T904-Acrylate Hydrogels with Surface-Immobilized Reduced Fibronectin 
These experiments are based on the immobilization method depicted in Figure 
6.1B.   
Reduction of Fibronectin 
Analysis of GenBank Accession No. P07589, bovine fibronectin (Appendix A) 
revealed that fibronectin contains 62 cysteines per mol.  Fibronectin is a 440 kDa protein, 
and a 1 mg/mL solution is equivalent to 0.00227 mmol/L concentration of protein.  
Protein solutions are typically reduced with 1mM to 10 mM DTT.  A 2.5 mM DTT 
solution was used to reduce fibronectin [276], resulting in an approximate 1000 molar 
excess of DTT to fibronectin, or an approximate 35-molar excess of DTT thiols to 
fibronectin cysteines.  A 10X 25mM stock solution of DTT in 50mM PBS pH 7.4 buffer 
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was made, 10% by volume was added to the 1mg/mL fibronectin solution for a final 2.5 
mM DTT concentration, and reacted for 1 hour at room temperature.  Unreacted DTT 
was removed by column filtration using a PD-10 column and 50mM PBS pH 7.4 buffer
followed by analysis of protein concentration via measurement of absrbance at 280nm.  
Protein samples were kept on ice following filtration and during protein concentration 
analysis. 
Preparation of Hydrogels 
PBS and DTT were directly added to room temperature 28.75% T904-acrylate 
solution, and the gel solution was vortexed briefly, tap-spinned, and 70µL was 
immediately pipetted directly into 96-well TCPS plate and allowed to polymerize via 
Michael addition in the dark for 1 hour at room temperature. After 1 hour, reduced 
fibronectin solution (100µL per well) of 100 µg/mL concentration was added and left for 
an additional hour at room temperature.  Hydrogel crosslinking and fibronectin reduction 
were coordinated such that reduced fibronectin solution was added to the hydrogels 
immediately upon completion of reduced fibronectin concentration analysis, to minimize 
the possibility of disulfide bond reformation. Hydrogels without reduced fibronectin were 
used as negative controls.  Blank 48-well TCPS wells and 96-well bacterial polystyrene 
wells with 10 µg/mL reduced fibronectin adsorbed overnight were seeded as positive 
controls for visual confirmation of cell health and bioactivity of reduced protein.  
Following 1 hour incubation in reduced protein at room temperature, the plat  was 
parafilmed and transferred to 37°C overnight with shaking. The next morning, gels were 
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rinsed with 200µL of sterile PBS three times and hydrated in 100µL of sterile PBS per 
well at 37°C until cell seeding. 
Cell Seeding 
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with L-
glutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL 
streptomycin and observed at 24 hours post-seeding for attachment and spreading. 
 
T904-Acrylate Hydrogels with Surface-Immobilized Acrylate-PEG-RGD 
A pilot study was conducted using stock 10 µmol/mL acrylate-PEG-RGD 
previously synthesized in our lab using 70µL hydrogels polymerized directly in 96-well 
TCPS plates.   
Immobilization of Acrylate-PEG-RGD 
PBS and DTT were directly added to room temperature T904-acrylate solution, 
and the gel solution was vortexed briefly, tap-spinned, and 70µL was immediately 
pipetted directly into 96-well TCPS plate and allowed to crosslink via Michael addition at 
dark for 1 hour at room temperature. After 1 hour, acrylate-PEG-RGD solution (diluted 
to 1 µmol/mL) was added and left for an additional hour at room temperatur.  Additional 
hydrogels were incubated in acrylate-PEG-RGD solution (1 µmol/mL) diluted in a 100X 
molar excess sodium acrylate solution to determine if this inhibited binding of acrylate-
PEG-RGD to the hydrogel surface.  Negative control samples included hydrogels without 
acrylate-PEG-RGD.  Positive control samples (for visual confirmation of cell hea th only) 
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included blank 96-well TCPS wells and encapsulated fibronectin gels.  All conditions 
used a sample size of n=3 independent gels. 
Following 1 hour incubation at room temperature, the plate was parafilmed and 
transferred to 37°C overnight with shaking. The next morning, gels were rinsed with 
200µL of sterile PBS three times and hydrated in 100µL of sterile PBS per well at 37°C 
until cell seeding. 
Cell Seeding 
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with L-
glutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL 
streptomycin. 
Cell Staining and Imaging 
At 24 hours post-seeding, cells were fixed in 4% paraformaldehyde in PBS for 
one hour at room temperature, permeabilized with 0.5% Triton X-100 for 2 minutes, and 
stained for actin filaments with rhodamine phalloidin (Molecular Probes).  Hydrogels 
were carefully removed from the wells and flipped over onto a glass slide for imaging, 
and digital fluorescent images were obtained using a 10X objective for each condition.  
 
Preparation of Acrylated Fibronectin 
Acrylation Reaction 
Bovine plasma fibronection (1mg/mL, Sigma-Aldrich) is supplied in 0.5 M NaCl, 
0.05 M Tris, pH 7.5.  Tris contains primary amines that interfere with fibronectin 
acrylation using acrylate-PEG-NHS because of competitive binding with the protein 
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lysine amines; therefore, prior to using the protein solution, a buffer exchange into 50mM 
PBS, pH 7.4 was performed utilizing 0.5 mL Zeba desalt columns (Pierce) ac ording to 
the manufacturer’s instructions.   
Standard reaction conditions for NHS-containing crosslinkers call for 0.1-10 mM 
concentrations.  Fibronectin is a 440 kDa protein, and a 1 mg/mL solution is equivalent to 
0.00227 mmol/L concentration of protein.  Typically, 2 to 50-fold molar excesses of 
crosslinker are used for reactions, and the 0.1M concentration of acrylate-PEG-NHS 
(Nektar, 3450 Da) used for this reaction resulted in a 44 molar excess of crosslinker to 
fibronectin.  A 10X solution of 3.45 mg/mL acrylate-PEG-NHS in anhydrous DMSO was 
made fresh for each reaction, 10µL of this solution was added to 100 µL of 1mg/mL 
fibronectin for an organic solvent carryover of 10% final volume in the aqueous reaction, 
and reacted for 2 hours at room temperature with shaking.  At the completion of the 
reaction, a buffer exchange into 50mM PBS, pH 7.4 was again performed to r move 
unreacted crosslinker and solvent contamination, and the acrylated protein was stored at 
4°C protected from light. 
Electrophoresis of Acrylated Fibronectin 
Samples of acrylated and non-acrylated fibronectin were immediately collected 
for SDS-PAGE (sodium dodecyl polyacrylamide gel electrophoresis) analysis (12 µL 
protein + 4 µL 4X reducing buffer) and immediately frozen at -80°C.  Protein samples 
were separated by SDS-PAGE on a 6% polyacrylamide gel using Tr s-glycine buffer 
under reducing conditions at 100V for 150 minutes.  The gel was stained with 0.2% 
Coomassie Brilliant Blue in Water:Methanol:Acetic Acid with volume ratios 5:4:1 for 45 
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minutes followed by destaining in Water:Methanol:Acetic Acid with volume ratios 5:4:1 
for 3 hours.  The gel was imaged using a Kodak Electrophoresis Documentation and 
Analysis System 120. 
T904 Acrylate Hydrogels with Encapsulated and Surface-Immobilized  
Acrylated Fibronectin 
 
These experiments are based on the immobilization methods depicted in Figure 
6.1A and C. Two separate experiments were conducted in order to quantify fibroblast 
spreading and proliferation in response to hydrogels with encapsulated fibronectin and 
surface-immobilized acrylated fibronectin (as depicted in the project rationale Figure 
4.3A).  The dose dependent response of cells to varying concentrations of fibronectin was 
characterized by analyzing fibroblast spreading at an intermediate time point of 18 hours 
post-seeding, prior to the typical cell doubling timepoint of 24 hours.  A cell proliferation 
assay was then conducted with protein concentrations chosen based on fibroblast 
spreading results. 
Dose Dependent Response Assay 
For hydrogels with encapsulated fibronectin, pilot studies were conducted to 
determine the optimum timepoint of fibronectin reduction with DTT prior to addition to 
the T904-acrylate solution (0, 2.5, 5, 10, 15, and 30 minutes) with encapsulated 
100µg/mL fibronectin hydrogels.  Hydrogels for the dose dependent response assay were 
made with varying concentrations of encapsulated fibronectin (1.0, 2.5, 5.0, 7.5, 10, 2 , 
50, 75, 100 µg/mL) with n=3 independent gels per condition.  Hydrogels without 
fibronectin (n=3 independent gels) were used as negative controls.  Blank 48-well TCPS 
wells and 96-well bacterial polystyrene wells with 10 µg/mL reduced fibronectin 
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adsorbed overnight were seeded as positive controls for visual confirmation of cell health 
and bioactivity of reduced protein.  Fibronectin was mixed with DTT for 5 minutes at 
room temperature with shaking.  This protein/DTT mixture was added to room 
temperature T904 acrylate solution, the gel solution was vortexed briefly, tap-spinned, 
and 60µL was immediately pipetted in between two glass slides separated by 1mm Teflon 
spacers.  The hydrogels were allowed to crosslink via Michael addition in the dark for 2 
hours at room temperature followed by overnight at 37°C in parafilmed petri dishes with 
sterile water to provide a humid environment.  The next morning, vacuum grease was 
added to the bottom of 48-well TCPS plates and sterilized under UV light for 20 minutes.  
The hydrogels were carefully removed from the glass slides by rinsing with sterile PBS 
and were placed in the wells, gently pressing them down onto the vacuum grease to 
prevent floating, and hydrated in 1 mL of PBS per well at 37°C until cell seeding.  
For hydrogels with surface-immobilized acrylated fibronectin, PBS and DTT 
were directly added to room temperature T904-acrylate solution, and the gel solution was 
vortexed briefly, tap-spinned, and 70µL was immediately pipetted directly into 96-well 
TCPS plate and allowed to crosslink via Michael addition in the dark for 1 hour at room 
temperature. After 1 hour, acrylated fibronectin solution (100µL per well) of varying 
concentrations (1.0, 2.5, 5.0, 7.5, 10, 25, 50, 75, 100 µg/mL) was added and left for an 
additional hour at room temperature, with n=3 independent gels per condition. Negative 
control samples included hydrogels without acrylated fibronectin (n=3 independent gels) 
and hydrogels with non-acrylated fibronectin (n=3 independent gels).  Blank 96-well 
TCPS wells were seeded as positive controls for visual confirmation of cell health.  
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Following 1 hour incubation in acrylated protein at room temperature, the plat  was 
parafilmed and transferred to 37°C overnight with shaking. The next morning, gels were 
rinsed with 200µL of sterile PBS three times and hydrated in 100µL of sterile PBS per 
well at 37°C until cell seeding. 
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with L-
glutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL 
streptomycin. 
Cell Proliferation Assay 
Three timepoints were chosen for cell proliferation analysis: 24 hours (1 day), 72 
hours (3 days), and 120 hours (5 days) post seeding.  Based on the results of the dose 
dependent response assay, hydrogels were made with varying concentrations of 
encapsulated fibronectin (2.5, 5.0, 25, 100 µg/mL) and acrylated fibronectin (7.5, 10, 25, 
100 µg/mL) with n=3 independent gels per condition.  Negative control samples included 
hydrogels without encapsulated and acrylated fibronectin (n=3 independent gels) and 
hydrogels with non-acrylated fibronectin (n=3 independent gels).  Blank 96-well TCPS 
wells were seeded as positive controls for visual confirmation of cell health.   
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with L-
glutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL 
streptomycin.  Media was changed daily to maintain an adequate supply of cell nutrints.   
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Measurement of Fibroblast Spreading 
Fibroblast spreading at 18 hours post-seeding was analyzed via measurement of 
the surface area of the cells.  Cells were fixed in 4% paraform ldehyde in PBS for one 
hour at room temperature, permeabilized with 0.5% Triton X-100 for 2 minutes, and 
stained for actin filaments with rhodamine phalloidin (Molecular Probes).  Hydrogels 
were carefully removed from the wells and flipped over onto a glass slide for imaging.  
Twenty digital fluorescent images per well using a 10X objective covering the entire 
hydrogel surface were recorded for each condition.  Cell surface area was quantitatively 
measured from the digital fluorescent images using ImagePro software (n=21 
measurements / experimental group, comprised of an average of 7 measurements from 
each of 3 independent wells).   
DNA Content Analysis 
PicoGreen (Molecular Probes) is a fluorescent binding dye and is an e t blished 
method of characterizing cell proliferation based on DNA content. [284, 334-3 6]  
Hydrogel samples were analyzed in triplicate for DNA content at 1, 3, and 5 days to 
assess cell proliferation.  The cell-seeded hydrogels were rinsed with PBS, and fibroblasts 
were lysed by freeze/thaw of the samples at -80°C three times.  Samples were suspended 
in 2mL of cold 10mM EDTA pH 12.3 solubilization buffer (2mL for encapsulated 
fibronectin samples, 200µL for acrylated fibronectin samples) as previously described. 
[337]  Following 20 minute incubation at 37°C, the samples were cooled on ice and the 
pH was neutralized with 1M potassium phosphate pH 4.19 (150µL for encapsulated 
fibronectin samples, 15µL for acrylated fibronectin samples).  Samples were analyzed 
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according to the manufacturer’s instructions using a SpectraMAX Gemini fluorometer 
(excitation filter at 480 nm and emission filter at 520 nm) based on standard curves 
derived from serial dilutions of the same cells and their DNA content. 
Statistical Analysis 
The data was analyzed by ANOVA using Tukey’s method for post-hoc 
comparisons with p<0.05 considered statistically significant.  All results are expressed as 
mean ± standard deviation. 
 
RESULTS AND DISCUSSION 
Synthesis and Purification of T904-Acrylate 
Figure 6.4 depicts the NMR from a typical T904-acrylate product.  A 30g reaction 
typically yielded approximately 15g of final product and 1H-NMR (CHCl3) demonstrated 










Figure 6.4  Structure and 1H-NMR Spectrum of Acrylated T904 Macromer 
 
NIH 3T3 Response to Surface-Immobilized Reduced Fibronectin 
Fibroblasts showed little evidence of attachment and no spreading on hydrogels 
with reduced fibronectin, comparable to hydrogels with no protein.  Positive controls of 
blank 48-well TCPS and 96-well bacterial polystyrene with 10 µg/mL reduced 
fibronectin adsorbed overnight demonstrated significant spreading and proliferation of 
fibroblasts. Acrylate groups are inherently hydrophobic because their CH=CH2 
carbonaceous side groups are non-polar and thus do not attract water strongly.  We 
hypothesize that this immobilization technique failed because the inherent 
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hydrophobicity of the acrylate groups contributes to their retreat within the hydrogel upon 
application of the hydrophilic reduced fibronectin solution, thus hindering the Michael 
addition protein conjugation reaction.  An alternative explanation is that the filtration 
method used may not be sufficient to remove all excess DTT, possibly resulting in a 
reformation of fibronectin disulfide bonds prior to adding the solution to the hydrogels.  
No further experiments were conducted utilizing reduced fibronectin. 
 
 
NIH 3T3 Response to Surface-Immobilized Acrylate-PEG-RGD 
 
This pilot study was conducted in order to demonstrate the feasibility of 
immobilizing acrylated protein to hydrogels through Michael addition reaction by 
demonstrating cell attachment to an immobilized acrylated peptide, and to prove that the 
cellular response was, in fact, a result of acrylate binding to unreacted pendant thiols on 
the hydrogel surface via a competitive binding assay using sodium acrylate. (Figure 6.5)  
Figure 6.5A depicts significant fibroblast attachment and spreading on hydrogels with 
immobilized acrylate-PEG-RGD at 24 hours.  Figure 6.5B depicts fibroblasts on 
hydrogels incubated in acrylate-PEG-RGD diluted in 100X molar excess of sodium 
acrylate, and significant inhibition of cellular response is shown with only slight 
improvement in fibroblast attachment and spreading over the negative control with no 
peptide depicted in Figure 6.5C, thus demonstrating that the RGD peptide immobilized 






Figure 6.5  Proof of Michael addition surface conjugation of RGD peptide.  NIH 3T3 
cells cultured on hydrogels with immobilized (A) acrylate-PEG-RGD (1 µM), (B) 
acrylate-PEG-RGD (1 µM) diluted in 100 molar excess sodium acrylate, and (C) no 
peptide.  Cells were stained for actin with rhodamine phalloidin.  Scalebar = 100 
µm.   
 
 
Acrylation of Fibronectin 
 
As stated previously, plasma fibronectin is a disulfide-bonded dimer consisting of 
a pair of 220 kDa subunits [324, 325]; therefore, a molecular weight marker with an 
upper limit of 250 kDa could be used with reducing SDS-PAGE for determination of 
molecular weight. [338]  Analysis of GenBank Accession No. P07589, bovine fibronectin 
(Appendix A) revealed that fibronectin contains 122 lysines per mol, and the acrylate-
PEG-NHS used to acrylate fibronectin has a molecular weight of 3450 Da.  Conjugation 
of 1-4 lysines per mol of fibronectin with acrylate-PEG-NHS should result in an 
estimated 3-13kDa increase in molecular weight.  Figure 6.6 demonstrates an 
approximate 8-10 kDa increase in molecular weight of the acrylated protein as evidenced 










Figure 6.6  Documentation of fibronectin acrylation.  Proteins were separated 
utilizing SDS-PAGE and stained with 0.2% Coomassie Brilliant Blue.  Lane 1, 
molecular weight marker; lane 2, acrylated fibronectin; lane 3, non-acrylated 
fibronectin.  Gels were loaded with equal quantities of total protein (12 µg/lane).  
Data is representative of three independent experiments. 
 
 
NIH 3T3 Response to Encapsulated and Surface-Immobilized  
Acrylated Fibronectin 
 
Dose Dependent Response of Fibroblast Spreading 
The purpose of this assay was to determine if fibroblasts display a dose dependent 
spreading response to hydrogels with varying concentrations of encapsulated and 
acrylated fibronectin, in order to determine the optimal fibronectin concentrations for cell 
spreading and to determine conditions for analysis of proliferation rates.   
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Positive controls of blank 48-well TCPS and 96-well bacterial polystyrene with 
10 µg/mL reduced fibronectin adsorbed overnight demonstrated significant spreading and 
proliferation of fibroblasts. For hydrogels with encapsulated fibronectin, pilot studies 
were conducted to determine the optimum timepoint of fibronectin reduction with DTT 
prior to addition to the T904-acrylate solution (0, 2.5, 5, 10, 15, and 30 minutes), and 5 
minutes resulted in maximum cell adhesion to hydrogels with encapsulated 100µg/mL 
fibronectin at 24 hours (data not shown).  The 2.5 and 10 minute timepoints resulted in 
limited cell adhesion at 24 hours and response greatly diminished at the0, 15, and 30 
minute timepoints, most likely a result of limited disulfide bond reduction at the 0 
timepoint and reformation of disulfide bonds at the 15 and 30 minute timepoints. 
Fibroblast spreading on hydrogels with encapsulated fibronectin is shown in 
Figure 6.7.  The data indicates a plateau beginning at 2.5 µg/mL, and the minimum cell 
spread area in the plateau region was 2277 µm2 at 2.5 µg/mL.  A statistically significant 
difference was observed between 25 and 100 µg/mL with a maximum average cell spread 
area of 3400 µm2.  A statistically significant difference was also observed b tween 1.0 
and 2.5 µg/mL concentrations; however, cell attachment upon visual observation was 
significantly reduced at 1.0 and 0 µg/mL concentrations, and minimal cell spread areas of 
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Figure 6.7 Fibroblast spreading on hydrogels with encapsulated fibronectin.  
Average cell areas (mean +/- standard deviation) of NIH 3T3 cells cultured on 
hydrogels with encapsulated fibronectin of varying concentrations.  Data is 
representative of three independent experiments. 
  
 
Figure 6.8 displays the cell spreading on hydrogels with encapsulated fibronectin 















Figure 6.8  Cytoskeletal organization of fibroblasts cultured on hydrogels with 
varying concentrations of encapsulated fibronectin.  (A) 100 µg/mL, (B) 75 µg/mL, 
(C) 50 µg/mL, (D) 25 µg/mL, (E) 10 µg/mL, (F) 7.5 µg/mL, (G) 5.0 µg/mL, (H) 2.5 
µg/mL, (I) 1.0 µg/mL, and (J) 0.0 µg/mL Cells were stained for actin with 
rhodamine phalloidin.  Images are representative of the average cell area for each 
condition.  Scalebar = 50 µm. 
 
 
Fibroblast spreading on hydrogels with acrylated fibronectin is shown in Figure 
6.9.  The data indicates an increasing trend of cell spread area in sponse to increasing 
fibronectin concentration with a maximum cell spread area of 3423 µm2 at 100 µg/mL.  A 
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statistically significant difference was observed between 25 and 50 µg/mL.  The 
minimum cell spread area measured was 523 µm2 at 5.0 µg/mL, which is comparable to 
the spreading seen on hydrogels with 1.0 µg/mL concentration of encapsulated 
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Figure 6.9 Fibroblast spreading on hydrogels with surface-immoblized acrylated 
fibronectin.  Average cell areas (mean +/- standard deviation) of NIH 3T3 cells 
cultured on hydrogels with acrylated fibronectin of varying concentrations.  No 
hydrogels with acrylated protein concentration below 5 µg/mL were measured due 





Figure 6.10 displays the cell spreading on hydrogels with acrylated fibronectin 









Figure 6.10  Cytoskeletal organization of fibroblasts cultured on hydrogels with 
varying concentrations of surface-immobilized acrylated fibronectin.  (A) 100 
µg/mL, (B) 75 µg/mL, (C) 50 µg/mL, (D) 25 µg/mL, (E) 10 µg/mL, and (F) 7.5 
µg/mL.  Cells were stained for actin with rhodamine phalloidin.  Images are 
representative of the average cell area for each condition.  Scalebar = 50 µm. 
 
  
For both encapsulated and acrylated fibronectin, concentrations of 50, 75, and 100 
µg/mL promoted maximum fibroblast spreading, and both methods displayed a 
maximum cell spread area of approximately 3400 µm2 with 100 µg/mL of fibronectin.  
Encapsulated fibronectin supported fibroblast spreading at lower concentrations than 
acrylated fibronectin; cell spread area of approximately 2000 µm2 was observed on 
hydrogels with 2.5 µg/mL of encapsulated fibronectin and 25 µg/mL of acrylated 
fibronectin. 
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Prior studies using 100 µg/mL of thiolated fibronectin immobilized to polystyrene 
surfaces through Pluronic-pyridyl disulfide (F108-PDS) modification demonstrated cell 
surface areas >8000 µm2 [339]; therefore, future work may include higher concentrations 
of fibronectin to determine if increased fibroblast spreading areas are attainable on 
encapsulated and surface-immobilized acrylated hydrogels. 
 
Fibroblast Proliferation Response 
 
The purpose of this assay was to analyze cell proliferation in response to varying 
concentrations of encapsulated and acrylated fibronectin over the course of 5 days.  
Based on the results of the dose-dependent response assay for encapsulated fibronectin, 
an optimum concentration of 100 µg/mL and three concentrations from the plateau region 
were chosen based on statistically significant differences in cell spreading: 25 µg/mL, 10 
µg/mL, and 2.5 µg/mL.  Hydrogels with no encapsulated protein (0 µg/mL) were used as 
a negative control for comparison.  Fibroblast proliferation on encapsulated fibronectin 
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Figure 6.11 Fibroblast proliferation on hydrogels with encapsulated fibronectin of 
varying concentrations.  Cells were seeded at a density of 10,000 cells per well.  




The data indicates significant variability in cell proliferation between 2.5 µg/mL 
and 25 µg/mL concentrations, which corresponds to the plateau region of fibroblast 
spreading.  Cell attachment at 2.5 µg/mL is comparable to the negative control.  Although 
similar numbers of cells are attached at Day 1 on the 10 µg/mL, 25 µg/mL, and 100 
µg/mL conditions, only the 100 µg/mL condition displayed a continual increase in cell 




Hydrogels with 100 µg/mL of encapsulated fibronectin exhibited the maximum 
average cell spread area of 3400 µm2 with a 240% increase in proliferation from Day 1 to 
Day 5.  This data is consistent with reports that cell proliferat on is improved with 
increased cell spreading. [339-342]  The inconsistency in fibroblast proliferation at 
fibronectin concentrations below 100 µg/mL may indicate an insufficient amount of 
surface protein to support cell spreading and cytoskeletal organizatio , thus 
demonstrating the importance of optimized surface-ligand densities for cell proliferation.  
In addition, T904-acrylate hydrogels are hydrolytically degradable, and greater 
connectivity of fibroblasts on hydrogels with 100 µg/mL fibronectin concentration may 
have prevented detachment of cells from the degrading hydrogel. 
Based on the results of the dose-dependent response assay for acrylated 
fibronectin, an optimum concentration of 100 µg/mL and three concentrations below 
optimum were chosen based on statistically significant differences in cell spreading: 25 
µg/mL, 10 µg/mL, and 7.5 µg/mL.  Hydrogels with no encapsulated protein (0 µg/mL) 
were included as a negative control for comparison.  Fibroblast  proliferation on acrylated 
fibronectin is shown in Figure 6.12.  Although significant numbers of fibroblasts were 
attached at Day 1 on both the 25 µg/mL and 100 µg/mL conditions, the data indicates no 
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Figure 6.12 Fibroblast proliferation on hydrogels with acrylated fibronectin of 
varying concentrations.  Error bars represent +/- standard deviation.  Data is 
representative of three independent experiments. 
 
This result is in stark contrast to the positive proliferation response observed for 
the encapsulated fibronectin 100 µg/mL condition at 3 and 5 days.  The measured cell 
areas at 18 hours post-seeding for the 50, 75, and 100 µg/mL conditions are comparable 
for both encapsulated and acrylated fibronectin, indicating that surface ligand density is 
high enough to support cell spreading and cytoskeletal organization that is critical to cell 
proliferation.  For both experiments, media was exchanged daily to ensure constant, fresh 
supply of cell nutrients, so this result is directly correlated to the immobilization strategy 
used.  In a hydrogel with encapsulated fibronectin, hydrolytic degraation may not be 
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detrimental to cell proliferation because it continually exposes the fibroblasts to 
fibronectin, and our encapsulated 100 µg/mL fibronectin data supports this theory; 
however, hydrolytic degradation of T904-acrylate hydrogels with surface-immobilized 
acrylated fibronectin may result in loss of the surface-conjugated protein layer and 
inhibition of proliferation.  
Another phenomenon was observed in that hydrogels incubated in non-acrylated 
fibronectin, an anticipated negative control, supported comparable fibroblast proliferation 
to hydrogels with surface-immobilized acrylated fibronectin (Figure 6.13).  Because of 
the similarity in the lack of support for fibroblast proliferation, we can deduce that this is 

















































Figure 6.13 Fibroblast proliferation on hydrogels with acrylated and non-acrylated 
fibronectin of 100 µg/mL concentration.  Error bars represent +/- standard 
deviation.  Data is representative of three independent experiments. 
 
 
The experiment with acrylate-PEG-RGD (Figure 6.4) demonstrated that fibroblast 
response was inhibited through competitive binding of sodium acrylate, proving the 
peptide was immobilized through a Michael addition conjugation. Several studies have 
demonstrated that fibronectin multimer formation occurs in vitro via the C-terminal free 
thiols upon exposure to a thiol reagent [343, 344] and in vivo depending upon exposure to 
metal ions. [345]  Another study has shown that homocysteine binding to plasma 
fibronectin in vivo is mediated through thiol-disulfide exchange at the C-terminal 
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disulfide bonds. [346]  We therefore hypothesize that non-acrylated fibronectin is 
immobilized to our hydrogel surfaces through a thiol-disulfide exchange mediated 
mechanism.  For these experiments, fibronectin solution was added to the gel at an early 
timepoint of 1 hour post-polymerization, possibly exposing the protein to reactive thiolate 
species capable of reducing the easily accessible C-terminal disulfide bonds.  In order to 
clarify this phenomena, further experiments with extended gelation times could be 
conducted to determine if more complete polymerization prior to addition of fibronectin 
solution will inhibit binding of non-acrylated fibronectin. 
 
CONCLUSION 
In conclusion, these studies demonstrated that surface-immobilization of reduced 
fibronectin to hydrogels with unreacted pendant acrylate groups is not feasible because of 
the inherent hydrophobicity of acrylate groups.  Surface-immobilization of acrylate-PEG-
RGD through Michael addition conjugation was demonstrated with a competitive binding 
assay using sodium acrylate to bind unreacted pendant thiols on the hydrogel surface to 
prevent RGD immobilization and limit fibroblast spreading and proliferation.  NIH 3T3 
fibroblasts exhibited maximum cell spreading at 18 hours and proliferation at 5 days on 
hydrogels with 100 µg/mL fibronectin concentration.  Future work may include higher 
fibronectin concentrations beyond 100 µg/mL to further maximize the cell spreading and 
proliferation response and to determine if higher protein concentrations will result in 
more uniform proliferation rates and possibly a second plateau region of fibroblast 
spreading response.  SDS-PAGE analysis demonstrated successfl acrylation of the 
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fibronectin protein.  NIH 3T3 fibroblasts seeded on acrylated fibronectin hydrogels 
displayed a positive dose-dependent spreading response to increasing concentrations of 
protein; however, long-term proliferation rates were significantly hindered, possibly by 
the hydrolytic mechanism of hydrogel degradation.  In addition, a second potential 
mechanism of fibronectin conjugation to hydrogel surfaces via thiol-disu fi e exchange is 
theorized, although it is likely that this mechanism will not be eff ctive for proteins with 
less accessible disulfide bonds.  Even with these concerns, the covalnt immobilization 
techniques described are useful for the design of selectively adhesive substrates and may 
be employed currently to study neural regeneration at earlytimepoints in a model system 





NEURONAL CELL LINE AND PRIMARY NEURON RESPONSE  
TO ACRYLATED TETRONIC ® HYDROGELS  
WITH IMMOBILIZED L1 
 
INTRODUCTION  
The objectives of these experiments were to evaluate the feasibility of using HT22 
mouse hippocampal B35 and rat neuroblastoma neuronal cell lines with immob lized L1, 
to establish primary mammalian neuron dissection protocols, to evaluate the 
cytocompatibility of acrylic-based Tetronic® hydrogels with primary neurons, and to 
demonstrate the feasibility of using acrylic-based Tetronic® hydrogels with covalently 
immobilized L1 for neural applications.   
Inherent challenges of primary neuronal cell cultures include animal to animal 
and developmental age variability and potential glial cell contamination; therefore, two 
neuronal cells lines, HT22 mouse hippocampal and B35 rat neuroblastoma, were first 
studied for their ability to respond to immobilized L1 and to differentiate nto neuronal 
phenotypes, in order to establish a model cell line to simulate neuronal response.  Both 
HT22 and B35 cells are typically maintained in media containing 10% serum to promote 
rapid growth and proliferation; however, a differentiated neuronal phenotype is pr ferred 
for these experiments in order to characterize neuronal response.  Hippocampal neurons 
are pyramidal cells, which is also the classification of neurons that are the primary 
excitation units of the mammalian corticospinal tract.  L1 is expr ssed on regenerating 
hippocampal axons following injury [347], and neurite outgrowth of primary 
hippocampal neurons has been demonstrated on adsorbed and immobilized L1-Fc.  [253]  
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HT22 cells are derived from mouse hippocampus, and both primary hippocampal and 
HT22 cells are typically used in neuronal survival studies. [348]  L1 has been described 
as a survival factor for rat embryonic hippocampal neurons, as evidence  by the 
prevention of apoptosis when cultured in serum-free media with both soluble and 
substrate-bound L1 [239]; therefore, it was hypothesized that HT22 cells can attach to 
immobilized L1 surfaces via homophilic interactions and can be induced to differentiate 
into a neuronal phenotype in low or serum-free media.  B35 cells express low levels of 
NCAM, primarily the 140 kDa isoform without the variable alternatively spliced exon 
(VASE) that downregulates neurite outgrowth, and close homologue of L1 (CHL1), but 
no detectable levels of L1 [349]; however, L1 and NCAM can bind via heterophilic 
interaction. [241, 350] [351]  These cells are normally loosely adherent with round phase-
bright cell bodies and short processes, but they have demonstrated the ability to 
differentiate reversibly and extend long neurites in low serum or with the addition of 
dibutyryl cAMP [349] ; therefore, it was hypothesized that B35 cells could attach to 
immobilized L1 surfaces via heterophilic interactions with NCAM and could be induced 
to differentiate in low or serum-free media.   
A protocol for embryonic day 8 chick forebrain dissection was establi hed in 
Chapter 5.  Although chick forebrain neurons are suitable for initial studies, it is 
preferable to use mammalian-derived cells for future work; therefore, rat postnatal day 7 
cerebellar and dorsal root ganglia dissection protocols were established.  
Michael addition methods established in the previous chapter were used to 
fabricate hydrogels and to evaluate immobilization of L1. 
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MATERIALS AND METHODS  
B35 and HT22 Cell Culture 
B35 rat neuroblastoma and HT22 mouse hippocampal cells were a generous gift 
from Dr. Karl Franek (Greenwood Genetics Center) and were routinely maintained in 75 
cm2 T-flasks in a humidified chamber at 37°C with 7% CO2 atmosphere in 50/50 
Dulbecco’s Modified Eagle’s Medium and Ham’s F-12 with L-glutamine (DMEM/F12 
1X, Mediatech) supplemented with 10% v/v bovine growth serum (BGS, Hyclone) and 
50 I.U./mL penicillin and 50 µg/mL streptomycin (Mediatech).  Culture medium was 
changed once every two days and cells were passaged weekly.  For experiments, 
monolayers of cells were trypsinized, centrifuged, resuspended, counted i a
hemacytometer, and adjusted to the appropriate final concentrations. 
 
Neuronal Differentiation of HT22 and B35 Cells 
96-well bacterial polystyrene plates were sterilized with etyl ne-oxide.  The 
laminin and fibronectin extracellular matrix proteins were included as positive controls 
for cell attachment and as a comparison to L1 for evaluation of neuronal differentiation.  
Laminin, fibronectin, and L1 were adsorbed overnight at room temperatur to bacterial 
polystyrene plates at 10 µg/mL concentration followed by two sterile PBS rinses.  Serum, 
reduced serum, and serum-free media formulations were tested: (1) DMEM/F12 
supplemented with 10% v/v BGS and 50 I.U./mL penicillin and 50 µg/mL streptomycin, 
(2) DMEM/F12 supplemented with 2% v/v BGS and 50 I.U./mL penicillin and 50 µg/mL 
streptomycin, and (3) Neurobasal-A (Gibco) supplemented with 2% v/v B27 supplement 
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(Gibco) and 2mM L-glutamine per manufacturer’s guidelines for tumor cell lines, and 50 
I.U./mL penicillin and 50 µg/mL streptomycin.  For the serum-free m dia condition, 
three cell seeding methods were employed: (1) cells were directly seeded in serum-free 
media, (2) cells were first seeded in 2% serum media for 2 hours followed by 
replacement with serum-free media to enhance attachment and survival, (3) cells were 
seeded according to condition 2 with the addition of 20ng/mL nerve growth factor (NGF) 
to further enhance differentiation into a neuronal phenotype.  HT22 and B35 monolayers 
were trypsinized, centrifuged, resuspended, counted in a hemacytometer, and seeded at a 
density of 10,000 cells per 96-well.  At 24 hours post-seeding, the cells were fixed in 4% 
paraformaldehyde in PBS for one hour at room temperature and and phase contrast 
images were obtained with a 20X objective. 
 
Primary Mammalian Neuron Dissection 
Postnatal day 7 rat neuron dissection protocols were developed for both cerebellar 
neurons [253, 352] and dorsal root ganglia (DRG) [353] and are included in Appedices 
C and D, respectively.  Laminin (10 µg/mL) was adsorbed to 96-well bacterial 
polystyrene plates overnight at room temperature.  Cerebellar neurons were seeded at a 
density of 20,000 cell per 96-well, and DRG were seeded at a density of 10,000 cells per 
96-well.  After 24 hours, cells were fixed for 1 hour in 4% paraformaldehyde and stained 
for actin microfilaments using Alexa Fluor® 594 phalloidin (Molecular Probes, 0.161 
µM) and digital fluorescent images were obtained. 
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Cytocompatibility of T904-Acrylate Hydrogels with Primary Neurons  
Poly-l-lysine (PLL) was absorbed to 24-well plates in a 0.1% concentration for 
one hour followed by three water rinses and overnight drying.   A 23% T904-acrylate 
hydrogel solution with a 1:1 acrylate:thiol ratio was prepared as previously described for 
encapsulated fibronectin hydrogels in Chapter 6.  A thin layer of hydrogel solution 
(10µL) was spread over the surface of two wells coated with PLL and llowed to 
polymerize via Michael addition for 2 hours at room temperature followed by overnight 
at 37°C.  Adsorbed 0.1% PLL wells were included as positive controls.  Primary chick 
forebrain neurons from embryonic day 8 chicks were dissected and prepared as described 
in Chapter 5 and were seeded at a density of 80,000 cells per well with no rinsing of the 
wells prior to seeding.  After 24 hours, the cells were fixed in 4% paraformaldehyde in 
PBS for one hour at room temperature and phase contrast images were obtain d with a 
10X objective. 
 
T904-Acrylate Hydrogels with Encapsulated L1 
These experiments are based on the immobilization method depicted in the 
Chapter 6 (Figure 6.1A).  The response of B35 and primary chick forebrain neurons to 
70µg/mL of encapsulated L1 was evaluated using 1mm thick, 30µL hydrogels in 96-well 
tissue culture polystyrene (TCPS) plates at 24 hours postseeding. 
Sterilization of Components Used in Hydrogel Fabrication 
Prior to making hydrogels, all components were sterilized. Uncharged glass 
coverslips (Fisher) were UV sterilized for 20 minutes in the cell culture hood.  Binder 
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clips, 1mm thick Teflon spacers, vacuum grease, spatulas, and forceps were autoclaved 
prior to use.  All experiments were conducted in the cell culture hood using aseptic 
technique. 
Concentration of L1 
The L1 protein produced as previously described in Chapter 5 typically displayed 
a concentration range of 60-160 µg/mL; therefore, the protein was first concentrated to a 
700µg/mL concentration in order be able to attain a 70µg/mL encapsulated L1 
concentration within the hydrogels.   A buffer exchange of six 600µL aliquots of 150 
µg/mL L1 protein into 50mM PBS, pH 7.4 with 21% salt concentration was performed 
utilizing a 5.0 mL Zeba desalt column (Pierce) according to the manufacturer’s 
instructions.  The protein was frozen overnight at -80°C, lyophilized, resuspended in 771 
µL of sterile water in order to maintain appropriate salt concentration, and store  at 4°C. 
Preparation of Hydrogels 
A 28.75% T904-acrylate hydrogel solution and a 1:1 acrylate:thiol ratio as 
described for encapsulated fibronectin hydrogels in Chapter 6 was used for this 
experiment.  L1 was mixed with dithiothreitol (DTT) for 5 minutes at room temperature 
with shaking.  This protein/DTT mixture was added to room temperature T904-acrylate 
solution, the gel solution was vortexed briefly, tap-spinned, and immediately pipetted in 
between two glass slides separated by 1mm Teflon spacers.  The hydrogels were allowed 
to crosslink via Michael addition in the dark for 2 hours at room temperatur  followed by 
overnight at 37°C in parafilmed petri dishes with sterile water to provide a humid 
environment.  The next morning, vacuum grease was added to the bottom of 96-well 
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TCPS plates and sterilized under UV light for 20 minutes.  The hydrogels were carefully 
removed from the glass slides by rinsing with sterile PBS and were placed in the wells, 
gently pressing them down onto the vacuum grease to prevent floating, and hydrated in 
100 µL of PBS per well at 37°C until cell seeding.  Hydrogels without pro ein were used 
as negative controls.  Bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL 
reduced L1 adsorbed overnight were used as positive controls for visual confirmation of 
cell health and bioactivity of reduced protein. 
Cell Seeding 
B35 cells were seeded at a density of 20,000 cells per 96-well in DMEM/F12 with 
L-glutamine supplemented with 10% v/v bovine growth serum (Hyclone) and 50 I.U./mL 
penicillin and 50 µg/mL streptomycin (Mediatech).  Medium containing 10% serum was 
chosen for initial experiments to enhance cell attachment to the hydrogels.  Primary chick 
forebrain cells derived from 8-day old chicks as previously described in Chapter 5 were 
seeded at a density of 20,000 cells per 96-well based on successful r ults of this seeding 
density on 96-well bacterial polystyrene wells with 10 µg/mL L1 adsorbed overnight.  
Cells were observed at 24 hours post-seeding. 
 
T904-Acrylate Hydrogels with Surface-Immobilized Reduced L1 
These experiments are based on the immobilization method depicted in the 
Chapter 6 (Figure 6.1B).  The response of B35 and primary chick forebrain cells to 
100µg/mL of surface-immobilized L1 was observed using 70µL hydrogels polymerized 
directly in 96-well tissue culture polystyrene (TCPS) plates at 24 hours postseeding. 
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Reduction of L1 
 Analysis of the amino acid sequence of the 140 kDa cloned fragment of L1 
based on GenBank accession no. NM_000425 (Appendix E) revealed that L1 contains 14 
cysteines per mol.  A 150 µg/mL solution is equivalent to 0.0011 mmol/L concentration 
of protein.  Protein solutions are typically reduced with 1mM to 10 mM DTT.  A 2.5 mM 
DTT solution was used to reduce L1 [276], resulting in an approximate 2273 molar 
excess of DTT to L1, or an approximate 325-molar excess of DTT thiols to L1 cysteines.  
A 10X 25mM stock solution of DTT in 50mM PBS pH 7.4 buffer was made, 10% by 
volume was added to the 1mg/mL fibronectin solution for a final 2.5 mM DTT 
concentration, and reacted for 1 hour at room temperature.  Unreacted DTT was removed 
by column filtration using a PD-10 column and 50mM PBS pH 7.4 buffer followed by 
analysis of protein concentration via measurement of absorbance at 280nm.  Protein 
samples were kept on ice following filtration and during protein concentration analysis. 
Preparation of Hydrogels 
A 28.75% T904-acrylate hydrogel solution and a 1:1.1 acrylate:thiol ratio as 
described for reduced fibronectin hydrogels in Chapter 6 was used for this experiment.  
PBS and DTT were directly added to room temperature T904-acrylate solution, and the 
gel solution was vortexed briefly, tap-spinned, and 70µL was immediately pipetted 
directly into 96-well TCPS plate and allowed to crosslink via Michael addition in the 
dark for 1 hour at room temperature. After 1 hour, reduced L1 solution (100µL per well) 
of 100 µg/mL concentration was added and left for an additional hour at room 
temperature.  Hydrogel crosslinking and L1 reduction were coordinated such that reduced 
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L1 solution was added to the hydrogels immediately upon completion of reduced L1 
concentration analysis, to minimize the possibility of disulfide bond reformation.  
Following 1 hour incubation in reduced protein at room temperature, the plat  
was parafilmed and transferred to 37°C overnight with shaking. The next morning, gels 
were rinsed with 200µL of sterile PBS three times and hydrated in 100µL of sterile PBS 
per well at 37°C until cell seeding.  Hydrogels without protein were used as negative 
controls.  Bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL reduced L1 
adsorbed overnight were used as positive controls for visual confirmation of cell health 
and bioactivity of reduced protein. 
Cell Seeding 
B35 cells were seeded at a density of 20,000 cells per 96-well in DMEM/F12 with 
L-glutamine supplemented with 10% v/v bovine growth serum (Hyclone) and 50 I.U./mL 
penicillin and 50 µg/mL streptomycin (Mediatech).  Medium containing 10% serum was 
chosen for initial experiments to enhance cell attachment to the hydrogels.  Primary chick 
forebrain cells derived from 8-day old chicks as previously described in Chapter 5 were 
seeded at a density of 20,000 cells per 96-well based on successful rults of this seeding 
density on 96-well bacterial polystyrene wells with 10µg/mL L1 adsorbed overnight.  
Cells were observed at 24 hours post-seeding. 
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Preparation of Acrylated L1 
These experiments are based on the immobilization method depicted in the 
Chapter 6 (Figure 6.1C).   
Concentration of L1 
The L1 protein produced as previously described in Chapter V typically displayed 
a concentration range of 60-160 µg/mL; therefore, the protein first had to be concentrated 
to a 1mg/mL concentration in order to prevent hydrolysis of the NHS-ester during 
acrylation.  A buffer exchange of two 1.5mL aliquots of 60 µg/mL L1 protein into 50mM 
PBS, pH 7.4 with 6% salt concentration was performed utilizing 2.0 mL Zeba desalt 
columns (Pierce) according to the manufacturer’s instructions.  The prot in was frozen 
overnight at -80°C, lyophilized, resuspended in 180 µL of sterile water in order to 
maintain appropriate salt concentration, and stored at 4°C. 
Acrylation Reaction 
Analysis of the amino acid sequence of the 140 kDa cloned fragment of L1 based 
on GenBank accession no. NM_000425 (Appendix E) revealed that L1 contains 71 
lysines per mol.  Standard reaction conditions for NHS-containing crosslinkers call for 
0.1-10 mM concentrations. The L1 fragment cloned as described in Chapter V is a 140 
kDa protein, and a 1 mg/mL solution is equivalent to 0.0071 mmol/L concentratio  of 
protein.  Typically, 2 to 50-fold molar excesses of crosslinker ar  used for reactions, and 
a 50 molar excess of crosslinker to L1 was used, resulting in a 0.36M concentration of 
acrylate-PEG-NHS used for this reaction.  A 10X solution of 12.4 mg/mL acrylate-PEG-
NHS in anhydrous DMSO was made fresh for each reaction, and 10µL of this solution 
 154
was added to 100 µL of 1mg/mL L1 for an organic solvent carryover of 10% final 
volume in the aqueous reaction, and reacted for 2 hours at room temperature with 
shaking.  At the completion of the reaction, a buffer exchange into 50mM PBS pH 7.4 
was performed using 0.5 mL Zeba desalt columns (Pierce), according to the 
manufacturer’s instructions, to remove unreacted crosslinker and solvent contamination.  
The acrylated protein was stored at 4°C protected from light. 
Electrophoresis of Acrylated L1 
Samples of acrylated and non-acrylated L1 were immediately collected for SDS-
PAGE (sodium dodecyl polyacrylamide gel electrophoresis) analysis (3 µL protein 
diluted in 6 µL PBS + 3 µL 4X reducing buffer) and immediately frozen at -80°C.  
Protein samples were separated by SDS-PAGE on a 6% polyacrylamide gel using Tris-
glycine buffer under reducing conditions at 100V for 150 minutes.  The gel was silver 
stained (SilverSNAP® Stain Kit II, Pierce) and imaged using a Kodak Electrophoresis 
Documentation and Analysis System 120. 
 
RESULTS AND DISCUSSION 
Neuronal Differentiation of HT22 and B35 Cells 
Figure 7.1 shows the phase contrast images of HT22 cells on different adsorbed 








2% Serum 2hr + 
Serum-free NGF
 
Figure 7.1  Phase contrast images of HT22 mouse hippocampal cells attached to 
protein-adsorbed wells under varying media conditions.  Scalebar = 100 µm.  
 
HT22 cells proliferated extensively on adsorbed laminin and fibronectin under all 
media conditions tested, and on blank wells under 10% and 2% serum conditions.  
Slightly less proliferation was observed on adsorbed L1 under 10% and 2% serum 
conditions.  The cells exhibited limited attachment to adsorbed L1 and bl k wells when 
plated directly in serum-free media (data now shown); however, plating in 2% serum 
media for 2 hours followed by replacement with serum-free media supplemented with 
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20ng/mL NGF enhanced differentiation into a neuronal phenotype on both adsorbed L1 
and blank wells, as evidenced by the arrest of proliferation and the dev lopment of 
pyramidal neuron morphology with neurite outgrowth.  Although L1 has been d scribed 
as a potential survival factor for primary rat embryonic hippocampal neurons in serum-
free media [239], its survival role for the HT22 cell line is unknown, ad in this 
experiment, HT22 cells did not attach when cells were plated directly in serum-free 
media.  The similar appearance of the L1 and blank wells for the 2% serum media for 2 
hours followed by replacement with serum-free media supplemented with 20ng/mL NGF 
condition may be attributed to adsorption of media proteins to the hydrophobic bacterial 
polystyrene surface during the 2 hour incubation in serum media.  Because T904-acrylate 
hydrogels limit protein adsorption, immobilization of L1 to these hydrogels may enable 
better evaluation of the role of L1 in HT22 attachment and neuronal differentiation. 
 
Figure 7.2 shows the phase contrast images of B35 cells on different adsorbed 








2% Serum 2hr + 
Serum-free
 
Figure 7.2  Phase contrast images of B35 rat neuroblastoma cells attached to 
protein-adsorbed wells under varying media conditions.  Scalebar = 100 µm.  
 
B35 cells survived and proliferated extensively on adsorbed laminin ad 
fibronectin under serum conditions with slightly less proliferation observed on the 2% 
serum followed by serum-free media condition.  Less proliferation was observed on L1 
and blank wells under serum conditions and limited attachment occurred when plat d 
directly in serum-free media (data not shown).  When cells were plat d in 2% serum for 2 
hours followed by serum-free media, arrestment of proliferation occurred on adsorbed L1 
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and blank wells, but because B35 cells appear to extend neurites even while proliferating, 
it is difficult to distinguish changes in morphology.  No differences wre observed with 
the addition of NGF to serum-free media (data now shown).  Although distinct 
morphological differences are not evident, limited attachment of cells to blank wells in 
2% serum for 2 hours followed by serum-free media as compared to L1 indicates that L1 
does support attachment of B35 cells.  Because T904-acrylate hydrogels limit protein 
adsorption, immobilization of L1 to these hydrogels may enable better evaluation of the 
role of L1 in B35 attachment. 
 
Primary Mammalian Neuron Dissection 
Primary neurons are sensitive to media osmolalilty; embryonic chi k brain has 
measured approximately 272 mOsm [Bray, 1991 #729] and adult rat brain has measured 
approximately 307 mOsm. [Bandaranayake, 1978 #730]  The measured osmolalities of 
three of our media formulations are Basal Medium Eagle (BME, 291 mOsm), 
DMEM/F12 with L-glutamine (322 mOsm), and Neurobasal (224 mOsm).  Although 
both BME and DMEM/F12 are close to the measured osmolality of rat brain, BME was 
chosen for CNS-derived chick and rat neurons because it does not contain L-glutamine, 
allowing supplementation at the time of use.  L-glutamine is unstable nd is rapidly 
decomposed into ammonia, which is toxic to CNS-derived neurons in concentrations of 
less than 600µM. [354] [355, 356] 
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Figure 7.3 shows extensive neurite outgrowth from rat postnatal day 7 cerebellar 





Figure 7.3  Rat postnatal day 7 cerebellar neurons cultured on adsorbed 10 µg/mL 
laminin.  Neurons were cultured 24 hours and then stained for actin (red).  Scalebar 
= 100µm. 
 
Figure 7.4 shows extensive neurite outgrowth and neural networks from rat 
postnatal day 7 dorsal root ganglia cultured on laminin. 
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Figure 7.4  Rat postnatal day 7 dorsal root ganglia cultured on adsorbed 10µg/mL 
laminin.  Neurons were cultured 24 hours and then stained for actin (red).  Scalebar 
= 100µm. 
 
Although DRG are a commonly used model to assess neural regeneratio , these 
cells did not attach to adsorbed L1, but did attach to adsorbed fibronectin, on which CNS-
derived chick forebrain and rat cerebellar neurons did not attach (data not shown).  All 
primary cells (chick forebrain, rat cerebellar, rat DRG) responded favorably to adsorbed 
laminin, as expected.  In addition, DRG cell bodies are surrounded by satellite Schwann 
cells that form a discrete anatomical unit. [25] Efforts to remove these contaminating 
Schwann cells by plating them out on bacterial polystyrene plates prior to DRG cell 
seeding resulted in incomplete removal of contaminating cells, with resultant Schwann 
cell proliferation and an inability to ascertain if neurite outgrowth was the result of glial 
cell support or the cell adhesion molecule.  Another approach taken to eliminate glial cell 
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contamination was to use cytosine arabinoside, a mitotic inhibitor, to prevent the 
proliferation of Schwann cells; however, the DRG did not survive under these conditions, 
possibly due to cytotoxicity resulting from noncompetitive antagonism of nerve growth 
factor (NGF) that is essential for DRG survival. [357, 358]  In conclusion, rat postnatal 
day 7 cerebellar neurons were determined to be the ideal mammalian primary cell model 
for future work with L1 immobilized to T904-acrylate hydrogels. 
 
Cytocompatibility of T904-Acrylate Hydrogels with Primary Neurons  
Figure 7.5 is a phase contrast image of chick forebrain neurons cultured on 0.1% 






Figure 7.5  Documentation of cytocompatibility.  Phase contrast images of chick 
embryonic day 8 forebrain neurons cultured on (A) 0.1% PLL and (B) 0.1% PLL in 




The bright, round cell bodies indicate healthy cells with no discernable difference 
between the positive control and cells exposed to the hydrogel with no rinsing prior to 
cell seeding. 
 
Neuronal Response to T904-Acrylate Hydrogels with Encapsulated L1 
B35 and primary chick forebrain neurons showed little evidence of attachment to 
hydrogels with encapsulated L1 70µg/mL, comparable to hydrogels with no protein.  
Positive controls of 96-well bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL 
reduced L1 adsorbed overnight demonstrated significant attachment and proliferation of 
B35 cells, and significant attachment and neurite outgrowth of primary chick forebrain 
neurons at 24 hours.  This is in stark contrast to the favorable spreading response of NIH 
3T3 fibroblasts on encapsulated fibronectin hydrogels of 50, 75, and 100 µg/mL 
concentrations.  NIH 3T3 cell attachment to fibronectin is primarily mediated through 
RGD, an integrin binding tripeptide in the FN-III repeat; however, Ig domains 1-6 
reproduce the full biological activity of the entire L1 extracellular region, while Ig 
domains 1-4 are the minimum regions necessary for homophilic binding. [274]  Ig 
domains 1-6 are linked by disulfide bonds and these bonds are reduced with DTT prior to 
encapsulation within the T904-acrylate hydrogels.  We therefore hypot esize that the L1 
protein loses bioactivity upon encapsulation into T904-acrylate hydrogels via Michael 
addition because of a change in conformation that occurs when the reduced disulfi e 
bonds of Ig domains 1-6 bind with acrylate groups within the hydrogel.  As a result, no 
further experiments were conducted utilizing encapsulated L1. 
 163
Neuronal Response to T904-Acrylate Hydrogels with  
Surface-Immobilized Reduced L1 
 
B35 and primary chick forebrain neurons showed little evidence of attachment to 
hydrogels with reduced L1, comparable to hydrogels with no protein.  Positive controls 
of 96-well bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL reduced L1 
adsorbed overnight demonstrated significant attachment and proliferation of B35 cells, 
and significant attachment and neurite outgrowth of primary chick forebrain neurons at 
24 hours.  Acrylate groups are inherently hydrophobic because their CH=CH2 
carbonaceous side groups are non-polar and thus do not attract water strongly.  We 
hypothesize that this immobilization technique failed because the inherent 
hydrophobicity of the acrylate groups contributes to their retreat within the hydrogel upon 
application of the hydrophilic reduced L1 solution, thus hindering the Michael addition 
protein conjugation reaction.  An alternative explanation is that the fil ration method used 
may not be sufficient to remove all excess DTT, possibly resulting in a reformation of L1 
disulfide bonds prior to adding the solution to the hydrogels.  As a result, no further 
experiments were conducted utilizing reduced L1. 
 
Acrylation of L1 For Surface-Immobilization To  
T904-Acrylate Hydrogels 
 
Analysis of the amino acid sequence of the 140 kDa cloned fragment of L1 based 
on GenBank accession no. NM_000425 (Appendix E) revealed that L1 contains 71 
lysines per mol, and the acrylate-PEG-NHS used to acrylate fibronectin has a molecular 
weight of 3450 Da.  Conjugation of 1-4 lysines per mol of L1 with acryl te-PEG-NHS 
should result in an estimated 3-13kDa increase in molecular weight.  Figure 7.6 
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demonstrates an approximate 8-10 kDa increase in molecular weight of t e acrylated 
protein as evidenced by lane 3.  This data demonstrates successful acrylation of the L1 









Figure 7.6  Documentation of L1 acrylation.  Proteins were separated utilizing SDS-
PAGE and stained with Silver Stain (Pierce).  Lane 1, molecular weight marker; 
lane 2, L1; lane 3, acrylated L1.  Gels were loaded with equal quantities of total 
protein (3 µg/lane).   
 
 
Previous efforts to acrylate lower concentrations of L1 were unsucce sful, likely due to 




In conclusion, these studies demonstrate that both HT22 and B35 cells may be 
used to model neuronal cell response to immobilized L1 on a hydrogel surface when 
cultured in 2% serum for 2 hours followed by serum-free media with and without NGF, 
respectively.  B35 cells display clearer evidence of attachment to L1 and do not require 
the addition of NGF; however, B35 are loosely adherent and care must be taken when 
changing media to avoid cell detachment.  Mammalian neuron dissection methods for rat 
postnatal day 7 cerebellar neurons and dorsal root ganglia were developed, but cerebellar 
neurons were determined to be the ideal primary mammalian neuronal m del for future 
L1 studies.  T904-acrylate hydrogels with no rinsing prior to cell seeding were not toxic 
to primary chick embryonic day 8 forebrain neurons cultured on PLL at 24 hours.  These 
studies also indicate that hydrogels with encapsulated and reduced L1 are not suitable for 
neural regeneration strategies, possibly due to a conformational change of the protein and 
hydrophobicity of acrylate groups, respectively.  SDS-PAGE analysis demonstrated 
successful acrylation of the L1 protein, but only when a 1 mg/mL concentratio  was 
used; lower concentrations were probably not sufficient to prevent hydrolysis of the 
NHS-ester during the acrylation reaction.  Future work should include further analysis of 
immobilized acrylated L1 to T904-acrylate hydrogels to study neural regeneration at 
early timepoints with the conditions described for HT22 or B35 neuronal cell ines and 





CONCLUSION AND RECOMMENDATIONS 
 
CONCLUSION 
The first objective of this research was to clone and express a bioactive 140kDa 
fragment of L1 neural cell adhesion molecule, chosen for its cr ical role in proper 
nervous system development and because it has demonstrated selectivity of neuron 
adhesion in the presence of astrocytes, which play a major role in nervous system 
inflammation.  These studies described the expression of a 140 kDa extracellular 
fragment of L1 in the baculovirus/insect cell expression system with an average yield of 
approximately 250-300 µg per 1x10
8
 High Five cells and comparable neurite outgrowth 
as compared to commercially available mammalian L1-Fc (R&D Systems).  
The second objective of this research was to synthesize acrylated Tetronic 
macromers and develop Michael addition methods for hydrogel crosslinking and protein 
immobilization, and to evaluate hydrogel cytocompatibility, immobilized protein 
bioactivity, and immobilization efficiency in terms of cell spreading and proliferation 
using NIH 3T3 fibroblasts and fibronectin.  Using a model cell line with a well known 
RGD-dependent interaction allowed the demonstration of the feasibility of this system for 
neural repair.  Acrylated Tetronic macromers were synthesized as previously described 
and typically demonstrated approximately 83% acrylation efficincy.  Methods 
developed for hydrogel crosslinking included using a 1:1 acrylate:thiol ratio for 
encapsulated protein, a 1.1:1 acrylate:thiol ratio for surface-immobilized reduced protein, 
and a 1:1.1 acrylate:thiol ratio for surface-immobilized acrylated protein.   
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Heggli et al. demonstrated functionalization of poly(styrene)-gr-PEG beads with 
acrylic groups using Michael addition conjugation of cysteine and a 13 mino acid 
peptide in aqueous solution [359]; however, the studies described in this dissertation 
demonstrated failure of fibroblast spreading on hydrogels with pendant acrylate groups 
incubated in reduced fibronectin solution.  The failure of cell spreading may be the result 
of (1) inaccurate acrylate:thiol ratio calculations, (2) limited protein conjugation to the 
surface, (3) a lack of conjugated protein bioactivity as a result of conformation change 
due to disulfide bond reduction, or (4) disulfide bond reformation prior to conjugation.  
The 10% excess acrylate may not be sufficient to leave pendant unreacted acrylate groups 
on the hydrogel surface because the acrylate:thiol ratio was calculated based on the 
estimated molecular weight of T904-acrylate.  Because our T904-acrylate products 
typically displayed approximately 83% acrylation efficiency, less acrylate groups may be 
present than what was assumed for the calculation, resulting in no unreacted pendant 
acrylate groups within the hydrogels.  The acrylate:thiol calcul tion should be refined to 
incorporate the acrylation efficiency for a more accurate raio estimation, and studies 
using varying percentages of excess acrylate should be conducted to optimize conditions 
for hydrogel crosslinking and for surface-conjugation of reduced protein.  Another 
potential problem is that acrylate groups are inherently hydrophobic because the 
CH=CH2 carbonaceous side group is non-polar and thus does not attract water strongly, 
and incubation of hydrogels with pendant acrylate groups in aqueous fibronectin solution 
may not favor Michael addition surface-conjugation of reduced protein.  An alternative 
method to coax hydrophobic acrylate groups to the surface by crosslinking hydrogels 
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between glass slides with a hydrophobic coating, such as Rain-X, may be employed to 
test this theory; however, polymerization between glass is not translatable to the long-
term objective of crosslinking hydrogels within the fiber grooves.     
As discussed in Chapter 6, control wells with adsorbed reduced fibronectin on 
bacterial polystyrene plates did demonstrate fibroblast spreading nd proliferation, which 
could either indicate that disulfide bond reduction did not impact bioactivity of adsorbed 
fibronectin or that disulfide bonds reformed.  Reduced fibronectin was dilute  to 100 
µg/mL in 50mM PBS pH 7.4, which does not contain divalent cations and is the 
appropriate buffer for Michael addition conjugation.  It is possible that e column 
filtration performed following fibronectin reduction was not sufficient to remove excess 
DTT resulting in a reformation of disulfide bonds and possibly conjugation of DTT thiols 
to hydrogel pendant acrylate groups; an alternative approach to using soluble reducing 
agents for protein reduction that would eliminate the need for column filtration and 
reduce the time prior to adding protein solution to the hydrogels is to u e an immobilized 
reducing agent, such as Pierce Immobilized TCEP Disulfide Reducing Gel (Product 
#77712).  An indirect Enzyme-Linked Immunosorbent Assay (ELISA) using an HRP-
conjugated anti-fibronectin antibody and a fluorogenic substrate (Pierce QuantaBlu) may 
be used to test if fibronectin is conjugated to the suface of the hydrogels but will not 
assay the bioactivity of the immobilized protein.  Conjugation of fibronecti  thiols to 
acrylate groups on the hydrogel surface may induce a different protein c nformation than 
adsorption that may interfere with bioactivity even if conjugation is successful; however, 
the success of encapsulated reduced fibronectin in promoting fibroblast spreading and 
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proliferation implies that covalent immobilization of reduced fibronecti  is not 
detrimental to bioactivity.  There is also evidence that disulfide bond reduction is 
important to fibronectin’s bioactivity in vivo.  Fibronectin multimer formation occurs in 
vitro via the C-terminal free thiols upon exposure to a thiol reagent [343, 344] and in vivo 
depending upon exposure to metal ions [345], and homocysteine binding to plasma 
fibronectin in vivo is mediated through thiol-disulfide exchange at the C-terminal 
disulfide bonds.[346]  In addition, fibronectin’s bioactivity is linked with the RGD 
tripeptide in the FN-III repeat, which does not contain disulfide bonds. [324, 325] 
For both encapsulated and acrylated fibronectin, concentrations of 50, 75, and 100 
µg/mL promoted maximum fibroblast spreading, and both methods displayed a 
maximum cell spread area of approximately 3400 µm2 with 100 µg/mL of fibronectin. 
Prior studies using 100 µg/mL of thiolated fibronectin immobilized to polystyrene 
surfaces through Pluronic-pyridyl disulfide (F108-PDS) modification demonstrated cell 
surface areas >8000 µm2 [339]; therefore, future work may include higher concentrations 
of fibronectin to determine if increased fibroblast spreading areas are attainable on 
encapsulated and surface-immobilized acrylated fibronectin hydrogels.  Encapsulated 
fibronectin supported fibroblast spreading at lower concentrations than acrylated 
fibronectin; cell spread area of approximately 2000 µm2 was observed on hydrogels with 
2.5 µg/mL of encapsulated fibronectin and 25 µg/mL of acrylated fibronectin.   
Only encapsulated 100 µg/mL fibronectin hydrogels supported fibroblast 
proliferation at 5 days, indicating that hydrolytic degradation of the hydrogel rapidly 
erodes the surface layer of conjugated fibronectin, within 48 hours.  An alternative 
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approach for enhanced control of hydrolytic degradation may be activation of the T904 
terminal hydroxyl groups with various chloroalkyl chloride chemical ntermediaries to 
generate an acrylamide-terminated Tetronic macromer (Figure 8.1).  
 
Figure 8.1  Acrylamide-Terminated Tetronic Macromer 
 
The final objective of this research was to assess HT22 and B35 response to L1 in 
order to establish a model neuronal cell line, to establish methods for primary mammali n 
neuron culture, to evaluate the cytocompatibility of T904-acrylate hydrogels with 
primary neurons, and to develop immobilization methods for L1.  These studies 
demonstrated that B35 cells displayed clearer evidence of attachment to L1, but only 
when cultured in 2% serum for 2 hours followed by serum-free media; however, bacterial 
polystyrene plates do adsorb protein which may account for the cell attachment observed 
with both serum media conditions.  B35 cells demonstrated a lack of attachment to T904-
acrylate hydrogels with no protein when used as negative controls, and immob lization of 
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L1 to these hydrogels may better enable the elucidation of L1 as a requirement for cell 
attachment.  Dissection protocols were established for both rat postnatal day 7 cerebellar 
neurons and DRG; however, only cerebellar neurons attached and extended n urites on 
L1, thus demonstrating their suitability for future studies with mamlian neurons out of 
the cell types tested.  T904-acrylate hydrogels with no rinsing prior to cell seeding were 
not toxic to primary chick embryonic day 8 forebrain neurons cultured in the presence of 
the hydrogel with no rinsing on PLL at 24 hours.   
These studies demonstrated failure of B35 cell and chick embryonic day 8 
forebrain neuron attachment to hydrogels with encapsulated and reduced L1.  The 
proposed mechanisms of failure as discussed for surface-immobilization of reduced 
fibronectin also apply to surface-immobilization of reduced L1; however, th  additional 
failure of encapsulated L1 indicates a loss of protein bioactivity not demonstrated with 
encapsulated fibronectin.  All six immunoglobulin domains of L1 have been shown to be 
required for full bioactivity [274], and their quaternary horseshoe structure depicted in 
Figure 8.2 is important for homophilic binding interactions that are critical for neural 
applications. Reduction of the L1 protein with DTT breaks the disulfide bonds 
responsible for this quaternary structure.  Although positive controls of adsorbed reduced 
L1 on bacterial polystyrene demonstrated B35 attachment and proliferation and chick 
embryonic day 8 neuron attachment and neurite outgrowth, covalent immobilization of 





Figure 8.2  Quaternary Structure of L1 Ig Domains 
(Reprinted from Haspel and Grumet, 2003 [241]) 
 
In addition, these studies demonstrated that a 1mg/mL concentration of L1 was 
necessary for acrylation of the protein to prevent hydrolysis of the NHS-esters during the 
acrylation reaction; however, surface conjugation and confirmation of bioactivity is yet 
unproven. Surface-conjugated acrylated L1 may not be bioactive if the quaternary 
horseshoe structure is disrupted or if the primary amine at the N-terminus is bound, 
effectively reversing the orientation of the protein as it appears on the cell surface. 
It was stated previously that selection of an appropriate immobilization chemistry 
is likely to be critical for full retention of L1 bioactivity based on the increased number 
and distribution of bioactive regions in L1.  An alternative approach to test the bioactivity 
of immobilized L1 in physiologically relevant orientation is encapsulation or surface-
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immobilization of NTA-PEG-acrylate previously synthesized in the lab for conjugation to 
the 6X Histidine tag added to the C-terminus of the insect cell-derived 140 kDa L1 
fragment (Figure 8.3). 






















Figure 2. Proposed mechanisms of L1 immobilization using various
                di-functional cross-linkers
L
Figure 8.3  Immobilization of L1 through 6X His Tag 
(Reprinted from Lee et al., 2007 [360]) 
 
Although this method will not overcome the instability of immobilized ligands 
within or on the surface of T904-acrylate hydrogels, resulting from hydrolytic 
degradation of the hydrogels and the potential for in vivo enzymatic degradation due 
to the presence of reducing enzymes such as thioredoxins [361], it may be useful for 
demonstrating the importance of maintaining physiologic protein orientat on for 
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bioactivity.  The insect cell-derived 140 kDa L1 fragment also contains a 14 amino 
acid V5 epitope (-Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr-) 
prior to the 6X His tag recognizable by Invitrogen anti-V5 antibody (IgG2a).  Another 
possible immobilization method to maintain physiologic orientation of L1, although 
with limited clinical applicability, is encapsulation or surface-immobilization of 
acrylated anti-V5 antibody generated using acrylate-PEG-NHS, to bind to the C-
terminus of the L1 protein. 
 
RECOMMENDATIONS  
A major limitation of using adherent cultures for protein production is that 
relatively small amounts of protein may be produced at any given time due to the 
requirement for large amounts of incubator space.  In addition, insect cells require a 
separate incubator from mammalian cells because they are cultured at 27°C with no CO2.  
The insect cell culture system described in Chapter 5 typically yie ded 1.8mL of 160 
µg/mL concentration of L1 from 4- 175cm2 T-flasks.  These studies have demonstrated 
the necessity for a 1mg/mL concentration of L1 in order to successfully acrylate the 
protein.  In order to obtain sufficient quantities of protein to continue this research, large-
scale transfections will be required.  For example, 1mL of 1mg/mL concentration L1 is 
enough protein to test 100 conditions in 96-well plates using 100µg/mL concentration.  
To produce 1mL of 1mg/mL will require 6.25mL of 160 µg/mL, or 14 flasks.  An 
alternative approach that may be considered is perfusion bioreators for higher protein 
production. [362, 363] 
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 Additional considerations for long-term studies include analysis of the appropriate 
mechanical properties for hydrogels to optimize neurite outgrowth, and the effect of loss 
of mechanical properties due to hydrogel degradation on neurite outgrowth.  Growth cone 
advance is mediated by a minimum “threshold” value of tension [364], and Gu n et al. 
demonstrated greatest neurite extension from PC12 cells seeded on PEG-diacrylate 
hydrogels with an elastic modulus in the range of approximately 50-200 kPa. [215]  In 
this work, only 23% T904-acrylate hydrogels were tested in order to evaluate protein 
conjugation strategies; however, future studies should be conducted to evaluate the 
hydrogel mechanical properties over a varying T904-acrylate concentration range in an 
effort to optimize conditions to provide a synergistic benefit to neurite outgrowth.  
Analysis of the appropriate mechanical properties for fibers based on spinal cord 
mechanics is also warranted.  Several studies have examined the viscoelastic behavior of 
the spinal cord. [201-204]  In addition, as discussed in Chapter 4, discrepancies exist in 
the reported values of elastic modulus for the spinal cord and no consensus has been 
reached regarding the appropriate elastic modulus for neural scaffolds. [203, 206, 208] 
A final future consideration is analysis of clearance of acryl te- and acrylamide-
terminated Tetronics and PLA breakdown products in the CNS.  Total volume of pH 7.33 
cerebrospinal fluid is 125-150ml with a turnover rate of 3-4 times per day, or 0.35 ml/min 
(500 ml/day). [365]  Radiolabeled PEG clearance following brain inject on has been 
examined [366], and the potential neurotoxicity of acrylic acid and acrylamide must be 
assessed. [367]  PLA has demonstrated biocompatibility for spinal cord applications 
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[289], and studies have demonstrated that cerebral spinal fluid (CSF) is capable of 




















Material/Chemical Vendor Part Number Storage 
Tetronic 904 BASF 30085638 Chemical cabinet 





61005-0040 Flammable cabinet 
Ethyl ether anhydrous, 
BHT stabilized 
Fisher E318-20 Flammable refrigerator in 505 
Hexanes HPLC Fisher H302-4 Flammable cabinet 
Triethylamine (TEA) Acros 
(Fisher) 
157911000 Chemical cabinet 
Acryloyl chloride 96% Sigma A24109-500 Flammable refrigerator in 505 




196791000 Flammable cabinet 
Molecular sieves 
(Grade 514, Type 4A, 
8-12 mesh) 
Fisher BP2631-500 Chemical cabinet 
Celite fine 500 Fluka 
(Sigma) 
22145 Chemical cabinet 
Sodium sulfate 
anhydrous 
Fisher S421-3 Chemical cabinet 
4-Methoxyphenol 99% Aldrich M18655 Chemical cabinet 
 





• Wear nitrile gloves when handling organic solvents and triple glove so that total 
glove thickness is at least 15mil (our gloves are 5mil).  If solvent spills on gloves, 
immediately remove outer glove and replace (solvents - particularly ether,
dichloromethane, toluene, hexane - can penetrate nitrile gloves in under 4 minutes).  
Latex gloves should not be worn to handle solvents as the permeation rate is much 
quicker (in seconds for dichloromethane). 
• Wear lab coat, safety goggles, and nitrile gloves when handling organic solvent  and 
always handle under the chemical fume hood. 





• Parafilm all chemical bottles to prevent moisture penetration. 
• Clean rotavap with acetone before and after each use. 
• Clean and dry glassware as it is used or there will not be enough for all steps, but 
allow solvent volatilization under the chemical fume hood first.  
 
 
Preparation for Synthesis 
 
Make sure all glassware has been cleaned with sodium hydroxide, rinsed at least six 




• Round bottom reaction flasks 
• Evaporator trap with inner vapor tube at bottom 
• Addition funnel 
• Separation funnel 
• Buchner funnels 
• Filter flasks 
• Erlenmeyer flasks 
• Glass stopper 
• Teflon valves with washers 
 
Glassware used for the reaction and final filter/rotavap/precipitation steps after sodium 
sulfate wash must be extremely dry and should be dried under vacuum at 100°C for 3 
hours and then left to cool under vacuum overnight until use (use vacuum oven). 
 
Make Dehydrated Dichloromethane In Advance 
 
• Typically prepare at least 500mL for each 30g reaction. 
• Prepare bottle for dehydrated dichloromethane storage and activated molecular sieves 
by drying under vacuum at 110°C for 3 hours and then leave to cool under vacuum 
overnight until use.  Activated molecular sieves may be stored under vacuum for one 
month. 
• Cover the bottom of a 1L glass bottle with calcium hydride, add 1L of 
dichloromethane and mix overnight with stirring.  The cap should be closed. 
• Filter dehydrated dichloromethane on ice bath using a vacuum-heated and dried 
Buchner funnel with filter paper and Celite fine 500 into a vacuum-heated and dried 
1L filter flask. 
• Repeat the previous step using only filter paper to remove any Celite. 
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• Transfer filtered dehydrated dichloromethane into vacuum-heated and dried 1L amber 
glass bottle with activated molecular sieves for storage.  Dehydrated dichloromethane 
may be stored for one month. 
• SAFETY NOTE: Calcium hydride reacts violently with water, acids, lower alcohols, 
and heat to produce hydrogen gas and caustic calcium hydroxide. The hydrogen gas 
may be ignited by the heat of the reaction.  In the event of fire, use dry chemical, li e 
or dry sand. DO NOT use water, foam, carbon dioxide, or halon. 
• PROPER DISPOSAL OF CALCIUM HYDRIDE : Allow solvent to volatilize off 
the calcium hydride overnight under the chemical fume hood.  Dispose of dried 
calcium hydride in the labeled plastic container that is stored in the flammables 





ALL STEPS MUST BE PERFORMED UNDER CHEMICAL FUME HOOD! 
 
Day 1 - Azeotropic Distillation and Reaction: 
 
• T904: 30g (MW6700) 
• Dehydrated dichloromethane: 300 mL 















1. Refer to figure A.1 at the end of this protocol for the azeotropic distillation set-up. 
2. Start this early in the morning so the reaction is begun early afternoon in order to 
allow time for Day 2 steps during the day (reaction needs 24 hours). 
3. Use oven dried glassware (condenser, connector, round bottom reaction flask). 
4. Weigh T904 with a beaker and dissolve it in 100ml toluene (tare a 150 mL beaker 
on the balance to measure T904).  Allow to dissolve for several minutes while 
stirring vigorously with spatula. 
5. Decant dissolved T904 of step 2 into the reaction flask. Add an additional 
100mL, stir vigorously, and decant into reaction flask.  Repeat for a total volume 
of 300mL. 
6. Set up the azeotropic distillation system with magnetic bar inside the flask 
(parafilm all connections, wrap with glass fibers and foil to insulate, connect 
water line and drain to condenser and clamp in place using binder clips).  Refer to 
the last page of this protocol for an explanation and diagram of azeotropic 
distillation. 
7. Allow T904 solution to stir for about 10 minutes prior to heating up the oil bath. 
8. Heat the reaction flask (hot oil bath) up to 130°C.   
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9. Boil the flask.  As water is removed, it will appear to be cloudy and white in the 
connector column.  
10. The connector column volume is approximately 30mL.  Boil off a total of 
approximately half of the solution volume (150mL).  Boil off 120mL, allow the 
column to fill and reflux for one hour, then stop the distillation and cool down the 
reaction and remove the final 30mL (approximately 2 hours). 
11. Vacuum-evaporate at 90°C to remove the toluene using the evaporator trap with 
inner vapor tube at bottom.   
a. Use the lower power vacuum pump, 90°C water bath, and maximum 
rotation (should take approximately 30mins - 1 hr).  Add ice on the 
cooling trap. 
12. Dissolve purified T904 in 240ml dehydrated dichloromethane. 
13. Set up the reaction batch with stirring system. 
14. Pipette TEA to the reaction flask and allow to mix for several minutes with 
stirring on an ice bath.  
15. Cool down the reaction flask for several minutes. 
16. Attach the addition funnel to the top of the reaction (parafilm the connection) and 
add the acryloyl chloride solution in 60ml dehydrated dichloromethane into the 
addition funnel. 
17. Dropwise-add step 12 solution into the reaction slowly (within 2hrs) using a 
steady continuous drip.  Add ice to ice bath as needed. 
18. When all the acryloyl chloride solution has been added, move the reaction system 
to cold room on 5th floor (put aluminum foil around the reaction flask to protect it 
from light, grease the fitting, parafilm the closure). 
19. Run the reaction with stirring in the cold room for 24 hours. 
 
Day 2 – Filtration, Ether/Hexane Precipitation: 
 
1. Stop the reaction and filter with filter paper and Celite fine 500 using a Buchner 
funnel once to remove TEA-HCl. Filter one more time with filter paper without 
Celite using a Buchner funnel to remove the remaining Celite in the product.  
Make sure to use dry funnels and filter flasks and use a new funnel/flask for each 
filtration step.  Add solution slowly as it is very viscous and will clog the filter if 
too much is added too quickly. 
2. Add 2 chips of 4-methoxyphenol and allow to dissolve for 5 minutes. 
3. Vacuum-evaporate at 30°C to remove the dichloromethane using the evaporator 
trap with inner vapor tube at bottom.   
a. Use the lower power vacuum pump, 30°C water bath, and maximum 
rotation (should take approximately 1 hour).  Add ice on the cooling trap. 
4. Using an Erlenmeyer flask, precipitate in 50/50 ether/hexane.  Total volume 
should be 500mL.  Add 250mL of ether to reaction flask and swirl and transfer to 
Erlenmeyer flask.  Then add 250mL of hexanes to reaction flask (to try and 
remove as much product as possible from the reaction flask) and swirl and 
transfer to Erlenmeyer flask.  Mix with stirring for at least 5 minutes. 
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5. Remove stir bar, seal Erlenmeyer flask with rubber stopper and wrap with 
parafilm, cover entire flask in foil and label, and place flask in flammable freezer 
in 505 at -20°C and allow precipitated product to settle overnight. 
 
Day 3 – pH Neutralizations and Final Precipitations (4 precipitations total): 
 
1. Quickly decant the waste solvent without disturbing the settled product at the 
bottom.  
2. Redissolve the product in 300 mL dichloromethane (does not have to be 
dehydrated as water will be added during washing steps).  Check pH (typically it 
will be pH 4.0 before starting the wash steps).  
3. Transfer the product to the separation funnel.  Make sure the Teflon valve has a 
gasket or it will leak. 
4. Wash it with 30ml 10% NaHCO3 once and shake the funnel gently, opening the 
valve periodically to release the gas.  If using different reaction sizes, us  10% of 
the total volume for washes.  Place the funnel back in the ring holder, remove the 
top, and allow the bicarbonate solution to separate out (water will rise to the top 
and appear opaque white).  Use a piece of rubber hose to “whip” the funnel to 
encourage separation if needed.  Open the valve to pour off the product into a 
clean, dry beaker, stopping when reaching the separated waste.  Remove the 
waste to a separate beaker. 
5. Check the pH of the product and repeat step 9 until the pH is neutralized (pH 7.0) 
by pouring the product back into the separation funnel (typically 2 washes). 
6. Once product pH is neutralized, add 30ml double-deionized (Millipore) water 
instead of 10% NaHCO3 and follow the method in step 9, to remove sodium 
bicarbonate. Ensure the pH of the product AND the water waste are neutral, and 
then do 2 water washes beyond what is required for neutral pH (typically 4-6 total 
water washes). 
7. Add sodium sulfate to the product beaker to dehydrate (approximately 4-6 times) 
until the solution becomes clear.  Add approximately one small weigh boat of 
sodium sulfate (just enough to cover the bottom of beaker), mix using a spatula 
for approximately 5 minutes, allow to settle, then pour into another beaker and 
repeat.  Add a very small amount of dichloromethane (not dehydrated) to the 
waste sodium sulfate to remove any remaining product and add this back to the 
product.  When all the water is removed, the sodium sulfate will become salt-like 
with individual particles moving instead of slushy and the product will be very 
clear. The final wash should be in an Erlenmeyer flask so it can be sealed 
overnight.  Dump waste sodium sulfate onto aluminum foil for disposal (allow 
solvent to evaporate first). 
8. Once the solution becomes clear (typically after 4 washes), allow sodium sulfate 
to settle and filter the product with filter paper using a Buchner funnel to remove 
sodium sulfate.   
9. Decant solution to a new dry round bottom flask.  
10. Add 2 chips of 4-methoxyphenol and allow to dissolve for 5 minutes. 
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11. Vacuum-evaporate at 30°C to remove the dichloromethane using the evaporator 
trap with inner vapor tube at bottom.   
a. Use the lower power vacuum pump, 30°C water bath, and maximum 
rotation (should take approximately 1 hour).  Add ice on the cooling trap. 
12. Using an Erlenmeyer flask, precipitate in 50/50 ether/hexane.  Total volume 
should be 500mL.  Add 250mL of ether to reaction flask and swirl and transfer to 
Erlenmeyer flask.  Then add 250mL of hexanes to reaction flask (to try and 
remove as much product as possible from the reaction flask) and swirl and 
transfer to Erlenmeyer flask.  Mix with stirring for 5 minutes. 
13. Remove stir bar, seal Erlenmeyer flask with rubber stopper and wrap with 
parafilm, cover entire flask in foil and label, and place flask in flammable freezer 
in 505 at -20°C and allow precipitated product to settle overnight. 
14. Quickly decant the waste solvent without disturbing the settled product at the 
bottom.  Dispose of waste solvent in the appropriate waste container. 
15. Using an Erlenmeyer flask, precipitate in 100% ether.  Total volume should be 
500mL.  Mix with stirring for 5 minutes. 
16. Remove stir bar, seal Erlenmeyer flask with rubber stopper and wrap with 
parafilm, cover entire flask in foil and label, and place flask in flammable freezer 
in 505 at -20°C and allow precipitated product to settle overnight.  If possible, try 
to do two precipitations per day (early morning and late evening), but if the 
product is not settled, leave overnight.  
17. Repeat 100% ether precipitations two more times for a total of three (3) 100% 
ether precipitations.  
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Final Day – Dry Product and NMR: 
 
1. Set-up a small dessicator with dessicant and place it in a large Styrofoam co ler 
on ice.  Vent the dessicator into the chemical fume hood.  Ensure the ice level is 
below the top of the dessicator to prevent moisture infiltration when opening and 
closing the dessicator. 
2. Allow the dessicator to cool down for at least 30 minutes under vacuum prior to 
drying any product in it.  Ensure vacuum pressure is > 20psi. 
3. Tare the balance and weigh a dry large Petri dish and take note of the weight (in 
order to determine final yield of product). 
4. Quickly decant the waste solvent without disturbing the settled product at the 
bottom.  Dispose of waste solvent in the appropriate waste container. 
5. Pour the remaining product/solvent mix into the Petri dish for drying.  Do not fill 
Petri dish beyond half full or the product will be forced out of the Petri dish when 
under vacuum.  Dry in multiple steps if necessary, but keep product cold and 
protected from light (in -20C freezer).  Ensure vacuum pressure is > 20psi. 
6. Place the Petri dish into the vacuum chamber and dry under vacuum on ice for at 
least 4 hours (6-8 hours if possible).  Replace ice as needed. 
7. Once the product is dried and all the ether is removed, weigh the Petri dish and 
determine the final yield of product. 
8. Check NMR of product in chloroform and determine reaction efficiency (25mg 
product in 1mL chloroform). 
9. Store the final dried product in a labeled closed container at -20°C (or cover the 






An azeotropic mixture has a boiling point that does not change when vapor is removed by 
evaporation. The boiling point may be higher or lower than any of the components of the 
mixture, e.g. a toluene / water mixture has bp 85.0°C, but bp toluene is 110.6°C and bp 
water is 100.0°C. Steam distillation is used to separate volatile from non-volatile 
components and the reduction in boiling point reduces thermal decomposition. For the 
toluene-water system, below 85°C the two liquid phases coexist. At 85°C the sum of the 
vapor pressures of water and toluene = one atmosphere, and boiling starts. 
 
In a mixture of toluene and water, boiling occurs at 85°C and both water and toluene are 
in the vapor that condenses to form two layers. The bottom layer of water has 0.06% 
toluene dissolved in it. The top layer of toluene has 0.05% water dissolved in it. The 
relative volumes are 18% water and 82% toluene. The excess toluene flows back into the 
flask and distils back over with more water. At 85°C, vapor pressure of water = 57.7 kPa 
















[The most common unit for vapor pressure is the torr. 1 torr = 1 mm Hg (one millimeter 
of mercury). The international unit for pressure is: 1 pascal = a force of 1 newton per 
square meter = 10 dyn/cm² = 0.01 mbar= 0.0075 mmHg = 0.00000969 atm= 0.00014 
psi.]  Be careful! Do experiment in a fume hood because toluene vapor is harmful. 
 





NOTE: Designed specifically for azeotropic distillation using solvents lighter than water. 
The set-up depicted in Figure A.1 uses a Dean-Stark trap that comes standard with  4mm 
bore PTFE stopcock. The 12mL and 25mL traps use a 2mm bore stopcocks.  We don’t 
use this set-up with the thermometer in a reaction flask. We simply connect the top of a 
round-bottom reaction flask directly to the connector end and wrap this part with glass 





GENBANK AMINO ACID SEQUENCE FOR BOVINE SERUM FIBRONECTIN 
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id=462100 
 
LOCUS       P07589                  2265 aa            linear   MAM 10-JUN-2008 
DEFINITION  Fibronectin (FN). 
ACCESSION   P07589 
VERSION     P07589.3  GI:462100 
DBSOURCE    swissprot: locus FINC_BOVIN, accession P07589; 
            class: standard. 
            created: Apr 1, 1988. 
            sequence updated: Feb 1, 1994. 
            annotation updated: Jun 10, 2008. 
            xrefs: K00800.1, AAA30521.2,  
 
 
L = LYSINE, 122 total 
C = CYSTEINE, 64 total 
 
1 qaqqivqpqs pLtvsqskpg Cydngkhyqi nqqwertyLg saLvCtCygg srgfnCeskp 
       61 epeetCfdky tgntyrvgdt yerpkdsmiw dCtCigagrg risCtianrC heggqsykig 
      121 dtwrrphetg gymLeCvCLg ngkgewtCkp iaekCfdqaa gtsyvvgetw ekpyqgwmmv 
      181 dCtCLgegsg ritCtsrnrC ndqdtrtsyr igdtwskkdn rgnLLqCiCt gngrgewkCe 
      241 rhtsLqttsa gsgsftdvrt aiyqpqphpq pppyghCvtd sgvvysvgmq wLktqgnkqm 
      301 LCtCLgngvs Cqetavtqty ggnsngepCv Lpftyngktf ysCttegrqd ghLwCsttsn 
      361 yeqdqkysfC tdhtvLvqtr ggnsngaLCh fpfLynnhny tdCtsegrrd nmkwCgttqn 
      421 ydadqkfgfC pmaaheeiCt tnegvmyrig dqwdkqhdmg hmmrCtCvgn grgewtCvay 
      481 sqLrdqCivd gitynvndtf hkrheeghmL nCtCfgqgrg rwkCdpvdqC qdsetrtfyq 
      541 igdswekyLq gvryqCyCyg rgigewaCqp Lqtypdtsgp vqviitetps qpnshpiqws 
      601 apesshisky iLrwkpknsp drwkeatipg hLnsytikgL rpgvvyegqL isvqhygqre 
      661 vtrfdfttts tspavtsntv tgettpLspv vatsesvtei tassfvvswv sasdtvsgfr 
      721 veyeLseegd epqyLdLpst atsvnipdLL pgrkytvnvy eiseegeqnL iLstsqttap 
      781 dappdptvdq vddtsivvrw srprapitgy rivyspsveg ssteLnLpet ansvtLsdLq 
      841 pgvqynitiy aveenqestp vfiqqettgv prsdkvpppr dLqfvevtdv kitimwtppe 
      901 spvtgyrvdv ipvnLpgehg qrLpvsrntf aevtgLspgv tyhfkvfavn qgreskpLta 
      961 qqatkLdapt nLqfinetdt tvivtwtppr arivgyrLtv gLtrggqpkq ynvgpaasqy 
     1021 pLrnLqpgse yavsLvavkg nqqsprvtgv fttLqpLgsi phyntevtet tivitwtpap 
     1081 rigfkLgvrp sqggeaprev tsesgsivvs gLtpgveyvy tisvLrdgqe rdapivkkvv 
     1141 tpLspptnLh LeanpdtgvL tvswersttp ditgyrittt ptngqqgysL eevvhadqss 
     1201 CtfenLspgL eynvsvytvk ddkesvpisd tiipavpppt dLrftnvgpd tmrvtwapps 
     1261 sieLtnLLvr yspvkneedv aeLsispsdn avvLtnLLpg teyLvsvssv yeqhesipLr 
     1321 grqktaLdsp sgidfsdita nsftvhwiap ratitgyrir hhpenmggrp redrvppsrn 
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     1381 sitLtnLnpg teyvvsivaL nskeesLpLv gqqstvsdvp rdLeviaatp tsLLiswdap 
     1441 avtvryyrit ygetggsspv qeftvpgsks tatisgLkpg vdytitvyav tgrgdspass 
     1501 kpvsinyrte idkpsqmqvt dvqdnsisvr wLpssspvtg yrvttapkng pgpsktktvg 
     1561 pdqtemtieg Lqptveyvvs vyaqnqnges qpLvqtavtt ipaptnLkft qvtptsLtaq 
     1621 wtapnvqLtg yrvrvtpkek tgpmkeinLa pdsssvvvsg Lmvatkyevs vyaLkdtLts 
     1681 rpaqgvvttL envspprrar vtdatettit iswrtkteti tgfqvdaipa ngqtpiqrti 
     1741 rpdvrsytit gLqpgtdyki hLytLndnar sspvvidast aidapsnLrf LattpnsLLv 
     1801 swqpprarit gyiikyekpg spprevvprp rpgvteatit gLepgteyti qviaLknnqk 
     1861 sepLigrkkt deLpqLvtLp hpnLhgpeiL dvpstvqktp fitnpgydtg ngiqLpgtsg 
     1921 qqpsLgqqmi feehgfrrtt ppttatpvrh rprpyppnvn eeiqighvpr gdvdhhLyph 
     1981 vvgLnpnast gqeaLsqtti swtpfqesse yiisChpvgi deepLqfrvp gtsasatLtg 
     2041 Ltrgatynii veavkdqqrq kvreevvtvg nsvdqgLsqp tddsCfdpyt vshyaigeew 
     2101 erLsdsgfkL sCqCLgfgsg hfrCdsskwC hdngvnykig ekwdrqgeng qmmsCtCLgn 
     2161 gkgefkCdph eatCyddgkt yhvgeqwqke yLgaiCsCtC fggqrgwrCd nCrrpgaepg 







RAT POSTNATAL DAY 7 CEREBELLAR NEURON DISSECTION PROTOCOL 
 
Supplies: 
• 25mm, 0.2 µm syringe filter (Nalgene 190-2520) 
• Sterile 35mm petri dishes (Falcon 353801) 
• Sterile 100mm petri dishes (Fisher 08-757-13) 
• Sterile 15mL centrifuge tubes (Fisher 05-539-12) 
• Sterile 50mL centrifuge tubes (Fisher 05-539-8) 
• 3mL syringe with 22G1½ needle (BD309574) 
• 96-well plates (Corning 3596) 
• Autoclave biohazard bags (Fisher 01-814A) 
 
Dissection Tools: 
• Large scissors 
• Fine scissors (Fine Science Tools 91500-09) 
• Dumont #5 fine forceps Inox – two pair (Fine Science Tools 91150-20) 
• Coarse straight forceps 
• Styrofoam base covered in foil and sterile needles (any size) 
 




Materials Part No. Storage 
Gibco Basal Medium Eagle (BME) without  
L-glutamine 
21010-046 +4°C 
Fisher Potassium Chloride (KCl) P217-500 Room Temp. 
Acros D(+)-Glucose 41095-5000 Room Temp. 
Gibco Fetal Bovine Serum OR 




Gibco L-glutamine 200 mM OR  
Hyclone L-glutamine 200mM 




Gibco 100X Antibiotic-Antimycotic 
10,000 IU/ml penicillin 
10,000 µg/mL streptomycin 
25 µg/mL amphotericin B 
15240-096 -20°C 
Gibco L15 Medium  +4°C 
Fisher DNase  -20°C 
 
Table C.1: Materials used for Rat Cerebellar Neuron Dissection 
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Preparation of Sterile HBSS with 1% Glucose: 
 
HEPES is added to 1X HBSS to replace the buffering action of the missing 
bicarbonate in order to maintain physiological pH 7.4 in air, so it can be used outside 
the CO2 incubator (HBSS is used in this protocol for the dissection and trypsin step , 
both of which are done in air). 
 
1L: 
• Make 1L of 1X HBSS: add 100mL of 10X HBSS without Ca, Mg, bicarbonate, or 
phenol red to 900mL of Millipore water with stirring. 
• Add 5 mM HEPES (1.3g/L, MW=260.3) to 900mL of 1X HBSS and wait until 
dissolved. 
• Add 10g of glucose and wait until dissolved. 
• Add 10 mL (1%) antibiotic/antimycotic. 
• Adjust pH to 7.4 with NaOH. 
• Bring liquid level up to 1L with 1X HBSS.  Verify pH is 7.4. 
• Filter-sterilize and store at +4°C. 
 
 
Preparation of 1.0% Trypsin: 
• Dilute 10mL of 2.5% trypsin without Ca, Mg, phenol red in 15mL of sterile HBSS 
with 1% glucose to make 1.0% trypsin. 




Preparation of 1.0% Trypsin/ 0.2% EDTA solution: 
• Dissolve 200mg EDTA in 10mL Millipore water (2% w/v) and sterilize with 0.2um 
syringe filter.  
• Add 10mL of 2.5% trypsin without Ca, Mg, phenol red and 2.5mL sterile EDTA 
solution to 12.5mL of sterile HBSS with 1% glucose to make 1% trypsin-0.2% 
EDTA. 
• Freeze in 5mL aliquots at -20°C.  Store ≤1 year. 
 
 
Preparation of 1.0% Dnase: 
• Dilute 40 mg DNase in 4  mL of L15 media for a 10 mg/mL concentration. 
• Syringe-filter with 0.2µm syringe filter. 
• Freeze in 500µL aliquots at -20°C.  Store ≤1 year. 
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Preparation of Serum Medium:   
 
Base Medium: BME without L-glutamine 
• 20 mM potassium chloride (KCl) 
• 33 mM glucose 
• 10% fetal bovine serum (FBS) 
• 50 U/ml penicillin, 50 µg/mL streptomycin, 125 ng/mL antibiotic/antimycotic 
solution (1:200 dilution) 
• 2mM L-glutamine (1:100 dilution) 
 
Instructions: 
1. Add media components in the order listed above. 
2. Sterile-filter media after adding KCl and glucose using a 25mm, 0.2 µm 
syringe filter (Nalgene 190-2520). 
3. Make stock solution of media without L-glutamine and store at +4°C. 
4. Add L-glutamine (2 mM final concentration) immediately prior to use.  Use 
media within 1 week of adding L-glutamine. 
 
To make 10 mL:    To make 50 mL: 
BME     9 mL   BME    45 mL 
KCl   15 mg   KCl    75 mg 
Glucose          59 mg   Glucose 295 mg 
FBS     1 mL   FBS      5 mL 
AB/AM  50 µL   AB/AM 250 µL 
L-glutamine  100 µL    L-glutamine   500 µL 
 
Preparation for Dissection: 
 
1. Prepare and sterilize media. 
2. Ensure dissection tools are autoclaved.  If autoclaving is not possible, sterilize tools 
with 70% ethanol for 30 minutes. 




1. Wipe the styrofoam base covered in foil with 70% ethanol and allow to dry. 
2. Carefully pin the rat head to the styrofoam base with two sterile needles through the 
nose to stabilize the head. 
3. Use the large scissors to carefully remove the skin covering the brain. 
4. Use the fine scissors to carefully remove the top portion of the brain and expose the 
cerebellum.  Refer to Protocols for Neural Cell Culture (Federoff and Richardson, 3rd 
edition) Chapter 4, Figure 1.  The cerebellum is sausage-shaped and sits directly 
below the pair of optic lobes. 
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5. Dissect the cerebellum and carefully remove the meninges and all blood vessels in a 
35mm petri dish in ice cold HBSS with glucose.  
 
Dissociation and Plating: 
 
1. Warm L15 and serum media in 37°C incubator with 7% CO2 for 30 minutes to bring 
temperature and pH up to physiological levels. 
2. Transfer the cleaned cerebellum to a clean 35mm petri dish, add 1 mL of 1% trypsin 
in HBSS, and mince the cerebellum into small pieces with the fine scissors. 
3. Under a sterile cell culture hood, add 100uL 1% DNase and mix gently. 
4. Incubate for 15 min in 37ºC water bath. 
5. Transfer minced tissue into a sterile 15mL tube, add 3 mL of serum media to 
deactivate the trypsin, and centrifuge at 1,000 rpm for 5 min. 
6. Carefully remove supernatant and add 1 ml fresh media to the cell pellet.  Gently
resuspend the cells by pipetting up and down a few times, avoiding air bubbles.  
7. Gently triturate cells at least 20 times using a 3mL syringe with 22G1½ needle 
(BD309574).  A sterile fire-polished glass pipet may also be used. Avoid air bubbles. 
8. Dilute the cell suspension 10-fold in serum media and count the cells using a 
hemacytometer (typically 7-12 million cells per cerebellum). 
9. Plate cells using the serum media.  REMINDER: L-glutamine  (Gibco or Hyclone, 
200 mM) must be added to the media immediately before use: 10 µL L-glutamine  to 
1 mL media (2mM final concentration) 
10. Plating densities of 20,000 cells per 96-well typically provide good results.  Corning 
3596 96-well plates have a well diameter of 6.4mm and growth area of 0.32 cm2, so 
this plating density is equivalent to 62,500 cells/ cm2.  
 
Conclusion of Dissection: 
 
1. Gently clean all dissection tools immediately with detergent to prevent dryi g of 
blood. 
2. Wipe the dissection hood with 70% ethanol and UV sterilize for at least 30 minutes. 
3. Dispose of all waste in an autoclave biohazard bag, tie the bag shut, and dispose of in 
the designated freezer. 
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APPENDIX D 




• 25mm, 0.2 µm syringe filter (Nalgene 190-2520) 
• Sterile 35mm petri dishes (Falcon 353801) 
• Sterile 100mm petri dishes (Fisher 08-757-13) 
• Sterile 15mL centrifuge tubes (Fisher 05-539-12) 
• Sterile 50mL centrifuge tubes (Fisher 05-539-8) 
• 3mL syringe with 22G1½ needle (BD309574) 
• 96-well plates (Corning 3596) 
• Autoclave biohazard bags (Fisher 01-814A) 
 
Dissection Tools: 
• Large scissors 
• Fine scissors (Fine Science Tools 91500-09) 
• Dumont #5 fine forceps Inox – two pair (Fine Science Tools 91150-20) 
• Coarse straight forceps 
• Styrofoam base covered in foil and sterile needles (any size) 
 






MATERIAL VENDOR PART NUMBER STORAGE 
DMEM-F12 with L-glut Mediatech 10-090-CV +4°C 
L15 Medium Gibco  +4°C 
BSA (bovine serum albumin) Sigma A3059-10G +4°C 
FBS (fetal bovine serum) Hyclone SH30070.02HI -20°C 
100X Antibiotic/Antimycotic 
-10,000 U/mL penicillin G 
-10,000 ug/mL streptomycin 
sulfate 
-25 ug/mL amphotericin 
Gibco 15240-096 -20°C 
NGF-7S Invitrogen 13290-010 -20°C 
2.5% Trypsin w/o Ca, Mg*, 
phenol red** 
Invitrogen 15090-046 -20°C 
EDTA*** Acros 32721-1000 Room Temp. 
10X HBSS w/o Ca, Mg*, 
bicarb, phenol red** 
Gibco 14185-052 Room Temp. 
Glucose Sigma G-7528 Room Temp. 
HEPES Fisher BP410-500 Room Temp. 
Collagenase Worthington  -20°C 
DNAse Fisher  -20°C 
 




*Ca2+ and Mg2+ in the trypsin and the salt solution can cause cells to adhere to each 
together. 
**Phenol red may damage neurons in alkaline pH during the dissection and dissociation 
steps. 
***EDTA (disodium ethylenediamine tetraacetic acid) may be added to trypsin as a 
chelating agent to bind Ca2+ and Mg2+ ions that can interfere with the action of trypsin. 
 
Preparation of NGF: 
20 µg/mL, 0.1% BSA 
• Make 1% BSA solution (10mg in 1mL Millipore water) and sterile filter through 
0.2µm syringe filter. 
• In laminar flow hood, dissolve 100ug NGF 7S in 4.5 mL DMEM-F12. 
• Add 500µL of sterile 1% BSA solution (to make 0.1% final concentration). 




Preparation of Sterile HBSS with 1% Glucose: 
 
HEPES is added to 1X HBSS to replace the buffering action of the missing 
bicarbonate in order to maintain physiological pH 7.4 in air, so it can be used outside 
the CO2 incubator (HBSS is used in this protocol for the dissection and trypsin step , 
both of which are done in air). 
 
1L: 
• Make 1L of 1X HBSS: add 100mL of 10X HBSS without Ca, Mg, bicarbonate, or 
phenol red to 900mL of Millipore water with stirring. 
• Add 5 mM HEPES (1.3g/L, MW=260.3) to 900mL of 1X HBSS and wait until 
dissolved. 
• Add 10g of glucose and wait until dissolved. 
• Add 10 mL (1%) antibiotic/antimycotic. 
• Adjust pH to 7.4 with NaOH. 
• Bring liquid level up to 1L with 1X HBSS.  Verify pH is 7.4. 
• Filter-sterilize and store at +4°C. 
 
 
Preparation of 1% Trypsin: 
• Dilute 10mL of 2.5% trypsin without Ca, Mg, phenol red in 15mL of sterile HBSS 
with 1% glucose to make 1.0% trypsin. 




Preparation of 1% Trypsin/ 0.2% EDTA solution: 
• Dissolve 200mg EDTA in 10mL Millipore water (2% w/v) and sterilize with 0.2um 
syringe filter.  
• Add 10mL of 2.5% trypsin without Ca, Mg, phenol red and 2.5mL sterile EDTA 
solution to 12.5mL of sterile HBSS with 1% glucose to make 1% trypsin-0.2% 
EDTA. 
• Freeze in 5mL aliquots at -20°C.  Store ≤1 year. 
 
Preparation of 1.33% Collagenase: 
• Dilute 53.2 mg collagenase in 4 mL of L15 media for a 13.3 mg/mL concentration. 
• Syringe-filter with 0.2µm syringe filter. 
• Freeze in 500µL aliquots at -20°C.  Store ≤1 year. 
  
Preparation of 1.0% Dnase: 
• Dilute 40 mg DNase in 4 mL of L15 media for a 10 mg/mL concentration. 
• Syringe-filter with 0.2µm syringe filter. 
• Freeze in 500µL aliquots at -20°C.  Store ≤1 year. 
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Preparation of Serum Medium: 
 
Base Medium: DMEM-F12 with L-glutamine 
• 10% FBS (100 µL per mL media) 
• 1% antibiotic/antimycotic (10 µL per mL media) 
• Add 1µL of NGF (20 µg/mL stock solution) per mL media for 20ng/mL 
concentration of NGF.  Add NGF immediately prior to use. 
• Complete culture medium with NGF can be stored at +4°C for up to 5 days. 
 
25mL: 
22.5 mL DMEM-F12 
  2.5 mL FBS 
 250 µL antibiotic/antimycotic 
   25 µL NGF (20 µg/mL stock solution) 
 
 
Preparation for Dissection: 
 
1. Prepare and sterilize media. 
2. Ensure dissection tools are autoclaved.  If autoclaving is not possible, sterilize tools 
with 70% ethanol for 30 minutes. 




1. Thaw out one 4mL aliquot of trypsin and warm to 37°C in water bath.  Use ice-cold 
sterile HBSS with glucose. 
2. Perform dissection in the open dissection hood with microscope. 
3. Set-up an autoclave bag for all waste products. 
4. Prior to the dissection, pour ice-cold HBSS with glucose into: 
a. 4mL in 100mm petri dish for postnatal rat 
b. 2mL in 35mm petri dish for storage of DRG during dissection 
c. 2mL in 15mL tube (for transfer of DRG from 35mm petri dish) 
5. Use the dissection microscope with the under-sided lamp to illuminate the rat. 
6. Turn the rat on its side and gently cut along the vertebral column with the large 
scissors to separate the spinal column. 
7. Use the small scissors to cut through the bone on each side of the spinal column and 
gently separate the two halves to expose the spinal cord. 
8. Carefully separate the spinal cord from the bone to expose the DRG. 
9. Pluck the DRG from spinal column using fine forceps, and cut the spinal nerves close 
to the DRG to minimize contamination by nonneuronal cells from nerve sheaths.  
Transfer the DRG to the separate 35mm petri dish containing cold HBSS with 
glucose. 
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10. Transfer DRG from 35mm petri dish to 15mL centrifuge tube with 1mL pipet.  The 
cells may adhere to the plastic tip and petri dish so rinse thoroughly to make sure all
tissue is transferred.   
11. It should take approximately 15 minutes per rat.  Do not take longer than 1 hour to do 
the dissection (limit time to 1-1/2 hours from start of dissection to plating to minimize 
cell damage, this includes 30 min dissociation in trypsin). 
 
Dissociation and Plating: 
1. Warm L15 and serum media in 37°C incubator with 7% CO2 for 30 minutes to bring 
temperature and pH up to physiological levels. 
2. In a cell culture hood, allow tissue to settle, remove HBSS, and add 2mL L15 media 
and 0.5mL of 1.33% collagenase and incubate in 37°C water bath for 30 minutes. 
3. Centrifuge cells at 1000 rpm for 5 minutes and discard supernatant. 
4. Add 4 mL of DMEM/F12 (no serum), 1mL 1% trypsin in HBSS, and 50µL of 1% 
DNase, and incubate in 37ºC with 7% CO2  incubator for 30 minutes. 
5. Centrifuge cells at 1000 rpm for 5 minutes and discard supernatant. 
6. Add 4 mL of serum medium to deactivate the trypsin, centrifuge again, and discard 
supernatant. 
7. Add 2 mL of warm serum medium and triturate at least 20 times with 3mL syringe 
with 22G needle (needle diameter is 0.7mm), avoiding air bubbles as this will damage 
cells.  Ensure all tissue is broken up.   
8. Add 4mL media and mix gently.  Add the 6mL cell suspension to 100mm petri dish 
and incubate for 2-4 hours in humidified 37°C, 7% CO2 incubator.  Non-neuronal 
cells should adhere to petri dish and neurons should remain floating or weakly 
attached. 
9. After 2-4 hours, tilt petri dish at 45 degrees and gently wash bottom twice to remove 
weakly attached neurons, then transfer to 15mL tube. 
10. Centrifuge at 1000 rpm for 5 minutes.  Ensure there is a pellet, remove media, and 
resuspend in 200µL warm serum media by triturating 3-4 times gently with 200µL 
pipet tip. 
11. Count cells using hemacytometer (1:2 dilution).  Neurons appear rounded and phase-
bright whereas non-neuronal cells are darker and irregularly shaped.  DRG neuron
diameters may be 7µm to 18 µm. 
12. Seed approximately twice as many neurons as you think you will need in each 96-
well as approximately 30-40% of cells will not attach in the first day of culture and up 
to 50% are lost after 3 days of culture.   
13. Plate cells using the serum media.  REMINDER: NGF must be added to the media 
immediately before use. 
14. Plate cells in 100µL media per well.  Change media after allowing 2 hours for 
attachment and add 200µL media per well.  OR Plate cells in 200µL media and 
change media the next morning. 
15. Incubate in a humidified 37°C, 7% CO2 incubator.   
16. Change media every 2 days. 
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17. Corning 3596 96-well plates (Fisher 07-200-90) have well diameter of 6.4mm and 
growth area of 0.32 cm2, currently seeding 2,000 DRG’s per 96-well. 
 
Conclusion of Dissection: 
1. Gently clean all dissection tools immediately with detergent to prevent dryi g of 
blood. 
2. Wipe the dissection hood with 70% ethanol and UV sterilize for at least 30 minutes. 
3. Dispose of all waste in an autoclave biohazard bag, tie the bag shut, and dispose of in 
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